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Abstract 
 
 DNA is constantly exposed to both exogenous and endogenous sources of 
DNA damage. Therefore, organisms evolved a plethora of DNA repair pathways to 
repair these distinct lesions and prevent mutations from arising. Mutations that occur 
in somatic cells can lead to disease, which may be detrimental to that single individual. 
However, germ line mutations can be passed on to the next generation. These mutations 
not only drive genome evolution but can also impair the fitness of the offspring. 
 It has been shown that primordial germ cells (PGCs), the germ cells specified 
during embryonic development, have the highest mutation frequency compared to germ 
cells belonging to other stages of gametogenesis. Furthermore, mutations in PGCs are 
particularly important because mutations in these cells can affect multiple offspring. 
Evidence shows that during PGC development, which entails extensive genomic and 
epigenomic transactions, there is the generation of DNA damage. However, the DNA 
repair pathways used in PGCs and the nature of DNA damage encountered by these 
cells which can provide mechanistic insight into how mutagenesis is suppressed in the 
germ line remains largely unexplored. 
 Here we describe the use of an in vitro system that generates PGC-like cells 
(PGCLCs) from ESCs to discover novel factors required for PGC development. Using 
this system, we have firstly shown that we can recapitulate the genetic requirement for 
DNA repair in PGCLCs in vitro. Secondly, we coupled this system with CRISPR/Cas9 
screening technology, which permitted us to identify novel factors required during the 
development of PGCLCs. We identified the translesion synthesis (TLS) factor Rev1 as 
a key factor involved in PGCLC development. Furthermore, we validated this 
requirement in vivo and showed that absence of Rev1 causes a numeric reduction in 
PGCs during the migratory period of PGC development. We also identified additional 
factors, namely involved in homologous recombination, chromosome cohesion which 
will be investigated in the future. 
 This screen permitted the identification for the first time of the requirement 
for TLS in PGCs suggesting that the germ cell lineage may employ this mutagenic 
pathway to promote genome evolution.  
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Chapter 1 - Introduction 
 
1.1 - DNA repair is essential to all life forms 
 
 All of the genetic information required to generate an entirely new organism is 
encoded in the DNA molecule. The structure of this molecule allows genetic 
information to be stored, replicated and also transcribed. However, in order to 
propagate life this genetic information has to be faithfully passed between generations. 
Therefore, the chemical stability and integrity of the genome is essential to life. 
Additionally, the processes of DNA replication and transcription pose significant 
threats to the integrity of the genome (Maya-Mendoza et al. 2018; Herman and Dworkin 
1971). However, like all biological macromolecules, DNA itself is chemically not inert 
(Lindahl 1993) and damage can occur not only to the bases but also the sugar-phosphate 
backbone. In contrast, DNA can undergo spontaneous damage due to the intrinsic 
chemical instability of the DNA molecule (Lindahl 1993). These lesions can also result 
from chemical insults from a wide variety of sources. Genotoxins can be generated as 
toxic byproducts of metabolism or exposure to exogenous or environmental agents. It 
is estimated that each cell in our bodies experiences up to 100,000 spontaneous DNA 
lesions per day (Hoeijmakers 2009) (Lindahl and Barnes 2000). Therefore, in order to 
maintain the sequence and structural integrity of the genome, organisms have evolved 
several DNA damage repair pathways with specialised mechanisms to detect, signal 
and repair DNA lesions (Figure 1). As these lesions are diverse in nature, they require 
different enzymatic activities in order to repair them. The majority of DNA repair 
transactions resolve the lesion in an error-free manner. However, errors in the sequence 
or the structure of the DNA, or DNA mutations, can still emerge either from illegitimate 
or error-prone repair of DNA lesions. The introduction of mutations in the genome can 
have catastrophic consequences. Whilst the acquisition of mutations can have 
deleterious consequences in somatic tissue, such as tumourigenesis, de novo 
mutagenesis in the germ line can have not only a deleterious effect, such as loss of 
fitness in the progeny, but also can drive genome evolution. 
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Figure 1. A plethora of DNA repair pathways have evolved to deal with defined lesions in the 
genome. DNA is continually exposed to a series of insults that cause a range of lesions. These lesions 
can occur not only at the base or sugar backbone level but can also include breaks in one or both of the 
DNA strands. Therefore, the choice of repair mechanism is largely defined by the type of lesion, but also 
influenced by factors such as the stage in the cell cycle. Both the types of lesion and the major pathways 
thought to repair or tolerate that kind of damage are depicted.  
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1.2 - The emergence of diverse DNA repair pathways 
 
1.2.1 – Base excision repair 
 
 Damage to the base, the fundamental unit of the genetic code, can occur due to 
the intrinsic chemical nature of the bases - their ability to form Watson-Crick base pairs 
(guanine-cytosine and adenine-thymidine). An example of this is the spontaneous 
deamination of cytosine to uracil (Lindahl and Nyberg 1974). This poses a threat to 
genome stability as uracil pairs with adenine, therefore when the genome is replicated 
a C to T mutation can be introduced. Alternatively, the base of the DNA molecule can 
react with an exogenous agent adducting the base, in general by oxidation, alkylation 
or hydrolysis (Lindahl 1993). Common sources of base adducts are not only the 
spontaneous decay of DNA (Lindahl 1993) but also environmental agents (such as 
chemicals in cigarette smoking (Phillips et al. 1988), radiation, or cancer chemotherapy 
treatment drugs). These lesions pose a threat to the genome integrity since they may 
lead to incorrect base pairing with the potential for mutagenesis. Alternatively, they 
may pose an obstacle to either the DNA replication or transcription machinery. In 
general, base adducts lead to small distortions in the topology of the DNA helix. One 
route to repair this class of lesions is known as base excision repair (BER) (Lindahl 
1976). Initially, a DNA glycosylase recognizes the adducted base and then removes the 
base by cleaving the covalent bond between the base and the sugar in the DNA 
(glycosidic bond). This leaves the sugar-phosphate backbone intact creating an 
apurinic/apyrimidinic (AP) site (Lindahl 1976). At least 12 distinct mammalian DNA 
glycosylases have been described, each of them recognizing a subset of lesions, 
frequently with some overlap in specificities (Krokan and Bjoras 2013). The resultant 
AP site is further processed by short-patch repair or long-patch repair that largely uses 
different proteins to complete repair (Fortini et al. 1998). Both routes of repair require 
cleavage of the sugar-phosphate backbone and then a polymerase fills in the gap using 
the other strand as a template (Lindahl 1976). Therefore, BER specifically removes the 
lesion and uses the undamaged strand as the template ensuring that the genomic 
information is not corrupted during the repair transaction. 
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1.2.2 – Nucleotide excision repair 
 
 In addition to small base adducts in DNA, bulky adducts which are more 
distorting to the DNA helix also occur necessitating repair. The archetypal lesions of 
this class are cyclobutane-pyrimidine dimers (CPDs) and 6–4 pyrimidine–pyrimidone 
photoproducts (6–4PPs) in which covalent bonds are formed between consecutive 
bases along the nucleotide chain (Ravanat, Douki, and Cadet 2001). As these lesions 
are much bulkier than simple base adducts, they cannot fit into the active site of DNA 
glycosylases and subsequently be removed from the helix. Instead, these lesions are 
repaired by the nucleotide excision repair (NER) pathway. There are two main branches 
of NER: global-genomic NER (GG-NER) and transcription-coupled NER (TC-NER). 
In GG-NER the entire genome is continually examined by proteins that recognize 
distortion of the DNA helix (Sugasawa et al. 1998; Sugasawa et al. 2001), whereas TC-
NER is activated by stalling of the RNA polymerase II (RNA Pol II) at lesions within 
the template strand of transcribed regions (Fousteri et al. 2006). Although these two 
sub-pathways of NER rely on different mechanisms to detect helix-distorting lesions, 
they both converge on common downstream apparatus to resolve the damage. In 
contrast to BER in which the glycosidic bond is cleaved, NER employs nucleases to 
cleave bonds in the sugar phosphate backbone (Hu et al. 2013). After binding to the 
lesion and melting the duplex to form a bubble, NER factors recruit two structure 
specific endonucleases: XPF (Xeroderma pigmentosum complementation group f) 
together with ERCC1 (Excision repair cross-complementation group 1) and XPG 
(Xeroderma pigmentosum complementation group g) (Evans et al. 1997; Bardwell et 
al. 1994). These nucleases incise the strand containing the lesions resulting in a short 
patch of single stranded DNA, which is filled in by the replicative DNA polymerases 
(Shivji et al. 1995). 
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1.2.3 – Mismatch repair 
 
 In addition to base lesions, the DNA helix may become distorted due to base 
mispairing (i.e. when a base is introduced which cannot form Watson-Crick pairing). 
These lesions often occur during DNA replication when the polymerase introduced the 
wrong nucleotide resulting in DNA mismatches or when the polymerase slips which 
leads to an insertion/deletion (indel) loop (Shcherbakova et al. 2003; Kroutil et al. 
1996). The frequency of these errors is significantly reduced by the proofreading 
activity of the replicative DNA polymerases (Tran et al. 1997; Shcherbakova et al. 
2003). Mismatches can also occur when a base is damaged altering its ability to form 
normal Watson-Crick base pairs (Mu et al. 1997). However, when this type of lesion 
persists, a repair pathway named mismatch repair (MMR) ensures that these lesions are 
corrected. MMR entails an enzymatic machinery that detects the mismatched base in 
the correct strand (Lahue, Au, and Modrich 1989) and initiates repair by activating an 
exonuclease-mediated degradation of DNA from a nick that is distant to the mismatch 
(Cooper, Lahue, and Modrich 1993). Then, DNA polymerase 𝛿 activity re-fills this gap 
by inserting the correct nucleotide and therefore repairing the mismatch (Lahue, Au, 
and Modrich 1989; Schaaper 1988). 
 
1.2.4 – Interstrand crosslink repair 
 
 Another consequence of chemical modifications of DNA bases is the formation 
of interstrand crosslinks (ICLs). These crosslinks covalently bind the opposite strands 
of DNA together and pose extremely toxic lesions to cells as they can block both DNA 
replication and also transcription. These lesions are caused by agents with 
independently reactive groups within the same molecule such as reactive aldehydes and 
cancer chemotherapy treatment drugs including mitomycin C or cisplatin (Stone et al. 
2008; Sasaki and Tonomura 1973; Poll et al. 1985). ICLs can be repaired by the Fanconi 
anemia (FA) repair pathway (Sasaki 1975; Auerbach 1988; German et al. 1987), which 
comprises 21 gene products (Fanca to Fancv) that act together with other DNA damage 
response pathways including NER but also double-strand break (DSB) repair and 
translesion sysnthesis (TLS), which both will be described next. The FA pathway 
operates mainly during the S phase of the cell cycle and requires converging replication 
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forks (Zhang et al. 2015) to orchestrate the various steps that are necessary for ICL 
repair: lesion recognition, DNA incision, lesion bypass and lesion repair. Lesion 
recognition is mediated by the protein FANCM that binds the ICL and serves as a 
platform for the FA core complex, which comprises 14 proteins (FANCA, FANCB, 
FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, FANCT, FAAP100, MHF1, 
MHF2, FAAP20 and FAAP24) (Xue et al. 2008; Kim et al. 2008). The FA core 
complex functions as a large ubiquitin ligase for two other FA proteins, FANCD2 and 
FANCI. After loading on to chromatin, ubiquitylated FANCD2-I controls the 
nucleotytic incision at the converging replication forks, which will ultimately release 
the ICL from one of the two parental DNA strands. This is achieved by FANCD2-Ub 
recruitment of SLX4 (Structure-specific Endonuclease Subunit 4 also known ans 
FANCP) which in turn recruits and activates several structure-specific endonucleases 
such as the XPF (also known and FANCQ)-ERCC1 heterodimer, MUS81 (MUS81 
Structure-Specific Endonuclease Subunit)-EME1 (Essential meiotic structure-specific 
endonuclease 1) and SLX1 (Structure-specific endonuclease subunit 1) (Knipscheer et 
al. 2009). Once the ICL has been released from one of the DNA strands, low-fidelity 
TLS polymerases that have larger binding pockets compared to replicative 
polymerases, bypass the lesion by incorporating nucleotides opposite the ICL and 
extending the nascent strand (Sarkar et al. 2006). The restoration of one intact DNA 
duplex permits its use as a template for homologous recombination (HR), a subset of 
DSB repair that permits the repair of DSBs by invading an undamaged DNA molecule 
and resynthesizing the missing strand using the other strand as template. Following 
strand invasion and repair synthesis, resolution and ligation give rise to an intact double 
stranded DNA duplex, thereby completing FA pathway mediated ICL repair. 
Interestingly, in addition to the structure-specific nucleases XPF-ERCC1, MUS81-
EME1 and SLX1, other nucleases including FAN1 (Fanconi-associated nuclease 1) and 
three genes from the SNM1 (Sensitive to nitrogen mustard 1) family have been 
implicated in ICL repair. FAN1 has been shown to interact directly with 
mono-ubiquitylated FANCD2–I via a ubiquitin-binding zinc finger domain, however 
this domain was shown to be dispensable for ICL recruitment and resistance to 
crosslinking agents (Liu et al. 2010; Smogorzewska et al. 2010; Thongthip et al. 2016). 
Also, epistasis studies suggest that FAN1 has ICL repair activities that are independent 
of the FA pathway (Yoshikiyo et al. 2010; Zhou et al. 2012). The Snm1 family of genes 
in vertebrates include SNM1A, APOLLO/SNM1B, ARTEMIS/SNM1C, ELAC2 and 
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CPSF73 of which SNM1A, APOLLO/SNM1B, ARTEMIS/SNM1C are reported to 
confer cellular resistance to ICLs (Cattell, Sengerova, and McHugh 2010). One 
hypothesis for the presence of additional structure-specific endonucleases may be that 
outside S-phase cells have additional factors that repair ICLs independently of the FA 
pathway. Alternatively, the different nucleases may have different substrates 
specificities to repair the diverse lesions caused by crosslinking agents. 
 
1.2.5 – DNA-protein crosslink repair 
 
 In addition to crosslinking to DNA itself, DNA can also be crosslinked to 
proteins forming DNA-protein crosslinks (DPCs) (Stingele, Bellelli, and Boulton 
2017). DPCs can be repaired by direct crosslink hydrolysis as exemplified by TDP1 
(Tyrosyl-DNA phosphodiesterase 1), which removes TOP1 (DNA Topoisomerase I) 
covalently bound to DNA (Yang et al. 1996; Pouliot et al. 1999). Furthermore, NER 
had been shown to be responsible for removing small protein adducts on DNA (up to 
10 kDa) (Baker et al. 2007; Nakano et al. 2007), whereas HR provided tolerance to 
DPC causing agents (de Graaf, Clore, and McCullough 2009) likely via promoting 
repair of replication forks that are stalled or collapsed in the presence of DPCs. 
Recently, a novel DPC repair pathway was identified which involves DPC removal via 
proteolytic activity of the protease SPRTN together with the proteasome in a 
replication-dependent manner (Duxin et al. 2014; Larsen et al. 2019). 
 
1.2.6 – Single-strand break repair 
 
 DNA lesions can occur at the base and nucleotide level but the DNA duplex can 
also be broken in one or both strands. If a break occurs in one of the DNA strands, a 
single-stranded DNA break (SSB) occurs. This type of lesions can also arise via direct 
sugar damage caused by reactive oxygen species (ROS) (Li, Trush, and Yager 1994) 
and from erroneous or abortive activity of cellular enzymes such as TOP1, which 
generates a nick in DNA to relax DNA during transcription and DNA replication 
(Pommier et al. 2003). The repair of this lesion requires a different DNA repair pathway 
named single-stranded break repair (SSBR) which has a partial overlap with the BER 
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in the enzymatic machinery required to process the DNA ends, fill and ligate the DNA 
gap (Caldecott 2008). 
 
1.2.7 – Double strand break repair 
 
 If the DNA duplex is broken on both DNA strands, a DNA DSB is formed. 
DSBs are highly toxic lesions which can cause genomic instability via chromosomal 
rearrangements and can trigger cell cycle arrest or cell death via apoptosis (Stephens et 
al. 2011; Lips and Kaina 2001; Di Leonardo et al. 1994). DSBs arise following 
exposure to exogenous clastogens, such as ionising radiation (IR) or ROS. Also, DSBs 
can also be generated endogenously when the replication fork encounters unrepaired 
DNA lesions causing fork collapse or when DNA interacting enzymes are not removed 
from DNA causing the DNA replication or transcription machinery to be blocked and 
ultimately released by endonucleases. DSBs can be repaired generally via two distinct 
repair pathways: homologous recombination (HR) or nonhomologous end-joining 
(NHEJ). The choice of DSB repair pathway is dependent on chromatin context and 
phase of the cell cycle. HR is the pathway normally used by cells in the G2 phase of 
the cell cycle when sister chromatids are available for serving as templates for repair. 
There are several subpathways of HR including single-strand annealing (SSA), 
synthesis dependent strand annealing (SDSA) or break induced replication (BIR) and 
studies have shown the complexity and mechanistic details of this repair pathway that 
are beyond the scope of this thesis. 
 
1.2.7.1 – Homologous recombination  
 
 In order for cells to repair a DSB via HR, several steps involving different 
machinery are required. HR mediated repair starts by processing of the DSB by 
nucleolytic resection. This resection generates a 3′ single-strand DNA (ssDNA) 
overhang, which becomes the substrate for the HR protein machinery to execute strand 
invasion of a partner chromosome. RAD51 proteins coat ssDNA forming a filament 
that guides strand invasion into a homologous sequence and a D-loop intermediate is 
formed. Then the replicative DNA polymerase extends from the 3′ end of the invading 
strand permitting then the capture of the second DSB end by annealing to the extended 
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D-loop. Finally, two crossed strands or Holliday junctions (HJs) are formed. HJs can 
be “dissolved” by the branch migration and topoisomerase activity of the BLM (Bloom 
syndrome RecQ like helicase)/TOP3a (DNA topoisomerase III alpha)/RMI1 (RecQ 
mediated genome instability 1) complex (Wu and Hickson 2003) and intermediates that 
escape this complex can be resolved by several different resolvases, including 
MUS81/EME1, GEN1 (GEN1 Holliday junction 5' flap endonuclease), and 
SLX1/SLX4 (Ho et al. 2010; Wechsler, Newman, and West 2011; De Muyt et al. 2012; 
Zakharyevich et al. 2012), the choice of which may be cell-cycle regulated (Matos et 
al. 2011). In addition to these resolvases, the nuclease XPF-ERCC1 complex has been 
shown to play a role in a subset of HR named SSA (Sargent et al. 2000). In SSA, the 
DSB occurs in two repeated sequences that after resection allow for the 3' overhangs to 
align and anneal to each other, restoring the DNA as a continuous duplex. The XPF-
ERCC1 nuclease complex has been suggested to promote the removal of the 
nonhomologous 3’ ssDNA tails to complete repair of the DSB by SSA (Sargent et al. 
2000). In addition to this, the XPF-ERCC1 nuclease complex has been proposed to play 
a role later in HR by nicking the D-loop during HJ formation or removing 5’ flaps 
during SDSA (Al-Minawi, Saleh-Gohari, and Helleday 2008). 
 In various specialised contexts, DSBs are programmed by the cell. For example, 
during meiosis, which entails a type of cell division specific to germ cells, the 
generation of DSBs and DSB repair is essential for correct chromosome pairing and 
segregation at the first meiotic division and also for gamete generation (Neale and 
Keeney 2006). This physiological process generates gametes with allele combinations 
distinct from the parental germ line therefore increasing genetic variability. Also DSB-
induced rearrangements at immunoglobulin genes are also critical for the multiplicity 
of antigen receptor diversity over limited numbers of loci (Dudley et al. 2005). 
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1.2.7.1 – End joining  
 
 NHEJ repairs DSBs via direct ligation of the broken ends of DNA without a 
homology template (Chang et al. 2017) and, in contrast to HR, NHEJ occurs in the G1 
phase of the cell cycle. After the DSB is generated, a protein complex slides onto the 
DNA end and translocates inward (Chang et al. 2017). The DNA end is then processed 
by removing damaged or mismatched nucleotides by nucleases and resynthesized by 
DNA polymerase activity (Chang et al. 2017). After end processing, the ends are then 
ligated via DNA ligase activity therefore rejoining the broken strands and repairing the 
DSB. Unlike HR in which a DNA molecule is used as template for repair, NHEJ joins 
together two broken helices, therefore being considered a more error-prone DSB repair 
pathway. 
  In addition to NHEJ another repair pathway named microhomology-mediated 
end joining (MMEJ) or alternative nonhomologous end-joining can repair DSBs. 
MMEJ differs from HR and NHEJ by the use of 5–25 base pair micro-homologous 
sequences to align the broken strands before joining. This results in frequent deletions 
and occasionally insertions which are much larger than those produced by NHEJ. 
MMEJ is completely independent from NHEJ and does not rely on NHEJ core factors 
(Simsek and Jasin 2010). 
  
1.2.8 – Translesion synthesis  
 
 Finally, all the above repair mechanisms act by detecting and repairing lesions 
in the genome. However, cells possess another important mechanism that permits to 
tolerate genomic insults. This DNA damage tolerance mechanism does not repair 
lesions but allows the cell to temporarily bypass the lesion. This provides a mechanism 
by which a cell can complete replication of the genome even when that genome contains 
damage, which is named translesion synthesis (TLS) (Yang and Gao 2018). Whenever 
absent, TLS causes cells to face the risk of replication fork collapse, translocations, 
chromosome aberrations, and cell death. Although this mechanism allows cells to 
survive, the cost is mutagenesis. This is because TLS makes use of a class of specialized 
DNA polymerases which can use damaged DNA as templates and insert nucleotides 
opposite to lesions, despite the conformational constraints that many modified bases 
  11 
may impose (Prakash, Johnson, and Prakash 2005). TLS polymerases differ from the 
replicative polymerases by being able to accommodate modified bases, therefore 
allowing the insertion of a base opposite the lesion. However, this very property causes 
TLS polymerases to become intrinsically more error-prone than the replicative 
polymerases. The low fidelity of TLS is therefore due partly to bypassing past lesions, 
the reduced fidelity of TLS polymerases and the fact that the TLS polymerases do not 
have proofreading activity (Cleaver et al. 1999; Limoli et al. 2002; Limoli, Laposa, and 
Cleaver 2002). On the other hand, this tolerance pathway can be advantageous in 
specific physiological scenarios as demonstrated in somatic hypermutation of 
immunoglobulin genes by increasing desired genetic variability. A critical player in the 
TLS pathway is the deoxycytidyl transferase REV1 (UV-induced reversion 1), an 
enzyme that inserts deoxycytidine (dC) across from DNA lesions (Nelson, Lawrence, 
and Hinkle 1996a). The importance of this factor in DNA damage tolerance is clear as 
absence of Rev1 in cells causes hypersensisitivity to DNA damaging agents (Lemontt 
1971; Simpson and Sale 2003). However, cells expressing a catalytic dead version of 
REV1 do not cause hypersensitivity to DNA damaging agents, suggesting an alternative 
function of Rev1 is required for genome stability (Ross, Simpson, and Sale 2005). 
Indeed, the extreme carboxyl terminus of vertebrate REV1 has been shown to interact 
with TLS DNA polymerases (Guo et al. 2003; Ohashi et al. 2004; Tissier et al. 2004) 
and with DNA polymerase ζ via its REV7 (UV-induced reversion 7) subunit 
(Murakumo et al. 2001). Interestingly, the deletion of this domain causes no sensitivity 
to DNA damaging agents suggesting that the recruitment of TLS enzymes via REV1 
permits to bypass lesions caused by genotoxic agents (Ross, Simpson, and Sale 2005). 
In addition to Rev1, post-translational modifications of PCNA (proliferating cell 
nuclear antigen) provide a scaffold to which the various TLS polymerases bind to gain 
access to the replicative ensemble stalled at the lesion site and to execute their roles in 
lesion bypass (Hoege et al. 2002; Stelter and Ulrich 2003; Kannouche, Wing, and 
Lehmann 2004; Watanabe et al. 2004; Bi et al. 2006; Garg and Burgers 2005). 
 Overall, the evolution of highly specialised pathways permitted cells to repair 
the diverse set of DNA lesions they are exposed to thereby preventing cell death. 
Furthermore, another critical role for DNA repair is to suppress mutations from arising.  
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1.3 - DNA repair and mutagenesis 
 
 DNA mutations exist in different forms: there are base substitutions or point 
mutations, in which a single nucleotide is changed; insertions and deletions, in which a 
sequence of one or more nucleotides is inserted or deleted from the DNA sequence, 
respectively; and also chromosomal abnormalities, which can change the number and 
the structure of chromosomes in a cell. These mutations arise via five main mechanisms 
which include errors in DNA replication (generated by TLS or by errors made by high 
fidelity DNA polymerases), genotoxin exposure (endogenous or environmental 
mutagens), DNA enzymatic activity (e.g. cytidine deaminase enzymes which 
introduces C to T mutations) and errors in DNA repair. DNA repair causes mutagenesis 
via misrepair of DNA lesions, which occurs namely when DNA lesions are not 
accurately repaired and hence accumulate mutations at the previously damaged site. In 
addition, mutations may also arise in the absence of DNA repair factors as exemplified 
by the increase in mutation rate whenever the BER (Sobol et al. 2002) or MMR 
pathways are depleted (Kato and Nakano 1981). Furthermore, HR repair generates 
genomic rearrangements involving repeated DNA elements with identical 
(homologous) or near-identical (homeologous) sequences which may also generate 
genomic mutations (Putnam, Hayes, and Kolodner 2009). The importance of DNA 
repair in regulating mutagenesis is evident as failure to correctly repair DNA damage 
results in mutations that at a cellular level cause neoplastic transformation or 
death/dysfunction (Nakane et al. 1995; Kaina et al. 1997). At a physiological level there 
is loss of tissue homeostasis or an increased cancer predisposition (Reitmair et al. 1995; 
Prolla et al. 1998). In the past few years, large-scale analyses have revealed many 
mutational signatures across the spectrum of human cancer types (Alexandrov, Nik-
Zainal, Wedge, Aparicio, et al. 2013; Alexandrov, Nik-Zainal, Wedge, Campbell, et al. 
2013; Nik-Zainal et al. 2012; Alexandrov and Stratton 2014). As examples of how 
failure to undergo DNA repair promotes mutagenesis is the emergence of mutational 
signature 3, which occurs in tumours lacking HR. This signature is associated with 
increased burden of large indels (up to 50 nucleotides) with overlapping 
microhomology at the breakpoints (Alexandrov, Nik-Zainal, Wedge, Campbell, et al. 
2013). In such tumours, DSBs in DNA are repaired by the imprecise repair mechanisms 
of NHEJ or MMEJ instead of via the high fidelity HR repair. Also, signature 6, which 
is observed in tumours defective of MMR exhibiting micro-satellite instability, also 
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features enrichment of 1 base pair indels in nucleotide repeat regions (Alexandrov, Nik-
Zainal, Wedge, Campbell, et al. 2013). Besides leading to cancer predisposition, the 
absence of DNA repair causes various syndromes in human patients with tissue specific 
phenotypes ranging from immunodeficiency, neurodegeneration, progeria and/or 
infertility. 
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1.4 - Tissue specificity in the DNA repair deficiency phenotypes 
 
 One example of the tissue specificity observed in DNA repair deficiency 
phenotypes is the absence of the repair factor BRCA1 (Breast cancer 1) which is 
involved in repairing DNA DSBs via HR. Women carrying a germ line mutation in 
BRCA1 have an increased risk of developing breast cancer from 12% to 72% and from 
1.3% to 40% to develop ovarian cancer (Kuchenbaecker et al. 2017). The underlying 
cause of oncogenesis in these defined tissues in female patients is not entirely clear. 
However, there is accumulating evidence for deregulated hormonal signalling in 
BRCA1 mutation carriers to drive oncogenesis. This is corroborated by the increase in 
cancer development during pregnancy, when there are high circulating levels of steroid 
hormones (Narod 2001) and a sharp decline in cancer risk after menopause (Antoniou 
et al. 2003). Evidence suggests that steroid hormones produced specifically in luminal 
progenitor cells promote cellular proliferation which therefore increases the chances of 
mutations to occur due to faulty DNA repair and/or replication leading to a biallelic 
mutation that promotes tumourigenesis (Nolan, Lindeman, and Visvader 2017). The 
development of cancer in defined tissues in the absence of DNA repair reflects a 
differential requirement for DNA repair mechanisms in different tissues. This tissue 
specificity for DNA repair has three main explanations: Firstly, some cells in our bodies 
are more exposed to certain sources of damage. To illustrate this, Xeroderma 
pigmentosum patients, who lack a form of DNA repair responsible to deal with damage 
caused by ultra-violet (UV) radiation, exhibit abnormalities in the skin tissue if exposed 
to sunlight due to increased mutagenesis in this tissue (de Vries et al. 1995). Secondly, 
cells of different tissues can use different repair mechanisms to repair the same lesion 
e.g. in Cockayne syndrome, patients lack the ability to perform transcription-coupled 
(TC) DNA repair of bulky DNA adducts, which causes these patients to develop 
neurodegeneration. One explanation for the specific requirement of TC repair in 
neurons may be the fact that neurons are post-mitotic cells and therefore cannot detect 
damage during replication. This may render neurons more dependent on TC repair than 
other cells, as this pathway may be the main or only mechanism to detect forms of 
damage in this cell type (Cockayne 1936). Thirdly, different cell types may have 
different DNA damage checkpoints that will respond to an insult in a differential 
manner. The DNA damage checkpoint is normally mediated by Trp53 
(Transformation-related protein p53), the so called guardian of the genome, which was 
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first described to be active upon DNA damage induced by UV irradiation (Kapoor and 
Lozano 1998). Furthermore, deletion of this gene confers cellular resistance to DNA 
damage which therefore avoid apoptosis and progress through the cell cycle (Lee and 
Bernstein 1993). Several DNA repair phenotypes in mice can be suppressed by co-
depleting Trp53. To illustrate this, Lig4 (DNA ligase 4) deficient mice display 
embryonic lethality due to neuronal apoptosis (Barnes et al. 1998). These mice also 
show defects in lymphocyte development and Lig4-deficient cells exhibit defective 
proliferation, senescence and sensitivity to ionising radiation (Barnes et al. 1998). It has 
been shown that co-depletion of Trp53 together with Lig4 can suppress the neuronal 
apopotosis phenotype rescuing the embryonic lethality. However, it does not rescue the 
lymphocyte development and radiosensitivity phenotypes observed in the single-
knockout mice (Frank et al. 2000). In addition to Trp53, two other genes from the same 
family exist: Trp63 and Trp73 (Belyi et al. 2010). Evidence suggests that both genes 
can also mediate DNA damage checkpoints (Bolcun-Filas et al. 2014; Urist et al. 2004). 
Interestingly, Trp63 but not Trp53 can rescue the oocyte numerical defect in ovaries 
treated with ionising radiation (Suh et al. 2006). This therefore suggests that different 
cell types may have different DNA damage checkpoints further highlighting the 
importance of the tissue specificity in the DNA damage response.  
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1.5 - The importance of DNA repair in the germ line 
 
 The tissue specificity observed in DNA repair suggests that different tissues 
may also have different rates of mutagenesis. Moreover, the tissue or cell type in which 
a mutation occurs is of critical importance. Whenever a mutation occurs in a somatic 
cell, the organism can develop a particular pathology linked to that mutation. However, 
the consequence of that mutation will be confined to a single organism and have no 
further consequences for the progeny. On the other hand, if a mutation occurs in the 
germ line, this mutation can be passed on to the progeny. If this mutation is deleterious 
it may negatively impact the fitness of the next generations but on the other hand, if a 
neutral or beneficial mutation occurs, it can drive the evolution of that species. 
Therefore, from an evolutionary standpoint, it is beneficial for a species to maintain the 
integrity of the genome in the germ line in order to protect the fitness of the future 
generations and the survival of the species but at the same time providing sufficient 
genetic diversity to permit potential advantageous phenotypes in changing selective 
pressures. In the “theory of the disposable soma” proposed in 1977 by T.B. Kirkwood 
he postulated that high-fidelity quality control that reduces errors made during somatic 
maintenance is costly and that these costs compete with the costs of reproduction. 
Because resources are limited, investing into error-proof somatic maintenance is 
wasteful and not an evolutionarily stable strategy. In this sense, the soma is disposable 
and investment into somatic maintenance has to be optimised to allow error-prone 
repair in order to invest the rest of the limited resources into reproduction (Kirkwood 
1977). This postulate suggests that organisms invest and have evolved mechanisms to 
maintain the integrity of the genome of germ cells pristine for the subsequent 
generations at the expenditure of more energy and in a differential manner compared 
to how the genome is protected in the disposable somatic cells. To corroborate this 
theory, evidence exists showing that mammalian germ cells have a reduced mutation 
frequency compared to the somatic counterparts (Kohler et al. 1991; Dycaico et al. 
1994; Hill et al. 2005). De novo mutations arise in the germ line at a rate of ~1-1.5 x 
108 for point mutations in humans, not only determining our genome evolution but also 
causing 20% of genetic disorders present in live-born human offspring (Michaelson et 
al. 2012). De novo mutations in the germ line include point mutations but also 
numerical and structural chromosomal abnormalities, changes in gene dosage due to 
duplications or deletions or remodelling of chromosomes by translocations or 
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inversions. These mutations arise during germ cell development and exhibit sexual 
dimorphism. On the one hand, the rate of chromosomal abnormalities transmitted by 
the female is greater than the rate passed by the male germ line (Hassold and Hunt 
2001). The majority of these abnormalities results from defects during meiosis. Meiosis 
is a significant threat to the stability of the genome as this process necessitates 
programmed DSB formation. The initiation of these breaks and the resolution of these 
very toxic lesions are essential to the meiotic process, however pose a significant threat 
to genome integrity and therefore necessitate the DNA repair machinery. Failure to 
correctly repair meiotic intermediates is an important source of structural abnormalities 
in the germ line. Even though meiosis occurs in both males and females it is the female 
germ line that is responsible for passing the majority of structural abnormalities to the 
progeny (Hassold and Hunt 2001). This is largely explained by the fact that all oocytes 
initiate meiosis during embryonic development but arrest immediately after synapses 
of homologous chromosomes and initiation of recombination. Oocytes, already 
committed to meiosis, remain arrested in prophase I until completion of meiosis, which 
occurs years later in the ovary of sexually mature females, prior to ovulation. Since this 
period can exceed 40 years in humans, it greatly increases the risk of abnormalities in 
the meiotic spindle, which have been further shown to accumulate with age (Battaglia 
et al. 1996). This explains the increased prevalence of structural abnormalities in the 
female germ line. On the other hand, it has been known for more than 60 years that the 
male germ line is responsible for the generation of the majority of de novo mutations 
(Haldane 1947). These are more frequently point mutations and the increased burden is 
largely due to the increased the number of mitotic divisions that the spermatogonial 
stem cells (SSCs) undergo during self-renewal and proliferation (Drost and Lee 1995). 
In stark contrast to the female germ cells (estimated to undergo 31 rounds of division 
in humans), male germ cells undergo ~401 rounds of divisions, which increases the 
chance of mutations occurring during DNA replication, thereby explaining the 
increased rate of de novo mutagenesis in the male germ line (Drost and Lee 1995). 
Furthermore, ageing also contributes to the accumulation of point mutations in the male 
sperm, with an estimated rate of 2 new mutations per year in humans (Kong et al. 2012). 
Moreover, the age of the father at the time of conception correlates with the incidence 
of polygenic disorders like schizophrenia and autism in progeny (Sipos et al. 2004; 
Hultman et al. 2011). This suggests that the increased burden of mutagenesis can lead 
to severe phenotypic consequences in the progeny. 
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 In addition to mature germ cells, primordial germ cells (PGCs), i.e. the 
precursors of egg and sperm that are specified early during embryonic development 
(Figure 2), may also be prone to mutagenesis. Indeed, a recent study showed that the 
highest mutation rate per cell division in the germ line of both males and females was 
observed during PGC development (Rahbari et al. 2016).  
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Figure 2. The mammalian germ cell lineage. The germ line is responsible for passing genetic 
information from one generation to the next. The germ line emerges as PGCs around E7.25 near the 
extra-embryonic ectoderm, at the base of the allantois. These cells migrate to the developing midgut at 
around E7.75, into the mesentery at E9.5 and colonise the genital ridges at ~E10.5. During migration, 
PGCs undergo an epigenetic reprogramming, most notably genome-wide DNA demethylation, including 
imprint erasure in both sexes (Saitou, Kagiwada, and Kurimoto 2012). In the fetal gonads a striking 
sexual dimorphism occurs in germ cell maturation. In females, PGCs proliferate until E13.5 in which 
25,000 cells (oogonia) start prophase I of meiosis These cells are then named oocytes and arrest at the 
diplotene stage of prophase I (Borum 1967). Upon hormonal stimulation, meiosis progresses with the 
extrusion of the first polar body and finally, during fertilisation, the second polar body is extruded 
finishing the second meiotic division. Subsequent formation of the zygote and embryo progression 
reinitiates the germ cell cycle. In males, PGCs undergo a mitotic arrest around E13.5 remaining quiescent 
in G0/G1 (gonocytes) until postpartum day 3-7 (P3-7) (Hilscher et al. 1974; Western et al. 2008). At P3-
7 gonocytes resume proliferation becoming spermatogonial stem cells (SSC). SSC proliferate and self-
renew producing spermatocytes that meiotically divide to form spermatids. During spermiogenesis, 
spermatids differentiate into mature and functional gametes, spermatozoa, which can fertilise the egg 
and further reinitiate the cycle. 
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 1.6 - Primordial germ cell development 
 
 In order to study the importance of DNA repair in PGCs and how germ line 
mutagenesis is suppressed in this particular cell population, one must first understand 
the unique biology of PGCs. PGCs are the precursors of egg and sperm which generate 
a new organism upon fertilisation. The specification of germ cells in animals occurs via 
two forms: in model organisms like D. melanogaster, C. elegans, D. rerio, and X. 
laevis the specification occurs via the inheritance of preformed germ plasm in a process 
named preformation or determinative mode of germ line establishment (Whittle and 
Extavour 2017). However, in mammals and axolotls, PGCs are specified by epigenesis 
which occurs via induction among equipotent cells in the embryo by instructive signals 
(Whittle and Extavour 2017). In mice, PGCs originate from the early postimplantation 
epiblast cells, which also gives rise to all somatic cells in response to signals from the 
extraembryonic tissues (Lawson and Hage 1994). In order to achieve totipotency, PGCs 
undergo extensive epigenetic reprogramming which permits the repression of the 
somatic transcriptional programme and activation of pluripotency genes such as Nanog, 
Oct4 (Octamer-binding protein 4), cMyc (Avian Myelocytomatosis Viral Oncogene 
Homolog) and Klf4 (Kruppel like factor 4) (Ohinata et al. 2005; Yabuta et al. 2006; 
Yamaguchi et al. 2005). Additionally, this epigenetic reset leads to the erasure of 
imprints, causes the reactivation of the X-chromosome and is believed to turn on 
specific genes required for the progression towards gametogenesis (Monk and McLaren 
1981; Hill et al. 2018). The maternal and paternal imprints are erased in PGCs to allow 
new imprints to be established (Lee et al. 2002). These imprints are not of parental 
origin but are determined by the sex of the developing embryo. This process is not only 
essential to make functional germ cells, competent of generating a zygote capable of 
normal development, but also prevents parthenogenesis (Surani, Barton, and Norris 
1984). In female somatic cells, one X-chromosome is inactivated, which balances X-
linked gene expression with that of the male XY cells (Lyon 1961). This process must 
be reversed in the germ line so that both X chromosomes are active following meiosis. 
The epigenetic reprogramming taking place in gonadal PGCs has also been recently 
shown to promote the activation of a subset of genes, named germ line reprogramming-
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responsive genes which are involved mainly in gamete generation and meiosis, 
therefore permitting sexual reproduction (Hill et al. 2018). 
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1.6.1 - Epigenetic reprogramming 
 
 In more detail, epigenetic reprogramming entails the erasure and remodelling 
of epigenetic marks, including DNA methylation but also covalent modifications of 
histones in order to permit the acquisition of pluripotency. This occurs during 
mammalian development and can also be induced in tissue culture. Epigenetic 
reprogramming in vitro can be recapitulated to some extent in three different systems: 
somatic cell nuclear transfer (SCNT) (Gurdon 1962), induced pluripotent stem cell 
(iPSC) generation (Takahashi and Yamanaka 2006) and cell fusion (Tada et al. 2001). 
The key feature outlining in vivo reprogramming processes are also observed in vitro 
suggesting that similar molecular pathways are involved. However, the efficiency in 
generating pluripotent cells in vitro is very low and time consuming in comparison to 
reprogramming observed in vivo. In vivo epigenetic reprogramming occurs in two 
distinct stages: during early mammalian pre-implantation development and also during 
embryonic germ cell development. During early mammalian pre-implantation 
development there is firstly the erasure of DNA methylation in the paternal pronucleus 
of the zygote a few hours after the fertilisation (Mayer et al. 2000); secondly, a gradual 
(passive) loss of DNA methylation during the cleavage stages (Rougier et al. 1998); 
and thirdly, reshaping of heterochromatin based silencing in the pluripotent cells of 
inner cell mass (ICM)/early epiblast connected with the re-activation of inactive X 
chromosome in female embryos (Okamoto et al. 2004). Epigenetic reprogramming in 
early pre-implantation embryos culminates with the appearance of pluripotent cells of 
ICM in the blastocyst. The second time in development in which epigenetic 
reprogramming occurs is during the development of the germ line. The developing 
germ cell lineage has the unique property of being able to reacquire totipotency as 
evidenced by the ability to generate gametes which will give rise to a new organism. 
This is achieved after specification of the germ line into PGCs and happens in two 
distinct phases of DNA demethylation: Phase I, which occurs in pre-gonadal PGCs 
from ~E8.0 to E10.5 in migratory PGCs and Phase II, which occurs in gonadal PGCs 
from E10.5 to E13.5 (Figure 3) (Hargan-Calvopina et al. 2016; Seisenberger et al. 
2012). Epigenetic reprogramming in PGCs has been suggested to occur in a DNA 
repair-dependent manner (Hajkova et al. 2010). This therefore may contribute for 
mutagenesis control in the germ line. In order to understand how epigenetic 
reprogramming occurs in PGCs and how this process affects germ line mutagenesis it 
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is essential to understand how these cells are formed and develop before becoming 
mature germ cells. 
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Figure 3 - A summary of mouse PGC development. A summary of the main genomic events occurring 
in PGCs from E5.5 to E13.5: temporal expression patterns of key proteins involved in PGC specification 
and epigenetic regulators responsible for epigenetic reprogramming; and chromatin modifications 
occurring from PGC specification to gonocyte formation. ND - not determined. 
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1.6.2 - Specification 
 
 In mice, the progenitors of PGCs are located in the most proximal region of the 
postimplantation epiblast, close to the extraembryonic tissues. These PGC precursors 
are detected in the epiblast at embryonic day (E) 6.0-6.5, and eventually generate a 
founding population of ~40 PGCs at the base of the incipient allantois at ~E7.25 
(Chiquoine 1954; Ginsburg, Snow, and McLaren 1990; Lawson and Hage 1994). The 
instructive signals for PGC specification are the bone morphogenetic proteins BMP4 
(Lawson et al. 1999; Fujiwara, Dunn, and Hogan 2001; Ohinata et al. 2009) and 
BMP8B (Ohinata et al. 2009; Ying et al. 2000) from the posterior extra-embryonic 
ectoderm and BMP2 (Ying and Zhao 2001) from the visceral endoderm. These 
cytokines bind to membrane receptors that phosphorylate SMAD1 and SMAD5, which 
dimerise then with SMAD4, translocate to the nucleus and induce transcriptional 
regulators of PGC fate (Hayashi et al. 2002; Lawson et al. 1999; Tam and Snow 1981; 
Ying, Qi, and Zhao 2001). These include Blimp1 (B-lymphocyte-induced maturation 
protein 1) initially expressed at ~E6.25 (Ohinata et al. 2005), Prdm14 (PR domain-
containing protein 14) at ~E6.5 (Yamaji et al. 2008) and Tcfap2c (Transcription factor 
AP-2 gamma) at ~E6.75 (Kurimoto et al. 2008; Auman et al. 2002). Blimp1 is a 
transcriptional repressor that is expressed in a few most proximal epiblast cells at 
~E6.25, marking the onset of PGC specification (Lawson and Hage 1994). Blimp1 
deficiency in mice results in a small cluster of aberrant PGC-like cells at ~E8.5 that 
resemble the neighbouring somatic cells due to failure to repress somatic gene 
expression and to induce PGC-specific genes (Ohinata et al. 2005). A comparison 
between Wild type and Blimp1-deficient PGCs was subsequently critical for the 
identification of Prdm14 (Grabole et al. 2013; Kurimoto et al. 2008; Yamaji et al. 
2008). Prdm14 is also a transcriptional repressor and its depletion from mice leads to 
the formation of aberrant PGCs that are lost by ~E11.5. These cells exhibit a defective 
epigenetic programme, based on the failure of the characteristic global erasure of 
H3K9me2 histone modification at ~E8.5, partly because the Ehmt1-Ehmt2 
(Euchromatic histone lysine methyltransferase) mediated H3K9 methylasae activity 
was not repressed. Prdm14-deficient PGCs also fail to show genome-wide induction of 
the EZH2 (Enhancer of zeste 2 Polycomb repressive complex 2 subunit) mediated 
H3K27me3. This suggests that Prdm14 is important at least for the epigenetic 
programme in early germ cells (Hajkova et al. 2008; Hajkova et al. 2010; Yamaji et al. 
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2008; Seki et al. 2007). Furthermore, Blimp1 expression is sustained by Prdm14, which 
might explain the induction of somatic genes in mutant cells (Grabole et al. 2013). 
Prdm14 also induces the expression of Stella and Sox2 (Sex determining region Y-Box 
2) at ~E8.5. Thus, neither PGC-specific gene expression nor the re-initiation of 
pluripotency gene expression occurs in Prdm14-null PGCs (Grabole et al. 2013; Yamaji 
et al. 2008). Finally, Tcfap2c, which encodes AP2γ (a direct target of BLIMP1), is a 
basic helix-span-helix domain transcription factor also crucial for PGC specification 
(Kurimoto et al. 2008; Magnusdottir et al. 2013; Weber et al. 2010). Depletion of 
Tcfap2c in mice causes a PGC numerical defect around E8.0 (Weber et al. 2010). 
Although these cells remain to be fully characterised, it is likely that AP2γ might also 
be involved in the repression of somatic genes, including the early mesodermal marker 
Hoxb1 (Homeobox b1)(Weber et al. 2010). Blimp1, Prdm14 and Tcfap2c together 
constitute a mutually interdependent transcriptional network that promotes PGC 
specification (Magnusdottir et al. 2013) via repressing somatic genes and promoting 
the totipotent state. In addition to these germ line specifiers, single-cell analysis of gene 
expression of the founder population of PGCs at E7.25 identified two genes, namely 
Fragilis and Stella, which are highly and specifically, respectively, expressed in PGCs 
(Saitou, Barton, and Surani 2002). Fragilis (also known as Ifitm3 - Interferon induced 
transmembrane protein 3) (Tanaka and Matsui 2002) is a member of the interferon-
inducible transmembrane proteins. This gene begins to exhibit expression around the 
most proximal epiblast cells at E6.25–E6.5, and its expression intensifies in the 
posterior extra-embryonic mesoderm, where alkaline phosphatase-positive PGCs arise 
at E7.0–E7.25. Stella (also known as Dppa3 - Developmental pluripotency associated 
3) is a small highly basic nucleo–cytoplasmic shuttling protein (Sato et al. 2002). Stella 
begins to be expressed specifically in Fragilis-expressing cells in the extra-embryonic 
mesoderm at E7.0–E7.25 and continues to be expressed in migrating PGCs. Stella-
positive cells show high expression of Tnap (tissue nonspecific alkaline phosphatase), 
a gene for AP activity of PGCs (MacGregor, Zambrowicz, and Soriano 1995). Stella-
positive cells and high levels of Fragilis repress the expression of Homeobox genes 
such as Hoxb1 and Hoxa1, whereas Fragilis-positive but Stella-negative cells retain 
Hox expression (Saitou, Barton, and Surani 2002). Thus, it has been proposed that the 
Stella-positive and Hox-negative cells are the established PGCs (Saitou, Barton, and 
Surani 2002). However, knocking out both Fragillis and Stella in mice shows that 
neither is essential for PGC specification (Payer et al. 2003; Lange et al. 2008). Instead, 
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Stella has been found to be a critical factor to protect the maternal genome and 
paternally imprinted genes from genome-wide DNA demethylation that occurs in the 
zygotes (Nakamura et al. 2007; Huang et al. 2017; Li, Zhang, et al. 2018), whereas 
Fragilis has a critical function in restricting the replication of multiple pathogenic 
viruses including influenza (Brass et al. 2009). After specification, PGCs start DNA 
demethylation, which permits the acquisition of the totipotent state. 
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1.6.3 - Migratory PGCs (E7.75 to E10.5) 
 
 Once specified, PGCs migrate to the developing midgut at around E7.75, into 
the mesentery at E9.5 and colonise the genital ridges at ~E10.5. During this migratory 
period, PGCs initiate a progressive cell-by-cell genome-wide DNA demethylation 
process which is associated with extensive chromatin remodelling, transcriptional 
quiescence and an arrest in the G2 phase of the cell cycle (Seki et al. 2007). It has been 
demonstrated that nascent PGCs downregulate Glp, a cofactor of EHMT2 H3K9 
histone methyltransferase, leading to a genome wide loss of H3K9me2 specifically in 
early PGCs (Hajkova et al. 2008; Seki et al. 2007). The combination of a lack of the 
common cross-talk between H3K9me2 and DNA methylation (Cedar and Bergman 
2009), and the additional observed downregulation of de novo DNA methyltransferases 
Dnmt3a and Dnmt3b in nascent PGCs (Kurimoto et al. 2008), may explain the 
reduction in DNA methylation after PGC specification. Considering these observations, 
a model of passive DNA demethylation has been proposed for migratory PGCs 
(Seisenberger et al. 2012). However, the complete lack of both maintenance and de 
novo DNA methylation would lead to much faster and extensive DNA demethylation 
than is observed in migratory PGCs (Seisenberger et al. 2012; Yamaguchi et al. 2013; 
Kagiwada et al. 2013). Additionally, some of the genomic regions, such as genomic 
imprints, seem to maintain DNA methylation levels throughout this period of PGC 
development (Hajkova et al. 2010; Seisenberger et al. 2012; Hajkova et al. 2008; 
Guibert, Forne, and Weber 2012). This suggests that the mechanism implicated in the 
loss of 5mC in pre-gonadal PGCs is likely to be more complex. In addition, during 
migration pre-gonadal PGCs undergo a period in which RNA polymerase II is quiescent 
(Seki et al. 2007). On the one hand this is believed to impede the toxicity of transposable 
elements that become active during DNA demethylation and on the other hand to 
restrict the transcriptional programme of PGCs impeding these cells to differentiate to 
somatic cells. This repression can be accomplished by the Polycomb family proteins 
through promoter inhibition and consequent chromatin remodelling, which leads to 
inactivation of transcription. Another level of RNA polymerase II-depended 
transcriptional repression in migratory PGCs is chromatin-based repression through 
post-translational modifications of histones and increased chromatin compaction. A 
prominent member of this class of proteins is HP1 (Heterochromatin protein 1), which 
is represented by several variants in Metazoa. The absence of Cbx3 (Chromobox 3) also 
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known as HP1γ (Heterochromatin protein 1 gamma) in mice causes failure to produce 
normal numbers of PGCs at E.7.25 which emphasises the importance of HP1 during 
PGC development (Abe et al. 2011). Nevertheless, there is no link between the RNA 
pol II quiescence and chromatin modification and Seki et al. observed no alterations in 
H3K4me2 and H3K4me3 that were previously associated with transcriptionally 
permissive/active states compared to the somatic counterparts. This therefore suggests 
that the RNA pol II quiescence may be independent of the chromatin status. 
Interestingly, a majority of migrating PGCs (∼60%) from around E8.0 to around E9.0, 
are shown to be in the G2 phase of the cell cycle. This has also been shown to occur in 
PGCs collected from pig embryos and in mouse PGCs induced in vitro from pluripotent 
stem cells (Hyldig et al. 2011; Hayashi et al. 2011). Blimp1 may be a key factor for the 
G2 arrest, since it is involved in the repression of S-phase promoting factors e.g. Ccne1 
and Ccnd1 (Cyclin E1 and D1), Cdc25a and Cdc6 (Cell division cycle 25A and 
6), Pold2 (DNA Polymerase delta 2), E2F3 (E2F transcription factor 3), and Myc 
(Kurimoto et al. 2008) These observations indicate that PGC specification creates a 
unique cellular state for the epigenetic reprogramming: PGCs repress key active 
epigenetic enzymes, arrest at the G2 phase of the cell cycle, and pause RNA Pol II-
based transcription. However, the interplay between these three processes in migratory 
PGCs remains largely unexplored. 
 
1.6.4 - Gonadal PGCs (E10.5 to E13.5) 
 
 The last major event that characterises early germ line development is the rapid 
and global epigenetic reprogramming that occurs in PGCs upon colonisation of the 
gonads where the germ cells will reside throughout the rest of embryonic and adult life. 
This process, also named as phase II of reprogramming, includes DNA demethylation 
which involves the erasure of parental imprints, demethylation of both single-copy 
genes and transposable/repetitive elements and reactivation of inactive X chromosome 
in females (Guibert, Forne, and Weber 2012; Monk, Boubelik, and Lehnert 1987; Kafri 
et al. 1992). Following gonadal epigenetic reprogramming, the genome of PGCs shows 
the lowest level of genome-wide DNA methylation seen at any point of development. 
This global hypomethylated state is long lived and lasts until postnatal development in 
female germ cells that start to reacquire DNA methylation only during the oocyte 
growth in postnatal ovaries (Kelsey and Feil 2013); on the contrary, male germ cells 
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start to accumulate DNA methylation relatively quickly only a few days following the 
global reprogramming (Kelsey and Feil 2013). 
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1.7 - Molecular mechanisms of DNA demethylation and link to DNA 
repair 
 
 The molecular mechanism underlying the active genome-wide removal of DNA 
methylation in PGCs remains subject of intensive study. Conceptually, the mechanism 
of DNA demethylation can be separated by their dependence on DNA replication: DNA 
methylation patterns are typically maintained during DNA replication in a faithful 
manner due to the activity of the Dnmt1 (de novo DNA methyltransferase 1) which is 
tethered by Uhrf1 (Ubiquitin like with PHD and ring finger domains 1) to the 
replication fork and hemi-methylated DNA (Sharif et al. 2007; Bostick et al. 2007). 
Loss of this maintenance methylation activity results in passive DNA demethylation, a 
gradual loss of DNA methylation which has been demonstrated in systems lacking 
Dnmt1 or Uhrf1. This system explains the demethylation of the maternal pronucleus in 
the early pre-implantation embryo but fails to explain the rapid replication-independent 
paternal pronucleus demethylation and DNA demethylation in gonadal PGCs. 
Therefore, as an alternative mechanism, active DNA demethylation would lead to the 
removal of 5mC in a replication independent manner. In flowering plants the 5mC 
specific glycosylases Dme (DEMETER) and Ros1 (Repressor of transcriptional gene 
silencing 1) are used to actively remove 5mC from DNA (Morales-Ruiz et al. 2006). 
However, the family of 5mC specific DNA glycosylases have evolved independently 
in flowering plants with no direct sequence homology in Metazoa. Since it was 
observed that Tet1 (Ten-eleven translocation 1) is upregulated in PGCs (Hajkova et al. 
2010; Hackett et al. 2013) a mechanism of Tet-dependent active demethylation in PGCs 
with TET enzyme-dependent modification of 5mC to 5hmC subsequently being 
removed via BER was proposed. This could occur via different mechanisms. There is 
evidence that the cytosine deaminases AID (Activation induced cytidine deaminase and 
APOBEC1 (Apolipoprotein B mRNA editing enzyme catalytic subunit 1) can convert 
5mC to thymidine (T) by deamination, creating thereby T:G mismatches, which then 
become targets of glycosylases such as TDG or MBD4 (Methyl-CpG binding domain 
4). Tdg knockout mice die during embryonic development (Cortazar et al. 2011; 
Cortellino et al. 2011). Furthermore, Tdg has been shown to maintain the unmethylated 
state of CpG islands in promoters of developmentally regulated genes (Cortazar et al. 
2011) and in promoters of Wild type cells, TDG forms a complex with BER pathway 
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components, including XRCC1 (X-ray repair cross complementing 1), APE1 
(Apurinic-apyrimidinic endonuclease 1) and PARP1 (Poly(ADP-ribose) polymerase 
1), and with the transcription-activating histone acetyltransferase CBP/p300 and the 
H3K4-specific Lysine methyltransferase 2A (Kmt2a). Moreover, TDG-deficient mouse 
embryonic fibroblasts (MEFs) show an iPSC conversion defect similar to Tet triple 
knockout (TKO) MEFs, supporting the model of DNA demethylation through TDG 
driven excision of higher 5mC oxidative derivatives (Hu et al. 2014). However, to 
counterpoint this, depletion of TDG in early zygotes does not affect active paternal 
pronucleus DNA demethylation (Guo et al. 2014). Tdg interacts with Gadd45a (Growth 
arrest and DNA damage inducible alpha) which is another factor reported to play roles 
in DNA demethylation (Li et al. 2015) and Aid. Aid-deficient male and female PGCs at 
E13.5 show median methylation levels of ~22% and 20%, respectively, which are both 
higher than the methylation levels of Wild type male and female PGCs (16.3% and 
7.8%, respectively), indicating that AID functions in genome-wide DNA demethylation 
in PGCs (Popp et al. 2010). Importantly, Aid deficiency does not impact genome-wide 
methylation levels in cells/tissues other than PGCs (Popp et al. 2010). However, AID 
is expressed at a very low level in PGCs (Hajkova et al. 2008; Muramatsu et al. 2000) 
and Aid-deficient mice are fertile showing that Aid does not play an essential role in 
germ cell development (Muramatsu et al. 2000). As the methylation levels of AID-
deficient PGCs are still lower compared to those of earlier Wild type PGCs, the 
demethylation events occur even without AID, possibly owing to compensation by 
other deaminases, including APOBEC1/2/3. Furthermore, it was reported that BER 
actively triggers DNA demethylation as evidence shows components of the BER 
pathway such as XRCC1, APE1 and PARP1 specifically concentrated in the nuclei of 
gonadal PGCs (Hajkova et al. 2010). To corroborate this, it has been recently shown 
that absence of the BER factor Xrcc1 in mouse zygotes results in DNA lesions in the 
paternal pronucleus in a Tet3-dependent manner (Ladstatter and Tachibana-Konwalski 
2016). This further suggests that there may be a requirement for BER to process DNA 
lesions generated during active DNA demethylation. Whether this process is intimately 
linked to active DNA demethylation in zygotes and PGCs still remains to be clarified. 
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1.8 - Evidence of genomic instability in developing PGCs 
 
 Even though it still remains unclear how DNA demethylation occurs in PGCs 
and how this is dependent on DNA repair, it is established that during PGC 
development there is a specific requirement for DNA repair to ensure the correct 
formation of this cell population. This is demonstrated by the sterility phenotypes 
observed in DNA repair deficient mice due to PGC numerical defects (Table 1). 
 
Gene Ontology 
Time of 
defect 
PGC phenotype Reference 
Rev7 TLS E9.5 ND Pirouz, M., et al. (2013) 
Espl1 Cell division E12.5 Proliferation Huang, X., et al. (2008) 
Pds5b Cohesion ≤ E12.5 Proliferation Zhang, B., et al. (2007) 
Fanca FA E11.5 Survival/proliferation Wong, J.C., et al. (2003) 
Fancb FA E9.5 Survival/proliferation Kato, Y., et al.(2015) 
Fancl FA E9.5 Survival/proliferation Agoulnik, A.I., et al. (2014) 
Fancm FA E12.5 Proliferation Luo, Y., et al. (2014) 
Ercc1 FA/NER/HR E11.5 DNA damage/apoptosis Hill and Crossan (2019) 
Mcm9 HR/replication/MMR E11.5 Proliferation Luo, Y., et al. (2015) 
Rad54 HR ≤ E11.5 ND Messiaen, S., et al. (2013) 
Prmt5 Arginine methyltransferase ≤ E11.5 TE activation Kim, S., et al. (2014) 
 
Table 1 - Representation of genome stability genes involved in PGC development. During PGC 
development, genes involved in DNA repair, cell division and chromatin modifications are required at 
different stages to ensure normal numbers of PGCs in the developing embryo. Depletion of any of these 
genes results in a temporally defined numerical defect with consequences for the integrity of the 
reproductive system. ND - not determined, TE - transposable elements 
 
 Furthermore, this suggests that during PGC development unique genomic 
transactions occur that render DNA repair essential for PGC development. During early 
development, PGCs undergo a unique G2 arrest that temporally overlaps with the phase 
I of DNA demethylation. It has been shown that mice deficient in Rev7 display a PGC 
defect that occurs during this period of PGC development (Pirouz, Pilarski, and Kessel 
2013; Watanabe et al. 2013). REV7 functions as an adaptor between the deoxycytidyl 
transferase REV1 and the catalytic subunit of Pol ζ, REV3 (UV-induced reversion 3), 
which is involved in replicating damaged DNA by TLS. Furthermore, Rev7 plays other 
roles in cell cycle regulation, pathway choice in DSB repair and chromatin remodelling 
(Listovsky and Sale 2013; Boersma et al. 2015; Rahjouei et al. 2017; Xu et al. 2015). 
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Therefore, it remains to be ascertained if TLS, namely polymerase ζ and its unique 
function of extending beyond the lesion, is indeed required for early PGC development. 
If proven true this suggests a unique requirement for TLS in PGCs and a potential 
source of damage occurring at this stage of development that should be avoided for 
correct formation of this cell population. Furthermore, the requirement for TLS in PGCs 
may present a strategy employed by the organism to promote genetic diversity by 
increasing the mutation rate. In addition to Rev7, there is emerging evidence showing 
that after the G2 arrest, inhibitory phosphorylation of separase plays a critical role in 
the maintenance of sister chromatid cohesion and genome stability in developing PGCs. 
Activity of separase, a cysteine protease that cleaves sister chromatid cohesin at the 
onset of anaphase, is tightly regulated via two mechanisms: inhibition by securin and 
phosphorylation on serine 1121. Point mutant mouse embryos unable to undergo this 
post-translational modification of separase show a PGC numerical defect at E12.5 
(Huang et al. 2008). Furthermore, mice lacking the sister chromatid cohesion factor 
Pds5b (Precocious dissociation of sisters 5b) also show PGC defects starting at least at 
E12.5 (Zhang et al. 2007). This indicates that during this proliferative expansion period, 
cells require cohesion for proper cell division to ensure the stability of the genome is 
maintained. Another repair pathway that has been shown to be involved in the 
proliferation of PGCs is the FA repair pathway. In female FA patients the reduced 
fertility manifests as primary ovarian insufficiency (POI) (Fouquet et al. 2017) whereas 
in males there is a severe decrease in spermatogenesis, often accompanied with 
diagnoses of non-obstructive azoospermia and Sertoli cell-only syndrome (Krausz et 
al. 2019). The requirement for the FA repair pathway for the correct development of 
PGCs and fertility has been shown in different mouse models of the disease (Kato et al. 
2015; Luo et al. 2014; Tsui and Crismani 2019; Wong et al. 2003; Agoulnik et al. 2002). 
The numerical defect in PGCs observed in the different mouse models seems to start 
around E11.5 and culminates with sub-fertility in both sexes (Luo et al. 2014). This 
defect therefore suggests that during gonadal PGC development there is a source of 
DNA damage that potentially crosslinks DNA, causing the requirement for the FA 
repair pathway. Notably, histone demethylation may cause the release of alkylating or 
crosslinking agents (namely formaldehyde) in close proximity to DNA, being a 
potential source of DNA damage encountered by PGCs at this stage of development 
(Shi et al. 2004). Furthermore, during PGC development at ~E11.5 there are chromatin 
changes that may cause replication stress to developing PGCs and further exacerbate 
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the requirement for this repair pathway in PGC development (Hajkova et al. 2008). In 
addition, the Mcm9 (Minichromosome maintenance complex component 9) gene has 
been shown to play roles in HR, MMR and DNA replication and whenever absent from 
mice causes a PGC defect at E9.5 (Luo and Schimenti 2015). Interestingly, depletion 
of both Mcm9 and Fancm (FA complementation group M) exhibits an additive effect 
suggesting these are not acting in the same pathway. This may suggest that PGCs during 
proliferation require HR or alternatively that something specific about replication in 
PGCs is causing a numerical reduction of these cells in the absence of the Mcm9 factor. 
To corroborate the first hypothesis, the Rad54 (X-ray sensitive 54) deficient mice also 
show a reduction in the number of PGCs as early as E11.5 (Messiaen et al. 2013), 
however this decrease in PGC numbers does not cause sterility in both sexes. It remains 
to be determined if the role of Mcm9 in PGCs is linked to its function in HR and also if 
there is a particular requirement for HR for the development of PGCs and to maintain 
the integrity of the germ line genome with high fidelity. Finally, it has been shown that 
during PGC development the arginine methyl transferase 5 (PRMT5) translocates from 
the cytoplasm to the nucleus between E8.5 to E10.5 playing a role in repressing histones 
H2A and H4R3me2. PGCs deficient in Prmt5 exhibit sterility in both sexes preceded 
by increased transcription of two transposable elements - IAP (intracisternal A particle) 
and LINE1 (Long interspersed nuclear element 1) which were shown to cause sufficient 
DNA damage to clear these cells from the embryonic gonads (Kim et al. 2014). The 
unique cellular and genomic transactions of PGCs make the genome of these cells prone 
to DNA damage. Overall, we can conclude that there are several steps in the 
development of PGCs in which there is a genetic requirement for DNA repair. 
However, the nature of the DNA damage encountered by PGCs during the different 
phases of development and the factors which are required for these processes still 
remain largely unexplored. To understand which DNA repair factors are required for 
PGC development will permit to gain insight into how germ line mutations are 
suppressed. 
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Summary 
 
DNA repair is required to suppress mutations. Furthermore, experimental evidence 
shows tissue specificity in DNA repair activity. The germ line has a lower mutation rate 
compared to the soma as mutations in the germ line can affect the progeny and fitness 
of subsequent generations. PGCs have the highest mutation frequency and the study of 
mutagenesis in PGCs is particularly important because mutations in these cells can 
affect multiple offspring. Genetic evidence shows that during PGC development, which 
entails extensive genomic and epigenomic transactions, there is the generation of DNA 
damage. Therefore, this makes DNA repair essential to ensure normal numbers of PGCs 
and control mutagenesis in the germ line. In order to understand the nature of DNA 
damage encountered by PGCs, it is critical to understand which DNA repair pathways 
are used during PGC development. To achieve this, it is crucial to investigate which 
genetic factors are required for the repair of DNA lesions generated during PGC 
development. In this thesis we developed a platform to screen for DNA repair factors 
required in PGCs using an in vitro system that generates PGCs from mouse embryonic 
stem cells. This screen permitted the discovery of novel factors that shed light into 
which repair pathways are required during PGC development. 
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Chapter 2 - In vitro system recapitulates 
the requirement for DNA repair in vivo 
 
2.1 - Ercc1-deficient mice show a numerical reduction in the PGC 
population 
 
 In order to study the genetic requirement for DNA repair during PGC 
development our lab chose to study the gene Ercc1. We chose this gene firstly because 
Ercc1-deficient mice have impaired fertility (Hsia et al. 2003) and secondly because 
Ercc1 is involved in several DNA repair pathways, including NER, crosslink repair and 
SSA. ERCC1 was the first human DNA repair gene to be cloned (Westerveld et al. 
1984) and ERCC1 is known to interact with XPF and form a structure-specific 
endonuclease that not only generates incisions at the site of UV-damaged DNA (Sijbers 
et al. 1996) but also causes incisions at ICL-generated lesions (Hodskinson et al. 2014). 
ERCC1–deficiency in cells causes hypersensitivity to UV irradiation and crosslinking 
agents such as mitomycin C (Melton et al. 1998). In mice, absence of Ercc1 causes 
severe runting at birth and death before weaning due to liver failure (McWhir et al. 
1993; Weeda et al. 1997). Two lines of Ercc1-deficient mice were independently 
generated and showed polyploidy in perinatal liver with elevated TRP53 levels, which 
were also detected in the kidney and brain. This observation led the authors to propose 
a model in which DNA damage generated endogenously via crosslinks would activate 
TRP53, which in turn induces p21, causing cell cycle arrest and nuclear ploidy 
(McWhir et al. 1993; Weeda et al. 1997). In addition to the two knockout mice 
described, an Ercc1-deficient mouse expressing an Ercc1 transgene under the control 
of a liver specific promoter, which allowed the mice to survive until adulthood, was 
generated therefore permitting the study of other phenotypes (Selfridge et al. 2001). 
Interestingly these mice were shown to display sterility in both sexes. Furthermore, 
38 
another study showed that these mice display an increased number of Sertoli cell-only 
tubules and increased levels of apoptosis in germ cells which culminate in the absence 
of sperm in the epididymis (Paul et al. 2007). However the nature and cellular origin of 
the sterility phenotype remained to be understood. Studies in flies suggested that Ercc1 
could play a role in meiotic recombination as the authors observed an absence of normal 
levels of crossovers in Ercc1-deficient flies. However, only recently our lab has shown 
that absence of Ercc1 causes sterility in mice due to a severe reduction in the PGC 
population and that the few remaining germ cells that are not lost can progress through 
meiosis (Hill, R.J. and Crossan, G.P 2019). This therefore shows that the fertility 
phenotype is not caused by failure to undergo meiosis. To quantify the number of PGCs 
we used a reporter mouse line named Stella-GFP. This line was generated by 
integration of a bacterial artificial chromosome (BAC) with all four exons of Stella (a 
marker of PGCs expressed at E7.25) fused in frame with EGFP (Payer et al. 2006). 
Using Stella-GFP reporter mice, we observed by epifluorescence microscopy a clear 
reduction in the number of PGCs in Ercc1-deficient embryonic gonads compared to 
Wild type controls (Figure 1a). Also, by staining cells from embryonic gonads of 
Stella-GFP embryos with SSEA1 (Stage-specific embryonic antigen 1), a surface 
marker that labels PGCs (Kudo et al. 2004), we could stringently quantify the PGC 
population using flow cytometry. As depicted in Figure 1b and c there is a 30-fold 
reduction in the number of PGCs present in Wild type versus mutant embryonic gonads, 
which likely causes the sterility observed in adult mice (Hsia et al. 2003). These results 
suggest that PGC development necessitates repair by Ercc1 and that loss of Ercc1 leads 
to the accumulation of unrepaired damage ultimately leading to PGC loss. This loss of 
germ cells is sufficient to explain the sterility phenotype observed in these mice. 
However, the nature and the source of the damage encountered by PGCs during 
development remain unknown. 
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Figure 1 – Ercc1-deficient mice show a numerical reduction in the PGC population which 
culminates in sterility in both sexes. 
a) Bright-field and epifluorescence microscopy images of E12.5 embryonic gonads from Wild type and 
Ercc1-/- embryos. 
b) Representative flow cytometric profile of embryonic gonads after SSEA1 staining. The frequency of 
PGCs refers to the frequency of GFP and SSEA1 double positive population. The data represent the 
mean of three independent experiments per genotype. 
c) Quantification of the number of SSEA1 and GFP positive cells (PGCs) from Wild type and Ercc1-/- 
embryos. The data represent the mean of three independent experiments. The statistical analysis 
performed was an unpaired t-test. 
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2.2 – Studying PGC development in vitro 
 
 In order to understand what genomic challenges PGCs encounter during 
development that render DNA repair essential to these cells, we set out to employ an in 
vitro system previously developed by Hayashi et al. (Hayashi et al. 2011). This system 
not only provides us with abundant experimental material which is not achievable by 
collecting PGCs from mouse embryos but most importantly makes the study of PGCs 
genetically tractable in vitro. This system is based on the differentiation of mouse 
embryonic stem cells (ESCs) into primordial germ cell-like cells (PGCLCs) by 
culturing the ESCs with a defined combination of cytokines. The differentiated 
PGCLCs are characterised not only by their ability to recapitulate the epigenetic 
reprogramming and cellular events observed during PGC specification but also for their 
spermatogenic potential (Hayashi et al. 2011; Miyoshi et al. 2016). Most notably, these 
cells undergo upregulation of genes involved in PGC specification such as Blimp1, 
Prdm14, Ap2γ and Stella. Despite the close resemblance that these cells pose to PGCs 
in vivo, there are several key differences. Firstly, whilst epigenetic reprogramming is 
initiated, it does not reach completion in vitro. Secondly, the embryonic stage 
recapitulated in this system is still under debate, varying from E9.5 to E12.5 according 
to different research groups (Hayashi et al. 2011; Miyoshi et al. 2016). And finally, 
since this system aims to recapitulate development in vitro, the physiological context 
and the interaction of PGCs with their niche cannot be fully recapitulated. 
 We used a reporter mouse ESC line named Stella-BAC9, which was derived 
from Stella-GFP reporter mice and the number 9 refers to the transgenic line used. In 
order to maintain ESCs in pluripotent state, referred to as a ground state, ESCs were 
cultured under serum and feeder free-conditions in a media containing MEK (mitogen-
associated protein kinase) inhibitors and GSK3 (glycogen synthase kinase 3) inhibitors 
(2i), which together lead to a decrease in the levels of global DNA methylation (Sim et 
al. 2017), and also mLIF (mouse leukaemia inhibitory factor) which promotes 
embryonic stem cell self-renewal (Smith et al. 1988). ESCs cultured in 2i + mLIF media 
are said to be in a ground state, resembling the inner cell mass/preimplantation epiblast 
(E4.5) (Ying et al. 2008), maintaining therefore the capacity to give rise to all germ 
lineages upon differentiation. 
 In order to differentiate ESCs into PGCLCs two steps are required (Figure 2a). 
In the first differentiation step, ESCs cultured in 2i + mLIF are differentiated into 
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epiblast-like cells (EpiLCs) by culturing the ESCs in N2B27 medium supplemented 
with activinA, FGFb (basic fibroblast growth factor b) and KSR (Knockout serum 
replacement) for 42 hours in tissue culture 12 well tissue culture plates. The EpiLCs 
display a transcriptional profile which resembles the cells present in pre-gastrulating 
epiblasts (Hayashi et al. 2011). Then, in the second step of differentiation, the EpiLCs 
are induced to differentiate into PGCLCs in Lipidure-Coat 96 well-plates in the 
presence of GK15 medium with BMP4 (Bone morphogenetic protein 4), SCF (Stem 
cell factor), mLIF and EGF (Epidermal growth factor) for 4 days, during which time 
they form cellular aggregates on top of which PGCLCs are formed in small colonies. 
These cytokines provided in the differentiation media are the same cytokines 
responsible for the specification of the germ cell lineage in vivo. We employed Stella 
BAC9 ESCs, which allows us to detect the formation of PGCLCs using the Stella-GFP 
reporter (Figure 2b). In order to quantify PGCLCs, we combined the Stella-GFP 
reporter with an anti-SSEA1 antibody, therefore permitting us to specifically and more 
stringently and quantify PGCLCs by flow cytometry (Figure 2c). 
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Figure 2 – PGCLC induction from ESC in culture. 
a) Schema outlining the steps involved in the induction of PGCLCs from ESCs. Firstly, ESCs are cultured 
in 2i + mLIF to be maintained in a ground state. Then, these cells are differentiated into EpiLCs by being 
cultured in the presence of N2B27 medium supplemented with bFGF, ActivinA and KSR for 42 hours. 
After this period the cells are differentiated into PGCLCs by being cultured in the presence of GK15 
media in the presence of BMP4, SCF, EGF and mLIF for 4 days.  
b) Bright-field and epifluorescence microcopy images ESCs, EpiLCs after 42 hours of differentiation 
and day 4 PGCLCs. 
c) Representative flow cytometric profile of PGCLCs induced from Stella BAC9 Wild type ESCs after 
SSEA1 staining. The frequency of PGCLCs refers to the frequency of GFP and SSEA1 double positive 
population. 
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 To further understand the requirement for Ercc1 in PGCs it is essential to assess 
which stage of PGC development our PGCLCs generated in vitro resemble. This would 
permit us to understand if the stage of differentiation obtained in vitro is comparable to 
the developmental stage observed in Ercc1-deficient embryos when there is a PGC 
numerical reduction. To achieve this goal we fluorescence-activated cell sorting 
(FACS)-purified E10.5 and E12.5 PGCs from mice and also ESCs, EpiLCs and 
PGCLCs following 2, 4 and 6 days of in vitro differentiation. Using these samples we 
determined the levels of expression of PGC specific genes using reverse-transcription 
quantitative PCR (RT-qPCR) (Figure 3a). We selected Ap2γ (Kurimoto et al. 2008) 
and Prdm14 (Yabuta et al. 2006; Yamaji et al. 2008) as these genes are expressed early 
in PGC development (around E6.25), Dazl (Deleted in azoospermia-like) as it is starts 
to be expressed at E11.5 (Seligman and Page 1998) and Mvh (Mouse vasa homolog) 
since this gene is expressed later in PGC development (starting at E12.5) (Toyooka et 
al. 2000). In Figure 3b it is depicted that day 6 PGCLCs have comparable levels of 
expression to E12.5 PGCs for Ap2γ and Prdm14 expression but this is not observed for 
later germ cell markers, namely Mvh or Dazl. Also, day 4 PGCLCs seem to 
transcriptionally resemble E10.5 PGCs for all markers tested. These results suggest 
that, at day 4 of differentiation, the PGCLCs we generated in our lab transcriptionally 
resemble E10.5 PGCs whilst at day 6 the PGCLCs resemble PGCs between E10.5 and 
E12.5. 
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Figure 3 – Transcriptional characterisation of PGCLCs. 
a) Representative flow cytometric profile of PGCLCs induced for 2, 4 and 6 days from Stella BAC9 
Wild type ESCs after SSEA1 staining. The frequency of PGCLCs refers to the frequency of GFP and 
SSEA1 double positive population. 
b) Expression analysis of PGC markers in day 2, 4 and 6 PGCLCs, E10.5 and E12.5 PGCs and ESCs 
and EpiLCs by qPCR. The data represent the mean of three independent experiments from one biological 
replicate and three technical replicates. The statistical analysis performed was an unpaired t-test. On all 
occasions the data were normalized to the expression of Gapdh and made relative to the expression in 
E12.5 PGCs. 
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2.3 - Generation of a DNA repair-deficient ESC line 
 
 As previously shown, Ercc1-deficient mice have a significant reduction in the 
number of PGCs at E12.5. In order to assess if we can exploit the PGCLC in vitro 
system to study DNA repair requirements during PGC development we set out to 
generate Ercc1-deficient PGCLCs. Firstly, we performed targeted disruption of the 
Ercc1 gene in ESCs. In order to disrupt this gene, we designed a targeting vector 
containing a neomycin resistance cassette disrupting the third exon flanked by two 1.5 
kb homology arms (Figure 4a). The third exon of Ercc1 encodes for part of the central 
domain which is structurally homologous to the XPF nuclease domain (Tsodikov et al. 
2005; Nishino et al. 2003). This targeting vector was co-transfected with a plasmid 
encoding for the Cas9 enzyme and a gene-specific single guide RNA (sgRNA) targeting 
the third exon of Ercc1. Two different sgRNAs were used to target Ercc1. Using this 
strategy, we stimulated HR by inducing a site-specific DSB and providing a template 
to change the outcome of repair by HR. Upon transfection, neomycin-resistant clones 
were selected and a long-range PCR (LR-PCR) permitted the detection of clones 
successfully disrupted in the Ercc1 locus. Only when the targeting vector recombined 
correctly did we obtain a 2.6 kb product. (Figure 4b). To confirm that the correct 
recombination of the targeting vector produced a homozygous mutation, we performed 
an immunoblot analysis using a mouse monoclonal anti-ERCC1 antibody. This analysis 
revealed that the targeted clone did not express Ercc1 (Figure 4c). Finally, since it has 
been reported in the literature that Ercc1-deficient cells are hypersensitive to the DNA 
crosslinking agent mitomycin C (Weeda et al. 1997), we performed a colonogenic 
survival assay using this agent to functionally test the cell line we generated. We found 
that the Ercc1-deficient ESCs we generated were hypersensitive to mitomycin C 
(Figure 4d). Taken together these data demonstrated that we have generated an Ercc1-
deficient ESC line. 
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Figure 4 – Disruption of Ercc1 in ESCs. 
a) Schema representing the Ercc1 locus, the targeting vector and the targeted locus. Coding exons are 
represented as boxes and the oligos used for the LR-PCR are indicated. 
b) LR-PCR amplification from genomic DNA of a Wild type BAC9 Stella and Ercc1-deficient ESC line. 
c) Western blot analysis of whole-cell extracts of Wild type BAC9 Stella and Ercc1-/- ESC lines, 
incubated with 1:100 dilution of anti-ERCC1 antibody and 1:2000 dilution of anti-VINCULIN antibody 
which served as a loading control. 
d) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate and made relative to the 
untreated of each cell line. 
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2.4 - Differentiation of Ercc1-/- ESCs into PGCLCs 
 
 We first assessed the ability of these Ercc1-/- ESCs to form EpiLCs in vitro. This 
would permit us to ascertain whether the absence of Ercc1 affects the differentiation 
potential of ESCs. In order to achieve this, we induced parental Stella BAC9 Wild type 
and Ercc1-/- ESCs to form EpiLCs (Figure 5a). After 42 hours of differentiation, we 
could observe by microscopy no clear difference in the morphology of Ercc1-/- EpiLCs 
compared to Wild type. Moreover, we set out to analyse the differentiation status of the 
ESCs by using c-Kit (or CD117), which is a surface marker expressed on 
undifferentiated stem cells (Motro et al. 1991). This permits us to accurately quantify 
the percentage of ESCs that have fully differentiated into EpiLCs and therefore lost c-
Kit expression. The quantification of ESCs and EpiLCs by flow cytometry 
demonstrated that there is no significant difference between the ability of Ercc1-
deficient ESCs to differentiate into EpiLCs compared to Wild type ESCs after 42 hours 
of differentiation (Figure 5b and c). In conclusion, Ercc1 is not essential for the 
differentiation of ESCs to EpiLCs. 
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Figure 5 – Ercc1-deficient ESCs do not show impaired differentiation potential to EpiLCs. 
a) Bright-field microscopy images of Stella BAC9 Wild type and Ercc1-/- ESCs and day 2 EpiLCs. 
b) Representative flow cytometry profiles of Stella BAC9 Wild type and Ercc1-/- ESCs and day 2 EpiLCs 
after c-Kit (CD117) APC stain. 
c) Quantification of the percentage of c-Kit (CD117) APC positive cells in Stella BAC9 Wild type and 
Ercc1-/- ESCs and day 2 EpiLCs. The data represent the mean of three independent experiments. The 
statistical analysis performed was an unpaired t-test. 
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              Then, in order to determine if the requirement for Ercc1 for PGC development 
observed in vivo can be recapitulated using the in vitro differentiation assay, we 
generated PGCLCs from both Wild type and Ercc1-deficient Stella GFP ESCs. We 
chose to generate Ercc1 PGCLCs after 6 days of differentiation since day 6 PGCLCs 
resemble transcriptionally PGCs between E10.5 and E12.5 and the PGC defect in Ercc1 
embryos starts around E10.5, therefore matching temporally with the day 6 PGCLCs 
(Hill, R.J. and Crossan, G.P. 2019). After 6 days of differentiation, we could see by 
microscopy a clear reduction in the number of Stella-GFP cells in the absence of Ercc1 
(Figure 6a). The frequency of GFP and SSEA1 double positive cells was determined 
by flow cytometry (Figure 6b). Ercc1-/- ESCs have a 3.3 fold-reduction in the 
frequency of SSEA1+ GFP+ cells per total number of cells relative to the parental Wild 
type cells (Figure 6c) and a numerical defect was also observed when we quantified 
PGCs previously in Ercc1-deficient embryos at E12.5 (Figure 6d). Overall we can 
conclude that our in vitro system recapitulates the requirement for Ercc1 in PGCs in 
vivo. Therefore we have generated a tool that allows us to study DNA repair in a system 
more close to physiology. This tool will permit us to dissect the genetic requirements 
for DNA repair in the mammalian germ line and facilitates investigation aimed at 
understanding the underlying mechanisms. Furthermore, using this tool we can aim to 
find novel genetic factors required for the development of PGCs. 
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Figure 6 – Differentiation of Ercc1-/- ESCs into PGCLCs. 
a) Bright-field and epifluorescence microscopy images of day 6 Stella BAC9 Wild type and Ercc1-/- 
PGCLCs. 
b) Representative flow cytometry profiles of PGCLCs induced from Stella BAC9 Wild type and Ercc1-
/- ESCs after SSEA1 stain. The percentage of PGCLC refers to the frequency of GFP and SSEA1 double 
positive population. The data represent the mean of three independent experiments. 
c) Quantification of the frequency of SSEA1 and GFP positive cells (PGCLCs) in Stella BAC9 Wild 
type and Ercc1-/- PGCLCs after SSEA1 stain. The data represent the mean of three independent 
experiments. The statistical analysis performed was an unpaired t-test. 
d) Quantification of the frequency of SSEA1 and GFP positive cells (PGCs) present at E12.5 in Wild 
type and Ercc1-deficient embryos. The statistical analysis performed was an unpaired t-test.   
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2.5 - Generation of a panel of CRISPR-mediated DNA repair ESC 
mutants 
 
 Having shown that the in vitro system recapitulates the requirement for Ercc1 
in PGC development, we aimed to further test the in vitro system so we could ultimately 
use it for finding novel DNA repair factors. To do this we set out to knockout other 
factors that similarly to Ercc1 are required for repairing ICLs. In order to generate 
knockouts (KOs) in ESCs in our reporter cell line in a fast manner we employed the 
strategy depicted in Figure 7. 
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Figure 7 – Generation of a panel of CRISPR-mediated DNA repair ESC mutants. 
Diagram representing the strategy employed to generate the panel of mutants. First, we designed three 
sgRNAs per gene, which would either specifically target an essential exon whose disruption would 
compromise the function of the gene or would target the 5’ end of the gene therefore likely causing a 
frameshift that would disrupt the majority of the coding sequence. Then, we co-transfected ESCs with 
the px458 plasmid, which encodes for the sgRNA aforementioned, the Cas9 enzyme and GFP, with a 
second plasmid that leads to expression of Tomato. The use of the Tomato expressing plasmid is 
necessary since the mouse ESCs express basal levels of Stella when in a naive state, therefore not 
allowing us to separate the transfected cells with the sgRNAs based only on GFP fluorescence. Therefore, 
the Tomato positive cells were FACS sorted, which permitted us to enrich for only cells which received 
both the Tomato and px458 plasmids by transfection. These cells were plated at 1000 cells per dish in 
10 cm dishes so that ESC colonies emerge after 7-9 days of ESC culture in 2i + LIF media from single 
cells in the putative KOs ESCs. These colonies were picked, expanded and then screened at the genomic 
level. In order to screen for KO clones at the genomic level we performed DNA fragment analysis, which 
permits us to identify indels with single base-pair resolution. DNA fragment analysis consists of first 
PCR amplifying the targeted locus with fluorescent primers. The fluorescent PCR product is then 
separated on a capillary electrophoresis system coupled with a fluorescent beam and detector which 
permits to determine the size of the PCR amplicon at a single base pair resolution. This permits us to 
identify clones in which indels are generated in the targeted loci and also to select clones in which the 
indel causes a frameshift therefore either disrupting the protein coding sequence or causing the 
emergence of a premature stop codon. Subsequently, for the putative clones we performed functional 
analysis, in which we treated Wild type and the putative clones with DNA damaging agents known to 
cause hypersensitivity in cells deficient in the gene of interest. To determine the nature of the genetic 
perturbation induced, the targeted genomic regions were amplified by PCR, cloned into a TOPO Zero 
Blunt vector and 10 colonies of each PCR product were used for Sanger sequencing. 
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 We decided to target three genes that, like Ercc1, encode for nucleases required 
to confer cellular resistance to DNA interstrand crosslinking agents. With this strategy 
we could interrogate if the requirement for nuclease activity for repairing DNA 
crosslinks during PGC development. In order to do this, we chose the nuclease genes 
Fan1, Mus81 and Snm1b. Furthermore, we decided to target another gene which is 
involved in TLS and was recently included in the FA repair pathway named Rev7 
(Bluteau et al. 2016). We chose both Fan1 and Mus81 since these genes not only encode 
for nucleases involved in ICL repair but also have been shown to be dispensable for 
fertility (Thongthip et al. 2016; McPherson et al. 2004). These factors would then be 
expected to generate normal frequency of PGCLCs. Then we decided to assess if other 
components known to act downstream of the Fanconi pathway in repairing crosslinks 
would be required for PGC development. This would also validate our approach since 
Rev7-deficient mouse embryos have been shown to have a reduction in PGC numbers 
(Pirouz, Pilarski, and Kessel 2013; Watanabe et al. 2013). (Pirouz, Pilarski, and Kessel 
2013; Watanabe et al. 2013). Finally to assess if this system can make predictions about 
the role of DNA repair factors in PGCs where KO mice have not been generated we 
decided to target Snm1b, a nuclease involved in ICL repair that when disrupted in mice 
causes embryonic lethality, therefore making the study of PGCs in vivo not possible 
(Akhter et al 2010). This approach would allow us to observe if genes expected to have 
no phenotype do display a frequency of PGCLCs similar to the one observed in the 
parental Wild type cell line. Also, this would further test if other factors, such as Rev7 
in this case, also recapitulate the reduction in PGC numbers observed in mice. Finally, 
we decided to interrogate if this system could make predictions of what is the genetic 
requirement for DNA repair factors in PGCs for genes that have not yet been studied 
in mice or cannot be studied in mice due to embryonic lethality. 
 The first gene we targeted was Fan1. Fan1 encodes a protein with 5’ flap 
endonuclease and 5’-3’ exonuclease activity (Smogorzewska et al. 2010). We 
succeeded in deleting Fan1 by targeting the third exon as it is located upstream of the 
catalytic site of this nuclease (Figure 8a and b). Absence of Fan1 in cells is known to 
cause hypersensitivity to DNA crosslinking agents as we observed in our Fan1 
disrupted ESCs (Figure 8c) and in mice causes karyomegaly and liver dysfunction but 
nevertheless these mice are fertile (Thongthip et al. 2016). 
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Figure 8 – Disruption of Fan1-/- in ESCs. 
a) DNA fragment analysis of Wild type and Fan1-deficient ESCs. The y-axis shows the fluorescent 
signal output and the x-axis shows the size of the PCR product. 
b) Schema representing the Fan1 locus with the targeted exon indicated in red locus and the sequence of 
disrupted alleles after CRISPR-mediated disruption. Coding exons are represented as black boxes. 
c) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate and made relative to the 
untreated of each cell line. 
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 The next gene we targeted was Mus81 which encodes an endonuclease that 
plays a critical role in the resolution of recombination intermediates, replication fork 
collapse, and DNA DSBs (Boddy et al. 2001). For Mus81 we targeted the ninth exon, 
where the nuclease catalytic domain is encoded (Figure 9a and b). The absence of 
Mus81 in cells causes hypersensitivity to DNA crosslinking agents, as we observed in 
the knockout cells we generated (Figure 9c) (Weeda et al. 1997). In mice Mus81 was 
initially reported to be dispensable for fertility (McPherson et al. 2004) however a more 
detailed analysis revealed a meiotic defect (Holloway et al. 2008). Nevertheless, this 
phenotype does not render the mice infertile (Dendouga et al. 2005; Holloway et al. 
2008).  
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Figure 9 – Disruption of Mus81-/- in ESCs. 
a) DNA fragment analysis of Wild type and Mus81-deficient ESCs. The y-axis shows the fluorescent 
signal output and the x-axis shows the size of the PCR product. 
b) Schema representing the Mus81 locus with the targeted exon indicated in red locus and the sequence 
of disrupted alleles after CRISPR-mediated disruption. Coding exons are represented as black boxes. 
c) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate and made relative to the 
untreated of each cell line. 
  
  57 
 We also disrupted Snm1b which encodes for an endonuclease with 5’-3’ 
exonuclease activity that plays a central role in telomere maintenance (Lenain et al. 
2006; van Overbeek and de Lange 2006). SNM1B has been shown to physically interact 
with MUS81, FANCD2 and MRE11 therefore potentially maintaining or recruiting 
these factors to damage sites and/or stalled forks (Bae et al. 2008). In order disrupt this 
gene, we targeted the second exon as it disrupts most of the gene, including the catalytic 
domain (Figure 10a and b). When disrupted in cells, Snm1b causes a moderate 
increase in sensitivity to crosslinking agents as we observed (Figure 10c) (Demuth, 
Digweed, and Concannon 2004) and in mice, absence of Snm1b causes embryonic 
lethality therefore impeding the study of fertility (Akhter et al. 2010). 
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Figure 10 – Disruption of Snm1b-/- in ESCs. 
a) DNA fragment analysis of Wild type and Snm1b-deficient ESCs. The y-axis shows the fluorescent 
signal output and the x-axis shows the size of the PCR product. 
b) Schema representing the Snm1b locus with the targeted exon indicated in red locus and the sequence 
of disrupted alleles after CRISPR-mediated disruption. Coding exons are represented as black boxes. 
c) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate and made relative to the 
untreated of each cell line. 
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 Finally, we decided to knockout Rev7 (also known as Mad2l2 for Mitotic arrest 
deficient 2 like 2 or Fancv) to ask if factors acting downstream of the FA repair pathway 
in dealing with ICLs are required for PGC development (Figure 11a). In order to do 
this, we targeted the second exon of Rev7 aiming to cause a frameshift that would 
disrupt the majority of the coding sequence since we did not know which function of 
this factor could be required for its function in PGCs. Rev7 encodes for a protein that 
forms an essential component of the heterodimeric polymerase zeta (Polζ) together with 
Rev3 (Nelson, Lawrence, and Hinkle 1996b). Polζ is a critical component in TLS as it 
extends beyond the site of translesion bypass to the next replication fragment. Loss of 
Polζ significantly reduces the ability of the cell to perform a wide range of TLS 
transactions rendering them sensitive to crosslinking agents as observed in the cell line 
we generated (Figure 11b) (Okada et al. 2005). REV7 is also thought to participate in 
pathway choice in DSB repair (Boersma et al. 2015; Xu et al. 2015) and fine tuning 
anaphase promoting complex/cyclosome (APC/C) activation by sequestering FZR1 
(Fizzy and cell division cycle 20 related 1, also known as CDH1) (Listovsky and Sale 
2013). Rev7-/- mice show growth retardation and infertility in both sexes, associated 
with a PGC defect after E8.5 (Pirouz, Pilarski, and Kessel 2013; Watanabe et al. 2013). 
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Figure 11 – Disruption of Rev7-/- in ESCs. 
a) Schema representing the Rev7 locus with the targeted exon indicated in red locus and the sequence of 
disrupted alleles after CRISPR-mediated disruption. Coding exons are represented as black boxes. 
b) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate and made relative to the 
untreated of each cell line. 
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2.6 – ICL repair nuclease genes apart from Ercc1 are dispensable for 
PGCLC formation but not TLS factor Rev7 
 
 In order to find out whether Fan1, Mus81, Snm1b and Rev7 are required for 
PGCLC development in vitro, we used the previously generated cell lines and induced 
them to form PGCLCs. Interestingly, flow cytometry analysis did not reveal a 
requirement for PGCLC differentiation for any of the nucleases except for Ercc1 
(Figure 12a and b). This therefore suggests that Ercc1 is the sole endonuclease 
required to deal with the damage encountered by PGCs during development. This result 
was expected in the case of Fan1 and Mus81 since the respective KO mice are fertile 
and should not display a perturbation in PGC numbers. However, it is interesting to 
observe that the Snm1b mutant does not also display a PGC numerical reduction as the 
KO mouse is embryonically lethal and the fertility phenotype cannot therefore be 
assessed. 
 Overall these results are important since they show that our system recapitulates 
the different requirements for DNA repair factors in PGCs as observed in vivo. Also, 
this permits us to conclude that not all DNA repair mutants have impaired ability to 
form PGCLCs in vitro and that the phenotypes we observed in vitro reproduce the 
phenotype of DNA repair deficient PGCs in a mouse. 
 In contrast to the nucleases tested, Rev7-deficient ESCs show a 3.4-fold 
reduction in the ability to differentiate into PGCLCs (Figure 12a and b). Since it is 
known that Rev7 is required for PGC development in vivo, this result further validates 
our in vitro system. We could speculate that Rev7 is required for PGC development due 
to its role in TLS. Furthermore, Rev7 acts together with the FA pathway to maintain 
cellular resistance to crosslinking agents (Bluteau et al. 2016). However, Rev7 also 
plays roles in cell cycle regulation, pathway choice in DSB repair and chromatin 
remodelling which could explain its requirement in PGCs. Therefore, the function of 
Rev7 in promoting the correct development of PGCs remains to be ascertained. Overall 
we can conclude that we have established and validated the PGCLC differentiation 
system for the study of DNA repair in PGCs which will permit us to find novel DNA 
repair factors required for PGC development. 
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Figure 12 – Panel of DNA repair deficient ESCs induction to PGCLCs. 
a) Representative flow cytometry profiles of PGCLC induced from Stella BAC9 Wild type, Fan1-/-, 
Snm1b-/-, Rev7-/- and Mus81-/- PGCLCs after SSEA1 stain. The percentage of PGCLC refers to the 
frequency of GFP and SSEA1 double positive population. 
b) Quantification of the frequency of SSEA1 and GFP positive cells (PGCLCs) in the different cell lines 
shown. The data represent the mean of three independent experiments. The statistical analysis performed 
was an unpaired t-test. 
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Summary 
 
The data presented here show that an in vitro system can recapitulate the requirement 
for DNA repair in the development of PGCs. Disruption of Ercc1 in ESCs showed a 
reduction in the number of PGCLCs similar in magnitude to what is observed in vivo. 
We further tested if there was a general requirement for genes encoding nucleases 
responsible for conferring resistance to crosslinking agents during PGC development. 
To achieve this we knocked out Fan1, Mus81 and Snm1b in ESC and found that the 
absence of these genes, contrary to Ercc1, is dispensable for PGCLC generation. This 
result recapitulates what happens in knockout mice in the case of Fan1 and Mus81, in 
which the respective knockout mice are fertile with no known reduction in PGC 
numbers, but not for Snm1b, since the knockout mice die during embryonic 
development and the fertility cannot be assessed. In addition, we disrupted Rev7 in 
ESCs in order to assess if a gene acting downstream of the FA pathway could be 
required for PGCLC formation. We found Rev7 to be required for PGCLC development 
as observed in Rev7-deficient mouse embryos. Overall, these results allowed us to 
conclude that the in vitro system recapitulates the phenotypes observed in PGCs in 
mouse embryos, therefore permitting us to use of this system to perform a genetic 
screen and find novel DNA repair factors in PGCs. 
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Chapter 3 - A screen to identify novel 
DNA repair factors required for PGC 
development 
 
3.1 - Introduction 
 
 Having established a system that recapitulates the requirement for Ercc1 in 
PGCs in vitro, we decided to develop a platform to perform a CRISPR/Cas9 dropout 
screen to find novel DNA repair factors required for PGC development. The discovery 
of the factors required for PGC development will elucidate which repair pathways are 
used during this developmental process and therefore give insight into the type and 
nature of DNA damage encountered by PGCs. This is particularly relevant since 
mutations emerging during this stage of development will affect not only the individual 
but also the next generations. Therefore, the discovery of factors acting specifically in 
the germ cell lineage may elucidate how the germ line suppresses the emergence of 
novel mutations early during embryonic development. 
 CRISPR/Cas9 based screens led to discoveries in many fields of molecular 
biology since the first screens performed in 2014 (Shalem et al. 2014; Wang et al. 
2014). Using the high efficiency of CRISPR, we can generate gene deletions in both 
alleles of mammalian cells thereby permitting the discovery of new genes or novel 
functions of previously known genes for a certain phenotypic readout. The general 
principle of CRISPR/Cas9 knockout screening is to generate a pooled library of 
sgRNAs, which is subsequently virally delivered into a Cas9 expressing cell line. Then, 
the cells containing a random integration of the sgRNA in the genome will be selected 
and expanded. Provided that the sgRNAs generate DSBs efficiently and therefore 
causing indels to disrupt the function of the gene, a pool of KO cells is generated. This 
pool of KO cells then undergoes a selective pressure, which can be either resistance to 
  65 
a drug or FACS sorting based on a reporter signal. The selected pool of KO cells before 
and after selective pressure are then collected, genomic DNA is extracted and PCR is 
used to amplify the sequence of the sgRNA that integrated in the genome. These PCR 
products are analysed by Next-Generation Sequencing (NGS) so that the abundance of 
each sgRNA is determined for the samples with and without selective pressure. By 
comparing the sgRNAs present in the treated vs untreated samples, it is possible to 
identify genes that are required for the selective pressure used. 
 In order to perform a robust screen in PGCLCs, we had to optimise, upscale and 
adapt the screening conditions to correctly address our question (Figure 1). Firstly, the 
in vitro system relied on the use of low adherence 96-well plates to form the aggregates 
on top of which the PGCLCs emerge. Each of these plates yielded only a few thousand 
PGCLCs, therefore causing the cell number to be a potential limitation for screening 
while using this system. Since using a genome-wide sgRNA library would not provide 
sufficient coverage of the whole genome having the number of cells as a limitation, we 
designed a sgRNA library targeting only mouse genes involved in DNA metabolism 
and genome stability. To obtain the list of genes to target in the library we searched for 
mouse genes with gene ontology of DNA metabolism, repair, replication, cell cycle and 
genome stability using the AmiGO 2 tool. In order to keep our library small, we decided 
to use sgRNAs obtained from the Brie library. This library has successfully permitted 
the discovery of novel genes whilst using only 4 sgRNAs per gene as opposed to other 
libraries that normally use 10 sgRNAs to target one gene (Doench et al. 2016). This 
therefore permits us to screen for DNA repair genes still maintaining a reasonable 
coverage of the sgRNAs used. Secondly, we aimed at expressing Cas9 only in the ESC 
population. This would prevent Cas9 to generate DNA breaks during the differentiation 
protocol to PGCLCs in our DNA repair deficient cells. The generation of DSBs in DNA 
repair deficient cells could generate false-positives as a consequence of these cells 
being unable to survive the damage caused by the Cas9 activity rather than being unable 
to differentiate into PGCLCs. Therefore, we generated an inducible Cas9 Stella BAC9 
cell line. In addition to this, we chose to keep a 2000-fold representation of each sgRNA 
throughout the screen. On the one hand, at low representation (e.g. 50-fold 
representation) the library becomes more spread out, leading to erroneous interpretation 
of dropout or enrichment but on the other hand, having a library representation beyond 
1000 or 2000-fold does not improve the interpretation of the results. Therefore, aiming 
to keep the library at 2000-fold would minimise the costs of potential cell loss in any 
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of the steps of the screen. Finally, in order to be able to have a 2000-fold representation 
of each sgRNAs per cell population we had to sort 6.6 million PGCLCs. This number 
of cells is achieved by multiplying the number of sgRNAs present in the library (3.300) 
by the fold-representation aimed at keeping throughout the screen (2.000). 
  
  67 
 
 
Figure 1 – A CRISPR/Cas9 based screen to discover novel DNA repair factors required for PGC 
development. 
a) Schema representing the approach employed to screen for novel DNA repair factors required for PGC 
development. Firstly, we will prepare a library of sgRNAs targeting genes involved in genome 
stability/replication, from which we will produce lentiviruses. Then, we will generate Stella BAC9 ESCs 
expressing a doxycycline inducible Cas9. These cells will then be transduced with lentiviruses containing 
the sgRNA library with a low multiplicity of infection (MOI). Then, we will culture these cells in the 
presence of doxycycline so that Cas9 expression is induced. After the pool of KOs is generated, the cells 
will be differentiated into EpiLCs. The representation of sgRNAs present in the EpiLC population will 
be determined by sequencing the pool of EpiLCs. These cells will then be induced to differentiate into 
PGCLCs. The population of GFP+ SSEA1+ cells (PGCLCs) will be sorted and subjected to NGS to 
determine the frequency of each sgRNAs in this population. Finally, by analysing the sgRNAs present 
in the EpiLCs (which represent all the genes that do not impair EpiLC formation) and comparing them 
to the sgRNAs depleted in PGCLCs, we will be able to obtain the genes required for PGC development. 
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3.2 - Generation of a sgRNA library targeting mouse genome stability 
genes 
 
 In order to perform the CRISPR screen, we cloned a library of sgRNAs. Since 
we could only generate a limited number of PGCLCs, we decided to clone a small 
library instead of performing a genome-wide screen so that the coverage of the sgRNAs 
per PGCLC is sufficient to perform robust statistical analysis. For this we selected the 
genes we aimed to target based on gene ontology. We prepared a list of 709 genes 
involved in cell cycle, DNA repair and DNA metabolism from which we designed four 
sgRNAs per gene using the sgRNAs in the Brie library (Doench et al. 2016). Also, 484 
non-targeting controls (NTCs) were included in the pool to use as a negative control. 
The oligos corresponding to the sgRNAs were designed and cloned into the pLentiguide 
Puro backbone (Figure 2a) (Sanjana, Shalem, and Zhang 2014). In order to ensure that 
all sgRNAs were present in the pool in a similar distribution, we performed NGS on a 
MiSeq sequencer (Figure 2b). We obtained around 486000 sequencing reads, which 
permitted us to observe that all sgRNAs were present in the library. Also, this analysis 
permitted us to test the distribution of the different sgRNAs in the pool. By calculating 
the skew ratio of the sgRNAs in the library, which is obtained by dividing the sgRNAs 
present in the percentile 90 by the sgRNAs present in the percentile 10, we observed 
that in our library this value is below 10 and close to 0 as expected in a evenly 
distributed library (Figure 2b). This is clearer in Figure 2c in which plotting the 
sgRNAs ranked by abundance vs the fraction of total sgRNAs represented displays a 
linear regression showing that there is equal distribution of the different sgRNAs in the 
library pool. Having cloned the library, we generated lentiviruses which we titrated by 
counting the number of puromycin resistant colonies, while using the same cell type 
we would use in the screen, in a 10-fold serial dilution (Figure 2d). This permitted us 
to obtain the number of transducing units per ml (5 x 105 transducing units (TU)/ml) in 
the library we generated. In order to obtain a single sgRNA per cell, the pool of 
lentiviruses was transduced at an MOI of 0.3. An MOI of 0.3 is based on the Poisson 
distribution which dictates that at MOI of 0.3, 70% of the cells remain untransduced 
(uninfected). This means that at an MOI 0.3 or less, greater than 95% of infected cells 
are predicted to have a single integration. In order to obtain a fold-representation of 
2000 (which means each sgRNA of the library is present in an average of 2000 cells at 
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all stages of the screen) and transducing the cells at an MOI of 0.3, we would need to 
transduce at least 30 x 106 ESCs. This means that the number of particles we would 
need to use to transduce is 9 x 106 (0.3 corresponding to the value of MOI aimed for 
multiplied by the total number of cells, 30 x 106). Finally, to determine the volume of 
lentiviruses to transduce 30 x 106 cells we divided the number of particles to use (9 x 
106) by the titre in TU/ml (5.0 x 105) obtained before. Therefore, in order to transduce 
30 x 106 ESCs at an MOI of 0.3 we would need 17.8 ml of lentiviruses. 
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Figure 2 – Generation of a pooled library of sgRNAs targeting mouse genes involved in maintaining 
genome stability. 
a) Schema representing the generation of a pooled library of sgRNAs to target mouse genes involved in 
maintaining genome stability. Firstly, a library of oligos containing the sequence of the sgRNAs was 
synthesised. Subsequently, these pooled oligos were detached and cloned by PCR and Gibson assembly 
into the pLentiguide Puro vector. After cloning, the pool of plasmids was run on the MiSeq to assess the 
representation of each sgRNAs in the pool. Finally, these pooled plasmids were assembled into lentiviral 
particles in order to be delivered to the cells used for the screen. 
b) Table depicting the number of genes, guides/gene, number of guides, NTCs, guides missing and the 
skew ration of the sgRNA library to be used in the screen. 
c) Graph depicting the distribution of sgRNAs in the pooled library after MiSeq analysis. 
d) Graph depicting the number of colonies of mouse ESCs that emerged after transduction with the 
lentiviral particles corresponding to the sgRNA pool in serial dilutions and after treatment with 
puromycin in order to determine the titre of viruses to then use in the screen. 
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3.3 - Generation of a Cas9 inducible cell line 
 
 Having generated the lentiviruses containing the pool of sgRNAs, the next step 
would be to generate an inducible Cas9 cell line. We achieved this by employing a 
Tetracycline-controlled transcriptional activation system using doxycycline in a Tet-
ON 3G system. This system would allow Cas9 to be expressed only before the 
differentiation protocol, during which doxycycline would not be used and Cas9 would 
not be expressed. To generate this cell line, we swapped the puromycin resistance 
cassette present in the pCWCas9 Puro plasmid with a hygromycin resistance cassette 
from the pCW57-MCS1-P2A-MCS2 (Hygro) plasmid by restriction cloning. This 
plasmid encodes for Cas9 under the expression of a Tet Response Element immediately 
followed by a minimal cytomegalovirus promoter and also the reverse tetracycline-
controlled transactivator required for the Tet-ON system. Additionally, having a 
hygromycin resistance cassette instead of puromycin permits us to select both the 
sgRNAs and the cell line with the integration of the inducible Cas9 construct. After 
transfecting cells and selecting for hygromycin, we picked and screened clones based 
on Cas9 expression after 24 hours in the presence or absence of 1 µg/ml doxycycline 
induction. We chose the clone with both the highest Cas9 expression after induction 
and no expression in the absence of doxycycline, which was the clone number 8 and 
therefore we named the cell line iCas9 8. In order to show this cell line was expressing 
Cas9 in a doxycycline inducible and dose dependent manner, we treated the cell line 
with increasing doses of doxycycline for 24 hours and assessed the level of Cas9 
expression by immunoblot. Figure 3a clearly shows that increasing the concentration 
of doxycycline caused an incremental increase in the expression of Cas9 up to 10 µg/ml 
of doxycycline after which we observed toxicity. Having generated a Cas9 inducible 
cell line, we asked if this cell line could still differentiate into PGCLCs both before and 
after being treated with doxycycline. For this we generated PGCLCs with the Wild type 
and the iCas9 8 cell line both in the presence and absence of 1 µg/ml of doxycycline 
induction for 48 hours. This showed that the cell line we generated is suitable to use for 
screening. 
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Figure 3 – Generation of a doxycycline inducible Cas9 Stella-GFP ESC line. 
a) Western blot analysis of whole-cell extracts of Stella BAC9 Wild Type cells containing a Cas9 
inducible (iCas9) construct treated with increasing doses of doxycycline for 24 hours. The lysates were 
incubated with anti-Cas9 antibody and anti-B-ACTIN antibody, which served as a loading control. 
b) Bright-field and epifluorescence microcopy images of day 4 PGCLC induced from Stella BAC9 Wild 
type and iCas9 clone 8 before and after 24 hour treatment with 1 µg/ml of doxycycline. 
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3.4 - Validation of the cell line to use in the CRISPR/Cas9 Screen 
 
 Then we aimed at finding if the Cas9 inducible cell line we generated would 
produce gene deletions efficiently in the presence of doxycycline. If this were to be the 
case, this experiment would also permit us to determine the optimal concentration and 
duration of the doxycycline treatment. To achieve this, we transduced cells with a 
sgRNA targeting a surface marker present on mouse ESCs and treated these cells with 
increasing doses of doxycycline. We decided to target c-Kit (CD117) since it is an ESC 
surface marker that permits us to easily follow protein expression using flow cytometry. 
We could then determine the proportion of ESCs in culture that contribute to normal 
levels of c-Kit expression (CD117 positive cells) and compare it to those in which the 
expression was lost due to disruption of the c-Kit locus (CD117 negative cells) (Figure 
4a). In order to ensure that the disruption of c-Kit was caused directly by the sgRNA 
targeting the c-Kit locus and to exclude potential effects of the doxycycline, Cas9, 
sgRNA expression or other variable to cause non-specific reduction of c-Kit expression, 
we decided to transduce cells using a different sgRNA targeting the Rosa26 locus. 
Using this strategy we observed that targeting the Rosa26 locus did not have any effect 
on the CD117 expression up until 5 µg/ml of doxycycline excluding the possibility that 
the decrease in CD117 was due to differentiation caused by the doxycycline treatment 
(Figure 4b). As observed in Figure 4c, treating the cells for 18 days caused up to 80% 
depletion of cells expressing CD117. This allowed us to conclude that the cell line we 
have generated permits the generation of CRISPR deletions in a highly efficient 
manner. These results also permitted us to select the optimal concentration and duration 
of doxycyclin treatment. We had observed loss of CD117 expression with 5 and 7.5 
µg/ml of doxycycline whilst targeting the Rosa26 locus, which was likely due to 
differentiation of the ESCs. Since we require the ESCs to be in a naive state so that we 
can differentiate them into PGCLCs with high efficiency, we decided to use 2.5 µg/ml 
of doxycycline throughout the screen. Furthermore, we decided to induce Cas9 
expression for 21 days to maximise the chances of efficient gene disruption for different 
sgRNAs targeting different genes. 
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Figure 4 – Efficiency of gene deletion in a doxycycline dose and time dependent manner using the 
iCas9 8 cell line. 
a) Representative flow cytometric profile of iCas9 8 ESCs transduced with a sgRNA targeting the CD117 
gene at a MOI inferior to 0.3 treated with increasing doses of doxycycline for 3 days after CD117 
staining. 
b) Representative flow cytometric profile of iCas9 8 ESCs transduced with a sgRNA targeting the 
Rosa26 locus at a MOI inferior to 0.3 treated with increasing doses of doxycycline for 3 days after CD117 
staining. 
c) Quantification of the percentage of CD117 positive iCas9 8 ESCs transduced with a sgRNA targeting 
the CD117 gene at a MOI inferior to 0.3 treated with increasing doses of doxycycline for 18 days after 
CD117 staining. The data represent the mean of three independent experiments. 
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3.5 - Identification of DNA repair factors required for the 
proliferation of mouse embryonic stem cells 
 
Having cloned the sgRNA library and generated and validated the Cas9 inducible cell 
line, we decided to perform a CRISPR screen using only the ESCs we developed and 
assaying the effect of proliferation in the pool of CRISPR KOs. This screen would 
permit us to test if the screening platform is sufficiently efficient at droping out sgRNAs 
targeting essenital genes and also if it permits us to identify known and novel factors 
required for ESC proliferation. In order to do this, we performed a CRISPR screen 
collecting 6.6 million ESCs after 21 days of doxycycline induction, thereby covering 
the sgRNA library at a representation of 2000-fold. Then we compared the sgRNAs in 
the sgRNA pool plasmid DNA before transduction into ESCs with the sgRNAs present 
in the ESC population after doxycycline treatment. sgRNAs which are enriched in the 
ESC population should target genes which when disrupted in ESCs cause a growth 
advantage; sgRNAs which are depleted in the ESC population should correspond to 
sgRNAs targeting essential genes or genes that when disrupted in ESCs cause a 
proliferative disadvantage; sgRNA without any effect in ESC proliferation should 
target genes which when disrupted from ESCs do not affect cell growth. In order to 
achieve this, we first ranked the sgRNAs of the libraries according to the number of 
counts in the ESC population when compared to the plasmid pool of sgRNAs. As 
expected we observed that at least the 11 most underrepresented sgRNAs in this 
analysis correspondeded to sgRNAs targeting essential genes (Figure 5a). Then we 
chose four genes that we knew were essential and also were present in our library, 
namely Mcm2 (Minichromosome maintenance complex component 2), Pcna 
(Proliferating cell nuclear antigen), Rpa2 (Replication protein a2) and Tuba1c (Tubulin 
alpha 1c)) and observed that the 4 sgRNAs targeting each of these genes were depleted 
from the ESC population in comparison to the plasmid pool of sgRNAs (Figure 5b). 
Furthermore, sgRNAs targeting the additional subunits of the RPA complex (Rpa1 and 
Rpa3) and the genes responsible for encoding the Mcm2-7 complex were also depleted. 
Also we observed that the NTC sgRNAs were generally distributed equally in the ESC 
population with equivalent numbers of reads as in sgRNAs targeting genes which are 
known to cause no alteration in cell growth (for example Xpa). This distribution was 
also observed in all of the other cell populations. 
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Figure 5 – Disruption of essential genes in the ESC population causes reduction of sgRNA counts. 
a) Table representing the rank of the sgRNAs with the fewest counts in the ESC population with the 
respective gene and gene function. 
b) Scatter plot representing the count of the four sgRNAs targeting essential genes (Mcm2, Pcna, Rpa2 
and Tuba1c) in the ESC population compared to the plasmid pool of sgRNAs. 
 
 
               Second, by analysing the distribution of sgRNAs in the ESC population whilst 
comparing to the plasmid pool of sgRNAs, we observed the four sgRNAs targeting 
Trp53 to the most strongly enriched (Figure 6a). sgRNAs targeting Trp53 have been 
previously reported to be enriched in the ESC population whenever depleted in other 
screens (Hackett et al. 2018; Li, Yu, et al. 2018) which shows that absence of this gene 
provides a proliferative advantage to ESCs. Trp53 has been shown to be required for 
the suppression of proliferation (Sabapathy et al. 1997) and differentiation of ESCs by 
repressing the pluripotency-associated transcription factor Nanog to induce 
differentiation and to be a barrier for reprogramming (Lin et al. 2005). The second most 
enriched set of sgRNAs in the ESC population corresponded to Setd2. Setd2 is a histone 
methyltransferase that is specific for lysine-36 of histone H3, and methylation of this 
residue is associated with active chromatin (Figure 6b). However no phenotype has 
been studied regarding its proliferation in ESCs. Furthermore we found Chek2 
(Checkpoint kinase 2) and Usp28 (Ubiquitin specific peptidase 28) to confer a 
proliferative advantage to ESCs. Chek2 is a DNA damage response cell cycle 
checkpoint regulator and a putative tumour suppressor that stabilises Trp53 (Figure 
6c). Usp28 is a deubiquitinase involved in the DNA damage response checkpoint, 
which recently has been shown to stimulate Trp53 DNA-binding activity (Cuella-
Martin et al. 2016). The discovery of sgRNAs targeting Trp53 and genes involved in 
the same DNA damage response axis and the fact that sgRNAs which are depleted in 
the ESC population correspond to sgRNAs targeting essential genes gives us 
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confidence that the targeting of the initial ESC population using the Cas9 inducible 
system occurred in an efficient manner. 
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Figure 6 – A CRISPR Screen identifies that disruption of Trp53-axis factors confer a proliferative 
advantage to ESCs. 
a) Scatter plot representing the count of the four sgRNAs targeting the Trp53 in the ESC population 
compared to the plasmid pool of sgRNAs. 
b) Scatter plot representing the count of the four sgRNAs targeting the Chek2, Usp28 and Setd2 in the 
ESC population compared to the plasmid pool of sgRNAs. 
c) Schema representing the factors found to be required for ESC proliferation that act on the Trp53-axis. 
DNA DSBs activate the ATM kinase, which then activates CHEK2 by phosphorylation. The 
phosphorylarion of CHEK2 causes this enzyme to homodimerise, subsequently permitting the 
phosphorylation of other substrates including TRP53. TRP53 when phosphorylated becomes stabilized 
and can therefore activate the transcription of genes involved in cell cycle arrest or apoptosis, ultimately 
mediating the response to DNA damage. USP28 has also been shown to form a complex with 53BP1 
and to stimulate TRP53 DNA binding activity. 
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3.6 - Upscaling of EpiLC differentiation to perform a genetic screen 
 
 In order for each sgRNA of the plasmid pool to be present in 2000 cells on 
average in the PGCLC population (fold-representation of 2000), we aimed to FACS 
sort 6.6 million cells. This posed a technical limitation since from a 96 well-plate 
containing one aggregate per well we could only generate a few thousand PGCLCs. 
Therefore, as a first step to reach the 6.6 million PGCLCs, we had to first be able to 
generate millions of EpiLCs to then differentiate into PGCLCs and so we could keep 
the fold-representation of 2000 throughout the screen. Previously, we were culturing 
the EpiLCs in 12 well-plates as described by Hayashi et al. (Hayashi et al. 2011). In 
order to more easily generate millions of EpiLCs, we aimed at culturing these cells in 
larger plates so we could more easily culture, wash and tryspinise these cells before 
differentiation into PGCLCs. In order to test if changing the culture dish had an effect 
on the differentiation, we cultured the iCas8 8 cell line to generate EpiLCs in 12 well-
plates as before but also in 10 cm dishes. Then we followed the protocol of 
differentiation using the adjusted volumes for the respective dishes and differentiated 
the EpiLCs grown in the two different ways into PGCLCs. Using flow cytometry we 
observed no difference in the profiles and percentages of SSEA1 and GFP positive cells 
(Figure 7a and b). 
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Figure 7 – Upscaling production of EpiLCs using 10 cm dishes. 
a) Representative flow cytometric profile of PGCLCs induced from EpiLCs grown in 12 well-plates and 
10 cm dishes. The frequency of PGCLCs refers to the frequency of GFP and SSEA1 double positive 
population. 
b) Quantification of the percentage of iCas9 8 day 4 PGCLCs induced from EpiLCs grown in 12 well-
plates and 10 cm dishes from iCas9 8 ESCs. The data represent the mean of three independent 
experiments. The statistical analysis performed was an unpaired t-test. 
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3.7 - Identification of DNA repair factors required for the exit of 
mouse embryonic stem cells from pluripotency 
 
 Having developed a system that permits us to generate millions of EpiLCs and 
having shown that the sgRNA library we cloned coupled to the Cas9 inducible ESC 
line permits the discovery of novel factors in ESCs, we aimed to perform a screen in 
which we would compare the ESCs with the EpiLCs. This screen would permit to test 
if the screening platform we developed together with the differentiation system permits 
the identification of factors required for ESC differentiation to EpiLC. To achieve this 
we collected 6.6 million ESCs and EpiLCs after doxycycline induction and compared 
the sgRNAs in both population to find factors required for exit to pluripotency in ESCs. 
We found no NTC sgRNAs in the top rank of gene dropouts, suggesting that the genes 
we found are very likely to play a role in the differentitation of ESCs to EpiLCs. The 
gene Dnmt1 (DNA methyltransferase 1) was in the top of the list of dropouts in the 
EpiLC population (Figure 8a). Dnmt1 is a maintenance DNA methyltransferase 
enzyme that transfers methyl groups to cytosine bases in genomic DNA. This protein 
is the principal enzyme responsible for maintaining methylation patterns after DNA 
replication with a preference for hemi-methylated DNA. It has been previously reported 
that Dnmt1 is required for ESC differentiation (Panning and Jaenisch 1996) and a 
CRISPR/Cas9 screen using the PGCLC system also identified Dnmt1 to be required for 
the transition from ESCs to EpiLCs (Hackett et al. 2018). This result suggests that 
inability to maintain methylation patterns in the genome impedes differentiation in 
ESCs. However, which genes are required for the transition from ESC to EpiLC and 
how they are regulated via Dnmt1 remains to be explored. In addition to Dnmt1, we 
found other factors in the top of the list of most depleted genes in EpiLCs, such as 
Usp28, Rnaseh2a (Ribonuclease H2 subunit a) and Cdh1 (Cadherin 1) (Figure 8b). 
Usp28 was previoulsy observed to be required for ESC proliferation and we 
hypothesised this gene would function together with Trp53 regulating proliferation and 
differentiation. Since Usp28-deficient mice are viable, which suggests absence of this 
gene still permits differentiation in vivo, this putative hit would have to be first validated 
in vitro before studying its role in ESC differentiation. We also found sgRNAs targeting 
Rnaseh2a to be depleted in EpiLCs in our screen. Rnaseh2a is a component of the 
heterotrimeric ribonuclease H enzyme (RNASEH2) (Jeong et al. 2004), an enzyme 
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responsible for removing ribonucleotides from genomic DNA (Hiller et al. 2012). Since 
Rnaseh2a-deficient mice die during embryonic development one can hypothesise that 
during differentiation an increase of ribonucleotides accummulates in the genome 
which, if not removed by RNASEH2A, cause lethality and impair differentiation. In 
addition to Rnaseh2a, the genes encoding the remaining subunits of the trimeric 
RNASEH2 complex (Rnaseh2b and Rnaseh2c), were not observed to be depleted in the 
EpiLC population since sgRNAs targeting these genes were not present in the initial 
library of sgRNAs. We also found Cdh1, which encodes for a calcium-dependent cell-
cell adhesion protein which has been shown to be required for ESC differentiation 
(Mohamet, Lea, and Ward 2010). In addition, Cdh1-deficient mice fail to survive 
embryonic development (Riethmacher, Brinkmann, and Birchmeier 1995) suggesting 
this gene may be required for differentiation. However, the requirement for Cdh1 
during exit from pluripotency has not been explored further. This screen allowed us to 
conclude that the platform we developed coupling CRISPR screening with ESC 
differentiation permits the discovery of known and novel genetic factors. The next step 
would then be to use this tool to find novel factors required for PGCLC differentiation. 
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Figure 8 – A CRISPR Screen identifies Dnmt1, Usp28, Rnaseh2a and Cdh1 to be required for the 
exit from pluripotency. 
a) Scatter plot representing the count of the four sgRNAs targeting the Dnmt1 in the EpiLC population 
when compared to the ESC population. 
b) Z-score rank of top depleted genes in the EpiLC population when compared to the ESC population. 
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3.8 - Upscaling of PGCLC differentiation to perform a genetic screen 
 
 
 In order to restrict the time of differentiation of ESCs to PGCLCs to the 
minimum so that DNA repair deficient cells with proliferative defects do not get 
outcompeted by other cells we decided to perform the PGCLC screen after 4 days of 
PGCLC differentiation. Also we observed that unlike after 4 days, aggregates after 6 
days start to extrude extracelular matrix components which make these samples harder 
to process and therefore difficult to generate and FACS sort millions of PGCLCs. We 
were previously generating PGCLCs in Lipidure-Coat 96 well-plates according to the 
protocol described by Hayashi et al. (Hayashi et al. 2011) which yielded only 96 
aggregates per plate corresponding to a few thousand PGCLCs. Therefore based on the 
method used by Ohta, H, et al. (Ohta et al. 2017) we adapted a new system for growing 
the PGCLC aggregates in 800 µm Aggrewell plates. These plates contain 800 µm 
diameter micro wells in which the aggregates can form, therefore permitting us to 
generate around 300 aggregates per well that corresponds to 7200 aggregates in a full 
plate and around 0.3 million PGCLCs after 4 days of differentiation. The aggregates 
we generated in Aggrewell plates achieved the same flow cytometry profile and 
percentage of PGCLCs as observed in Lipidure-Coat 96 well-plates (Figure 9a). 
Additionally, microscopic analysis did not reveal any morphological differences 
between the PGCLC aggregates grown in 96 well-plates compared to Aggrewell plates 
(Figure 9b). Altogether we can conclude that we have devised a method that permits 
to generate millions of PGCLCs so we can perform a robust genetic screen. 
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Figure 9 – Large scale production of PGCLCs using 800 µm Aggrewell plates. 
a) Representative flow cytometric profile of PGCLCs induced in 96 well-plates and 800 µm Aggrewell 
plates from iCas9 8 ESCs after SSEA1 staining. The frequency of PGCLCs refers to the frequency of 
GFP and SSEA1 double positive population. 
b) Bright-field and epifluorescence microcopy images of day 4 PGCLC induced from iCas9 clone 8 
ESCs in both 96 well-plates and 800 µm Aggrewell plates. 
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              Having optimised the concentration and duration of doxycycline treatment, 
we asked if we could observe a defect in the PGCLC population when targeting GFP 
after the ESC KO generation and differentiation step. This would ultimately provide us 
with some evidence regarding the efficiency of this screening strategy. To achieve this, 
the iCas9 8 cell line was transduced at a low MOI with sgRNAs targeting GFP, selected 
these with puromycin and treated them in the presence or absence of 2.5 µg/ml of 
doxycycline for 21 days. These cells were then induced to differentiate into EpiLCs and 
into PGCLCs and subsequently analysed by flow cytometry. Figure 7a and b show the 
presence of a GFP negative population in the experiment done in the presence of 
doxycycline wheres this GFP negative population is not observed in the untreated 
control. The GFP quantification in the SSEA1 positive cell population showed a 
striking reduction in the GFP signal, which led us to conclude that this system will 
permit the discovery of new factors required for the development of PGCLCs. The 
reduction in percentage of the GFP-positive cells in this experiment (around 40%) 
which is a proxy for gene disruption, is not as striking as the reduction of up to 80% 
observed in Figure 10a and b for CD117 disruption. This observation may be 
explained by an inferior efficiency of the sgRNAs used in both strategies. However, it 
is more likely that since there may be multiple copies of GFP in the Stella BAC9 cell 
line, it makes it more challenging to fully disrupt GFP in comparison to CD117 which 
has only two copies in the genome. 
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Figure 10 – Deletion of GFP in ESCs using optimised conditions for screening causes a reduction 
in the frequency of PGCLCs. 
a) Representative flow cytometric profile of iCas9 8 day 4 PGCLCs transduced with a GFP sgRNA at a 
MOI inferior to 0.3 treated with 0 and 2.5 µg/ml of doxycycline for 21 days and after SSEA1 staining. 
b) Quantification of the percentage of iCas9 8 day 4 PGCLCs transduced with a GFP sgRNA at a MOI 
inferior to 0.3 after treatment with 0 and 2.5 µg/ml doxycycline for 21 days and after SSEA1 staining. 
The data represent the mean of three independent experiments. The statistical analysis performed was an 
unpaired t-test. 
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3.9 - A CRISPR screen identifies novel repair factors in PGCLCs 
 
 Having developed all of the reagents and tools to perform the CRISPR screen 
and having shown that the developed strategy works for GFP, which is our reporter of 
PGCLCs, we performed the PGCLC screen. In order to do this, we infected the iCas9 
cell line with the sgRNA library, which we then treated with doxycycline for 21 days. 
After this period, the ESCs were differentiated into EpiLCs. In order to generate 6.6 
million PGCLCs, we had to plate 13 full Aggrewell plates since we generated around 
0.02 million PGCLCs per well after plating 600.000 EpiLCs into one well of an 
Aggrewell plate. This therefore meant that we had to plate around 200 million EpiLCs 
into Aggrewell plates to then differentiate into PGCLCs and also collect 6.6 million 
EpiLCs for NGS. Finally, since from one 10 cm dish we could generate around 6 
million of EpiLCs, we differentiated initially around 100 million ESCs to EpiLCs while 
also keeping 6.6 million for NGS. During the FACS purification loss of cells due to 
cell death caused the average representation of each guide in the PGCLC population to 
be slightly over 100-fold. Even though we did not reach the aimed representation of the 
sgRNAs in all populations of the screen, we performed subsequent NGS and compared 
the abundance of sgRNAs present in the EpiLCs with the sgRNAs present in the 
PGCLCs. 
 We ranked the genes corresponding to sgRNAs that were the most depleted in 
PGCLCs and observed that from the ones which did not cause embryonic lethality a 
considerable proportion (80%) were involved in fertility phenotypes described in the 
literature (Figure 11 a and b). No NTC sgRNAs were observed in this list. 
 Interestingly, we did not observe Ercc1 to be one of the most depleted genes in 
the PGCLCs (rank = 368) (Figure 11a and c). This may be due to the fact that the 
reduction in PGCs observed in Ercc1–deficient embryos occurs later in PGC 
development (around E11.5) whereas the day 4 PGCLCs transcriptionally resemble 
E10.5 PGCs where a significant numeric reduction is not yet observed. 
 Also we observed some essential genes to be on the top of the list including: 
Rfc1 (Replication Factor C Subunit 1), Snprd1 (Small nuclear ribonucleoprotein D1 
polypeptide) or Smc5 (Structural maintenance of chromosomes 5). The presence of 
sgRNAs targeting these genes may be explained by inefficient gene disruption which 
would cause the absence of depletion from the ESC population. Furthemore, the cells 
containing these sgRNAs can be either false-positives and therefore these genes would 
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have no effect on PGCLC formation or the consequence of having truncated but still 
functional versions of these genes that would confer cells an inabilty to generate 
PGCLCs. 
 However, we found several known factors to be required for PGC development 
to be highly depleted in the PGCLC population. This included Pds5b (Precocious 
dissociation of sisters 5b), which encodes a protein that interacts with regulatory 
component of cohesin and genetically or physically interacts with the cohesion factors 
Scc1, Scc2 and Scc3 (Sister chromatid cohesion), Esco1 (Establishment of sister 
chromatid cohesion N-acetyltransferase 1), Smc1 and Smc3 (Structural maintenance of 
chromosomes 1 and 3) (Losada, Yokochi, and Hirano 2005; Panizza et al. 2000) to 
ensure proper sister chromatid cohesion during mitosis and meiosis (Panizza et al. 
2000; Hartman et al. 2000; van Heemst and Heyting 2000). Furthermore, absence of 
Pds5b has been previously shown to be required for PGC development in mice (Zhang 
et al. 2007). 
 Also, we observed some new interesting factors. One of them is named Spidr 
(Scaffold protein involved in DNA repair) (Figure 11e). SPIDR is known to interact 
with BLM and RAD51 and has been shown to cause increased rates of sister chromatid 
exchange and defects in HR (Wan et al. 2013). Furthermore, SPIDR has also been 
shown to interact with FIGNL1 and the authors claim that these factors act together in 
HR repair (Yuan and Chen 2013). Interestingly, patients in a consanguineous family 
with a mutation in SPIDR presented failure to reach puberty and exhibited very high 
levels of the hormones that stimulate gonad development (Smirin-Yosef et al. 2017). 
This is exactly the phenotype we would expect if this factor was to be required for the 
development of PGCs. 
 In the top of our list ranking number 8, we found Tdg which is a DNA 
glycosylase shown to play roles in maintaining epigenetic stability and DNA 
demethylation. However Tdg knockout mice die during embryonic development so the 
fertility phenotype cannot be assessed (Cortazar et al. 2011; Cortellino et al. 2011). 
Also, we found the Msh2 (MutS homolog 2) (rank=2) and Msh6 (MutS homolog 6) 
(rank=14) mismatch repair genes which together form the heterodimer MutSα. Even 
though both mouse models for these genes have been generated and were shown to be 
fertile (Reitmair et al. 1995; Edelmann et al. 1997), mice deficient in Msh2 have been 
proposed to have germ cell defects in adults comparable to what is observed in Ercc1-
deficient mice (Paul et al. 2007). 
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 In addition to this, we found Rev1 in the screen (rank=15) (Figure 11a and f). 
Rev1 is a deoxycytidyl transferase enzyme that also serves as a scaffold to recruit DNA 
polymerases involved in TLS (Pustovalova, Bezsonova, and Korzhnev 2012; Masuda 
et al. 2001). Rev1-deficient mice were previously generated and exhibited growth 
retardation and impaired class-switch recombination (Jansen et al. 2006). Interestingly, 
no germ cell or fertility defects were studied in detail in these mice. Overall we can 
conclude that we have optimised and developed a system which we used to perform a 
genetic screen to find novel DNA repair factors required for PGC development. We 
found known factors to be essential for PGC development such as Pds5b but more 
interestingly we found novel factors with potential roles in fertility such as Spidr or 
Rev1. The next logical step is to validate these hits which will inform us if these factors 
are indeed required for PGC development in vitro and in vivo. 
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Figure 11 – A CRISPR Screen identifies Rev1 and Spidr to be required for PGCLC development. 
a) Z-score rank of top depleted genes in the EpiLC population when compared to PGCLCs. 
b) Pie chart representing the proportion of genes from the table of top hits which when disrupted cause 
embryonic lethality in mice or that have been shown to be involved in sterility or fertility phenotypes. 
c) Scatter plot representing the count of the four sgRNAs targeting Ercc1 in the EpiLC population when 
compared to PGCLCs. 
d) Scatter plot representing the count of the four sgRNAs targeting Pds5b in the EpiLC population when 
compared to PGCLCs. 
e) Scatter plot representing the count of the four sgRNAs targeting Spidr in the EpiLC population when 
compared to PGCLCs. 
f) Scatter plot representing the count of the four sgRNAs targeting Rev1 in the EpiLC population when 
compared to PGCLCs. 
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Summary 
 
The data presented here represent all of the steps of optimisation towards performing a 
CRISPR/Cas9 knockout screen using the PGCLC in vitro system. These steps included 
the cloning and assembly of a sgRNA library targeting genes involved in genome 
stability in the mouse genome, generating a doxycycline inducible Cas9 cell line and 
testing the cell line for CRISPR screening. First, we performed a screen in ESCs to test 
if the tools we generated would yield known factors required for ESC proliferation and 
to test if essential genes would be depleted as anticipated. As expected, we found 
sgRNAs targeting Trp53 to be highly enriched in ESCs whereas the most depleted 
sgRNAs targeted essential genes. Having validated this step we upscaled the production 
of EpiLCs to generate enough cells for PGCLC differentiation. Having a tool to 
generate vast numbers of EpiLCs we performed a screen to test if differentiating ESCs 
to EpiLCs would yield known and novel factors required for ESC differentiation. We 
observed Dnmt1 to be in the top of the list as observed in similar screens in the past. 
Finally, we upscaled the production of PGCLCs to perform a screen using this 
population. We performed a screen in PGCLCs, which permitted us to identify known 
factors required for PGC development including Pds5b but also putative new factors 
such as Spidr and Rev1. 
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Chapter 4 - Identification of Rev1 as a 
critical factor required for early PGC 
development 
 
4.1 - Disruption of Rev1 in ESCs 
 
 One of the most interesting putative hits we obtained from the screen was Rev1. 
REV1 is a deoxycytidyl transferase enzyme that also acts as a scaffold to recruit DNA 
polymerases involved in TLS (Pustovalova, Bezsonova, and Korzhnev 2012; Masuda 
et al. 2001). Rev1 is recruited to chromatin upon DNA damage via its BRCT domain 
(Guo et al. 2006) and is required to maintain cellular resistance to a number of DNA 
damaging agents including UV irradiation. However, its deoxycytidyl transferase 
activity is dispensable for maintaining resistance to DNA damage. REV1 interacts with 
other TLS DNA polymerases via its C-terminus, which implicates it as an adaptor for 
polymerase switching at the lesion site. This region is critical for cells to repair damage 
caused by DNA damaging agents. The potential discovery of the requirement for Rev1 
in PGCs is particularly interesting because it is known that Rev7-deficient mice and 
ESCs have reduced abilities to generate PGCs in vivo and in vitro, respectively (Pirouz, 
Pilarski, and Kessel 2013; Rahjouei et al. 2017; Watanabe et al. 2013). In addition to 
this, Rev1-deficient mice not only exhibit growth retardation and impaired class-switch 
recombination but have also been shown to be sterile. Since the origin of the sterility 
phenotype has not been explored, we decided to follow up on this putative hit, which 
would further validate the screen. 
 In order to perform the validation, we generated a new sgRNA that was not 
initially present in the sgRNA library used in the screen to therefore remove the 
consequence of off-target effects. Using this sgRNA we disrupted Rev1 in our reporter 
ESC line to interrogate if absence of Rev1 is required for PGC development in vitro. 
We chose to target the exon 10 since this exon encondes for the deoxycytidyl 
transferase domain, which is responsible for the cataltic activity of REV1 (Figure 1a). 
The targeted region was amplified by PCR, cloned into a TOPO Zero Blunt vector and 
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Sanger sequencing was performed to confirm the identity of the indels disrupting the 
genes (Figure 1a). Finally, to confirm biallelic disruption, we performed a colonogenic 
survival assay, which showed clear hypersensitivity to mitomycin C (Figure 1b) as 
previously described (Hicks et al. 2010). 
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Figure 1 – Disruption of Rev1 in ESCs. 
a) Schema representing the Rev1 locus with the targeted exon indicated in red and the sequence of 
disrupted alleles after CRISPR-mediated disruption. Coding exons are represented as black boxes. 
b) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate made relative to the untreated 
of each cell line. 
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4.2 - Rev1 is required for PGC development in vitro 
 
 In order to ascertain if Rev1 is required for PGC development in vitro and 
validate our screen, we induced Rev1-deficient ESCs to differentiate to PGCLCs. 
Microscopic examination revealed a clear reduction in the number of Stella-GFP 
positive cells in the absence of Rev1 (Figure 2a). Furthermore, the frequency of 
PGCLCs was determined by flow cytometry revealing that loss of Rev1 leads to a 4-
fold reduction in PGCLC frequency (Figure 2b and c). This set of experiments 
therefore validated one of the hits found in our screen and indicates the requirement for 
the TLS enzyme Rev1 for the development of PGCs in vitro. 
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Figure 2 – Absence of Rev1 impairs the development of PGCs in vitro. 
a) Bright-field and epifluorescence microscopy images of day 4 Stella BAC9 Wild type and Rev1-/- 
PGCLCs. 
b) Representative flow cytometry profiles of PGCLC induced from Stella BAC9 Wild type and Rev1-/- 
PGCLCs after SSEA1 stain. The percentage of PGCLC refers to the frequency of GFP and SSEA1 
double positive population. 
c) Quantification of the frequency of SSEA1 and GFP positive cells (PGCLCs) in the different cell lines 
shown. The data represent the mean of three independent experiments. The statistical analysis performed 
was an unpaired t-test. 
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4.3 - Rev1-/- mice display a numerical defect in PGCs which results in 
impaired fertility 
 
 Having observed that disruption of Rev1 in ESCs caused a decrease in the 
number of PGCLCs in vitro, we tested whether this would also happen in mice. This 
served as a first validation of our hits in vivo and would provide further evidence that 
the system we setup is giving us new valuable insight into the biology of PGCs. One 
potential caveat of this system could be that the factors we found, namely DNA repair 
genes, would only have a reduction in PGCLC frequency since certain DNA repair 
genes impair cell proliferation. Also, using this system we only used one marker of 
PGCs – Stella – therefore making it possible that some of the factors we found directly 
affect the ability to express this marker rather than having an effect on PGC 
development. Finally, since we are using an in vitro system, many of the aspects such 
as the interaction with the niche cells in which PGCs are specified cannot be reproduced 
as when using a developing organism. This may also contribute for the presence of 
false-positive and false-negative putative hits in our screen. Therefore, the use of an 
organism as a model and a new reporter would bypass most limitations of using an in 
vitro system in order to validate putative hits from the screen. To achieve this goal, we 
first investigated the histology of the testis and ovaries of adult Rev1-deficient mice. In 
the Rev1-deficient testis we can observe a complete absence of germ cells in the 
seminiferous tubules with all tubules showing a Sertoli-cell only phenotype (Figure 
3a). The absence of germ cells in the male gonads causes therefore these mice to 
become sterile as previously reported (Jansen et al. 2006). In the Rev1-deficient females 
we can observe absence of primary and maturating follicles therefore causing the 
absence of oocytes. This phenotype causes the sterility we observed by in the absence 
of Rev1. Then, in order to investigate if the absence of germ cells in adult mice was due 
to inability to develop PGCs, we performed timed matings between Rev1 heterozygous 
mice carrying a PGC-reporter in which the expression of GFP is driven by a fragment 
of the Oct4 promoter (known as Gof18-GFP) (Szabo et al. 2002; Yeom et al. 1996). 
This would show that disruption of Rev1 is not directly affecting the expression of Stella 
which would reduce the PGC numbers due to failure to activate the reporter rather than 
inability to correctly specify or develop PGCs. Also, since we performed the screen 
with day 4 PGCLCs, which transcriptionally resemble early PGCs, we chose to perform 
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the PGC analysis earlier in development, at E9.5, and not at E12.5 as done before for 
Ercc1-deficient embryos. This analysis would permit us therefore to uncover genes 
required for PGC specification and early development which should present a 
phenotype already at this developmental stage unlike Ercc1. In order to analyse E9.5 
PGCs, we trypsinised and ressuspended the cells of the entire embryo which we 
analysed using flow cytometry (Figure 3b and c). Comparably to the in vitro system, 
we observed a 4.45-fold reduction in the ability to make PGCs in Rev1-deficient 
embryos while comparing to the Wild type littermates (Figure 3c). Therefore, these 
results demonstrated for the first time that Rev1 is required during PGC development 
and the absence of this enzyme causes sterility in both sexes. 
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Figure 3 – Rev1 deficient mice have an early PGC defect and are sterile. 
a) Haematoxylin and eosin (H&E) stained sections of ovaries and testes of 8-week old Wild type and 
Rev1-/- mice. 
b) Representative flow cytometric profile of PGCs obtained from E9.5 embryos after SSEA1 staining. 
The frequency of PGCs refers to the frequency of GFP and SSEA1 double positive population. 
c) Quantification of the number of SSEA1 and GFP positive cells (PGCs) from Wild type and Rev1-/- 
embryos. The data represent the mean of three independent experiments. 
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4.4 - Generation of a deoxycytidyl transferase catalytically inactive 
Rev1 cell line 
 
 In light of the data implicating the role of Rev1 in the development of PGCs, 
the next step was to separate the functions of Rev1 in order to understand which function 
of Rev1 is required to maintain genome stability in PGCs. Interestingly, in yeast and 
bacteria the catalytic activity of Rev1 is responsible for almost all of the point mutations 
(Cox and Horner 1982; Glassner et al. 1998). However, in vertebrates the importance 
of the catalytic activity of Rev1 in promoting TLS seems to be less significant (Ross, 
Simpson, and Sale 2005). Therefore, in order to separate the catalytic activity of Rev1 
from its other functions in vivo, we aimed to generate a catalytically inactive form of 
Rev1 in ESCs. Mice carrying a point mutation that generates a catalytically inactive 
Rev1 exhibit a great decrease in G to C and C to G transversions in the immunoglobulin 
locus of B cells (Masuda et al. 2009). The Rev1 catalytically inactive cell line 
(Rev1D568A/E569A from now on named Rev1AA) was generated by substituting the catalytic 
aspartate and glutamate residues, responsible for the deoxycytidyl transferase activity, 
with two alanine residues. This substitutions have been shown to cause absence of 
enzymatic activity in terminally mismatched primer template assay using mouse Wild 
type and REV1AA purified proteins (Guo et al. 2003). In addition to this, the level of 
mRNA expression in both Wild type and Rev1AA spleen B-cells is equivalent (Masuda 
et al. 2009) however it has not been shown that the protein is equally stable as the Wild 
type. In order to generate this mutant cell line, we transfected ESCs with two plasmids: 
the sgRNA and Cas9-containing plasmid and the plasmid expressing tdTomato. We 
additionally co-transfected a single stranded oligonucleotide (ssODN) containing the 
mutation of interest in the Rev1 exon 10, flanked by two homology arms. This sequence 
was designed to introduce a new AciI restriction site, which allows the screening for 
the correct integration of the ssODN (Figure 4a and b). We found a clone that after 
PCR amplification of the region and digestion with AciI revealed the correct integration 
of the ssODN and loss of the Wild type allele. This suggested that the ESCs were 
homozygous for the catalytically inactive form of Rev1 (Figure 4c). To confirm that 
the ssODN was correctly integrated into the targeted locus we amplified the targeted 
region, cloned it into a TOPO Zero Blunt vector and confirmed the modification by 
Sanger sequencing (Figure 4a and b). Furthermore, we observed that unlike complete 
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absence of Rev1, the catalytic function of Rev1 is not required to confer resistance to 
DNA crosslinking agents (Figure 4c) as previously described (Ross, Simpson, and Sale 
2005) further suggesting that the REV1AA protein is still sufficiently stable to provide 
resistance to crosslinking agents. 
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Figure 4 – Generation of a deoxycytidyl transferase catalitically inactive Rev1AA ESC line. 
a) Schema representing the Rev1 locus and the sequencing chromatogram covering the deoxycytidyl 
transferase domain coding region. Coding exons are represented as boxes. 
b) Schema representing the Rev1AA targeted locus, the sequencing chromatogram spanning the 
deoxycytidyl transferase domain coding region after targeting with the Cas9 enzyme, the sgRNAs and 
the ssODN. The insertion of a new AciI restriction site is also depicted. Coding exons are represented as 
boxes. 
c) TBE urea polyacrylamide gel showing the PCR products of the Rev1 targeted regions after AciI 
digestion for 1 hour at 37°C in both Wild type and mutant ESC lines. 
d) Colonogenic survival assay with mitomycin C. ESCs were incubated with increasing doses of 
mitomycin C and the number of colonies observed were counted following 6 days. The data represent 
the mean of three independent experiments each carried out in duplicate. 
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4.5 - The catalytic activity of Rev1 is dispensable for PGCLC 
development 
 
 In order to clarify the role of the deoxycytidyl transferase domain of REV1 in 
germ cells, we used the same strategy as above, by looking at the capacity of Rev1-/- 
and Rev1AA ESCs to form PGCLCs (Figure 5a and b). The Rev1AA ESCs showed 
equal capacity to form PGCLCs as the parental Wild type ESCs (Figure 5c). This result 
allows us to conclude that the deoxycytidyl transferase activity of REV1 is not 
responsible for its requirement in PGCLC development. 
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Figure 5 – REV1 catalytic activity is dispensable for PGCLC development in vitro. 
a) Bright-field and epifluorescence microscopy images of day 4 Stella BAC9 Wild type, Rev1-/- and 
Rev1AA PGCLCs. 
b) Representative flow cytometric profiles of PGCLCs induced from Stella BAC9 Wild type, Rev1-/- and 
Rev1AA PGCLCs after SSEA1 stain. The percentage of PGCLC refers to the frequency of GFP and 
SSEA1 double positive population. 
c) Quantification of the frequency of SSEA1 and GFP positive cells (PGCLCs) in the different cell lines 
shown. The data represent the mean of three independent experiments. The statistical analysis performed 
was an unpaired t-test. 
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4.6 - Generation of Rev1AA mice 
 
 Having generated an ESC cell line which carries a point mutation inactivating 
the catalytic activity Rev1 but still capable of generating PGCs in vitro, we decided to 
generate transgenic mice using this cell line so we could validate this phenotype in vivo. 
In order to achieve this, we aimed at generating transgenic mice by ESC injection into 
blastocysts. The Rev1AA ESCs were derived from a mixed background (B6CBA). 
Therefore when injected into blastocysts derived from B6-albino mice, which have 
white fur due to a mutation in the tyrosinase gene, the chimeric progeny of this mice 
may exhibit varying percentages of brown fur. This percentage permits to estimate the 
contribution of the ESC line to the different germ layers when injected into albino 
blastocysts. In order to generate Rev1AA mice, we then injected the Rev1AA ESCs into 
the ICM of E3.5 mouse embryos which were transplanted to pseudopregnant females 
(Figure 6a). After birth, chimeric mice were generated which permitted us to conclude 
that the Rev1AA ESCs contributed to the development of the chimeric mice (Figure 
6b). These chimeras were backcrossed with B6-albino mice to allow germ line 
transmission of the Rev1AA allele into constitutive heterozygous mice. These mice were 
then interbred to obtain the homozygous Rev1AA mice.  
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Figure 6 – Generation of Rev1AA mice. 
a) Schema representing the strategy employed to generate Rev1AA mice. First, ESCs carrying the Stella-
GFP reporter were derived from blastocysts of a B6CBA mixed background. Then, the point mutation 
in Rev1 was introduced in the genome of these cells as previously described. Afterwards, ESCs were 
injected into blastocysts derived from B6-albino mice. These blastocysts containing Rev1AA ESCs were 
then implanted into a pseudo-pregnant female mouse. The progeny of this female mouse (F0) yielded 
chimeric mice of different percentages. The highest percentage chimeras were then backcrossed with 
B6-albino mice to generate Rev1AA heterozygous mice. Provided the allele was transmitted via the germ 
line of the chimeric mice, the offspring of this cross (F1) would yield constitutive heterozygous Rev1AA 
in a proportion of 1 in 4. The constitutive heterozygous Rev1AA mice were then crossed to generate the 
F2 offspring in which a homozygous Rev1AA mouse is generated at a proportion of 1 in 4. 
b) Representative image of chimeric mice with different percentages of chimerism (from 0 to 99%) which 
are attributed based on the colour of the fur. 
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4.7 - The catalytic activity of REV1 is dispensable for fertility in mice 
 
 Having generated the Rev1AA mouse allele, we asked if the deoxycytidyl 
transferase activity of Rev1 is responsible for fertility and PGC development in vivo. In 
order to achieve this goal, we performed crosses between both female and male Rev1AA 
mice with Wild type mice and observed that the absence of the catalytic activity of 
REV1 does not affect fertility in adult mice (Figure 7a). Also, we investigated the 
histology of the testis and ovaries of 8-week old Rev1AA mice. H&E staining of 
Rev1AA testis revealed the presence of germ cells at all stages of development (Figure 
7b). In the Rev1AA females we could observe by H&E staining of the ovaries the 
presence of all stages of maturation of follicles in a comparable manner as in the Wild 
type (Figure 7b). Finally, we assessed the reproductive capacity of both male and 
female Rev1AA mice. Then we performed timed matings between heterozygous 
Rev1+/AA mice and Rev1+/- to produce embryos with one copy of catalytically dead and 
Wild type embryos. We analysed the PGCs by flow cytometry at E9.5 (Figure 7c and 
d). Similarly to the in vitro system, we observed no reduction in the ability to make 
PGCs in Rev1AA mice compared to Wild type mice. These results show that the 
deoxycytidyl transferase activity of Rev1 is not required for the development of PGCs 
in mice and therefore is dispensable for fertility. The catalytic activity of REV1 was 
shown to be dispensable for conferring resistance to DNA damaging agents in 
vertebrates (Ross, Simpson and Sale 2005). In addition, normal development of PGCs 
was shown to be dependent on different DNA repair pathways such as the FA repair 
pathway (Hill and Crossan 2019) and HR (Luo et al. 2015; Messiaen et al 2013). This 
suggests that an alternative function of REV1, which most likely confers resistance to 
DNA damage, may repair the damage encountered by PGCs. It has been shown that the 
C-terminus of REV1, which is required for a direct interaction with TLS enzymes and 
also with polymerase ζ via REV7, is essential for conferring cellular resistance to DNA 
damaging agents (Ross, Simpson and Sale 2005). Since Rev7 but not any of other TLS 
polymerases has been shown to be required for fertility and PGC development, one can 
hypothesize that Rev1 is required in PGCs to recruit DNA polymerase ζ via Rev7. In 
order to test this hypothesis, we would generate a mouse encoding a truncated version 
of Rev1 in the C-terminus or a point mutation which impairs the ability of REV1 to 
interact with the REV7. Then the number of PGCs in the gonads of these mouse 
embryos would be quantified to ascertain if the interaction of REV1 with DNA 
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polymerase ζ is indeed essential for the correct development of PGCs. Provided this is 
the case it would be of interest to explore whether REV7 is required in PGCs as a 
subunit of polymerase ζ therefore extending beyond the lesion encountered in PGCs or 
if there is a requirement for a different role of this multifunctional factor. 
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Figure 7 – The catalytic activity of REV1 is dispensable for PGC development and fertility. 
a) Quantification of the accumulative number of offspring per liter when male or female Rev1AA or 
controls were mated with Wild type mice. The data represent the mean of three mice. 
b) Haematoxylin and eosin (H&E) stained sections of ovaries and testes of 8-week old Wild type and 
Rev1AA/AA mice. 
c) Representative flow cytometric profile of PGCs obtained from E9.5 embryos after SSEA1 staining. 
The frequency of PGCs refers to the frequency of GFP and SSEA1 double positive population. 
d) Quantification of the number of SSEA1 and GFP positive cells (PGCs) from Wild type and Rev1AA/- 
embryos. The data represent the mean of three independent experiments. The statistical analysis 
performed was an unpaired t-test.  
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Summary 
 
The data presented above validate and show that screening in PGCLCs is a useful 
system to explore new PGC biology. We validated a hit from our screen both in vitro 
and in vivo. This not only validates the system but also yields new insight into how the 
genome stability of PGCs is maintained. Using a different sgRNA as the ones used in 
the screen, we showed that disruption of Rev1 in ESCs reduced the ability of cells to 
differentiate into PGCLCs. Then, using Rev1-deficient mice we found that absence of 
Rev1 in adult mice caused loss of germ cells and infertility. In addition to this, we found 
that the sterility phenotype observed in Rev1-deficient mice is caused by a numerical 
reduction of PGCs early in development. Furthermore, we showed that the catalytic 
activity of REV1 is dispensable for PGC development both in vitro and in vivo. These 
result suggests that TLS may act in PGC development to promote mutagenesis in the 
mammalian germ line. 
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Chapter 5 - Discussion 
 
5.1 - PGCLC system recapitulates the requirement for DNA repair in 
vivo 
 
 DNA repair has been studied for over 30 years since the initial discovery that 
the DNA molecule could be damaged and therefore would require some form of repair 
(Lindahl 1993). Most genetic studies have aimed to understand how DNA is repaired 
by treating DNA repair deficient cell lines with DNA damaging agents. This approach 
permits to study the role of a determined factor in an experimental setting which is far 
from resembling what happens in a physiological scenario. Our lab decided to study 
Ercc1-deficient mice and we observed that these mice exhibit a reduction in the number 
of PGCs during embryonic development. This provides an example of a requirement 
for DNA repair in a physiological system. Using an in vitro system, we were able to 
recapitulate the reduction in PGC numbers. The system we have employed therefore 
enables the study of DNA repair factors in a setting closer to physiology. This system 
has the advantages of avoiding the use of mice, permitting us to produce vast amounts 
of this very rare population of cells. The PGCLCs generated in vitro have the ability to 
start epigenetic reprogramming and have spermatogenic potential upon transplantation. 
Furthermore, this in vitro system permits the use of genetics to understand which DNA 
repair pathways are required for PGC development and permits to study genes required 
for development which would not be possible to study in PGCs using in a developing 
embryo. However, this system also has caveats, namely the extent to which the DNA 
demethylation process occurs in vitro. There is no consensus as to how far in 
development PGCLCs go with labs claiming this system recapitulates early PGC 
development (from E7.5-E9.5) whereas the DNA demethylation process is only 
finished by E13.5 in PGCs (Hargan-Calvopina et al. 2016). Also, the physiological 
context, cellular environment and dynamics observed in a developing embryo cannot 
be fully recapitulated using an in vitro system. Considering the limitations of this 
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system we were able to show that the genetic requirement for DNA repair in PGCs can 
be recapitulated using the PGCLC system. This provided us with a tool to study DNA 
repair in a system closer to physiology and that would permit the discovery of novel 
genetic factors required for PGC development. 
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5.2 - Identification of DNA repair factors required for the 
proliferation of mouse embryonic stem cells 
 
 We used an in vitro system to screen for novel DNA repair factors essential for 
PGC development. To achieve this, we compared the frequency of sgRNAs present in 
the EpiLCs and PGCLCs. However, this system first requires the generation of a pool 
of KOs in ESCs that subsequently differentiate to EpiLCs and then to PGCLCs. This 
permitted us to initially find factors that when depleted are required for proliferation in 
ESCs. First, we observed that the most depleted sgRNAs in ESCs targeted essential 
genes. This result allowed us to validate the screening strategy by showing that gene 
deletions occured in an efficient manner since genes which are essential for cell 
viability are depleted from the pool of ESCs. Furthermore, searching for the most 
enriched sgRNAs in ESCs we observed the four sgRNAs targeting Trp53. Trp53 has 
been previously shown to be the most enriched gene identified in other CRISPR screens 
using ESCs (Li, Yu, et al. 2018; Hackett et al. 2018). Furthermore, it has been shown 
that in human pluripotent stem cells negative P53 mutations are acquired and expanded, 
further suggesting absence of P53 to confer a selective advantage in these cells (Merkle 
et al. 2017). The Trp53 gene encodes for a transcription factor which in somatic cells 
responds to cellular stress signals by activating the transcription of genes that trigger 
cell cycle arrest or apoptosis which either promote repair or eliminate abnormal cells, 
respectively (Martinez et al. 1991; Yonish-Rouach et al. 1991). Interestingly, it has 
been suggested that in stem cells Trp53 may have additional functions. It has been 
shown that in hematopoetic stem cells and neural stem cells p53 negatively regulates 
the proliferation and self-renewal of these cells and maintains their quiescent state (Liu 
et al. 2009; Meletis et al. 2006). Also, Trp53-/- mouse ESCs have been shown to have a 
proliferative advantage compared to Trp53+/- cells which is associated with decreased 
susceptibility to apoptosis (Sabapathy et al. 1997). Mouse ESCs have been shown to 
experience higher levels of DNA damage compared to MEFs, exemplified by the 
elevated levels of phospho-H2AX (histone H2A variant X) and chromatin bound RPA 
or RAD51 (Ahuja et al. 2016). This observation may be due to persistent replication 
stress caused by the high proliferative rate (Waisman et al. 2019). Nevertheless, mouse 
ESCs accumulate mutations at a slow rate when compared to MEFs, suggesting either 
a robust mechanism of repair of lesions and/or an efficient mechanism for clearing 
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damaged cells (West et al. 2009). Therefore, one can hypothesise that absence of Trp53 
in ESCs causes the survival of cells that otherwise would be cleared by apoptosis or 
would arrest in the cell cycle therefore ultimately increasing the total number of cells 
in culture. In order to test this we could initially generate Trp53-deficient mouse ESCs 
and record the growth advantage in comparison to Wild type cells. Having observed a 
growth advantage in the Trp53-deficient ESCs, we could then separate the functions of 
Trp53 using complementation. Complementing the Trp53-deficient cells with Wild 
type and a mutant version of Trp53 which is unable to promote cell cycle arrest but 
maintains apoptosis-inducing function (Toledo et al. 2006) we could assess if it is the 
ability to induce apoptosis or cell cycle arrest or both that rescue this phenotype. 
 Having observed a striking depletion of sgRNAs targeting essential genes and 
an enrichment for Trp53 sgRNAs in the ESC population allowed us to conclude that 
the we have successfully generated a pool of KO ESCs to then differentiate into EpiLCs 
and PGCLCs. In addition to Trp53, we found Chek2 and Usp28 to confer a proliferative 
advantage to ESCs. Chek2 is a DNA damage response cell cycle checkpoint regulator 
and a putative tumour suppressor. When active, Chek2 is known to inhibit the Cdc25c 
phosphatase thereby preventing entry into mitosis (Chaturvedi et al. 1999) and also has 
been shown to stabilise the tumor suppressor protein Trp53, leading to cell cycle arrest 
in G1 (Dumaz et al. 2001). Usp28 is a deubiquitinase involved in DNA damage induced 
apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such 
as CLSPN (Claspin) (Zhang et al. 2006). USP28 has been shown to form a complex 
with 53BP1 (Tumor protein p53 binding protein 1) which stimulates Trp53 DNA-
binding activity (Cuella-Martin et al. 2016). Also, USP28 has been shown to directly 
deubiquitinate p53 in vitro and to stabilise p53 in cells (Fong et al. 2016). This therefore 
suggests that failure to activate Trp53 via Usp28 depletion causes the proliferative 
advantage observed in ESCs. Notably, sgRNAs targeting another kinase - Atm (Ataxia 
telangiectasia mutated) - which is upstream of Chek2 in the phosphorylation cascade to 
activate TRP53, were also highly enriched in ESCs. These results further emphasize 
the requirement not only for Trp53 but also of the downstream factors required for 
TRP53 activation to therefore mediate a robust mechanism of DNA damage repair 
and/or clearance of damaged cells in mouse ESCs. 
 The second most enriched set of sgRNAs in the ESC population corresponded 
to Setd2. Setd2 is a histone methyltransferase that is specific for lysine-36 of histone 
H3, and methylation of this residue is associated with active chromatin (Sun et al. 
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2005). This protein also contains a novel transcriptional activation domain and has been 
found associated with hyperphosphorylated RNA pol II (Carvalho et al. 2013). Setd2 
has been shown to be required for endoderm differentiation (Zhang et al. 2014) but no 
phenotype has been observed regarding disruption of Setd2 in mouse ESCs and 
proliferation. Interestingly, SETD2 is frequently mutated or deleted in several human 
tumours (Dalgliesh et al. 2010). In mouse models of colorectal cancer inactivation of 
Setd2 promotes tumourigenesis by counteracting Wnt signaling, responsible for 
controlling proliferation and growth of cells, therefore facilitating self-renewal of 
intestinal stem/progenitor cells (Yuan et al. 2017). Therefore, one hypothesis for the 
selective advantage observed in Setd2-deficient cells could be that absence of Setd2 
disregulates Wnt signaling causes a proliferative advantage in mouse ESCs. To further 
support this hypothesis it has been shown that Wnt signaling is particulalry important 
in mouse ESC as the inhibitor of GSK3 used in the 2i media has been shown to activate 
the Wnt signaling pathway to promote ESC growth and viability (Ying et al. 2008). 
Our further steps will be to validate experimentally these results and explore what may 
be the basis of this effect. 
 Overall, we observed an enrichment for sgRNAs targeting genes involved in the 
activation of Trp53 and Trp53 itself. These results suggest that failure to activate Trp53 
in ESCs may allow cells that encounter DNA damage to progress in the cell cycle and 
to avoid clearance via apoptosis therefore gaining a proliferative advantage. 
  
  117 
5.3 - Identification of DNA repair factors required for the exit of 
mouse embryonic stem cells from pluripotency 
 
 Then, we searched for factors required for the exit from pluripotency by 
comparing the frequency of sgRNAs in the ESCs with the sgRNAs in the EpiLC 
population. We found Dnmt1 at the top of our gene list. Dnmt1 is a maintenance DNA 
methyltransferase enzyme that transfers methyl groups to cytosine nucleotides of 
genomic DNA. DNMT1 is the major enzyme responsible for maintaining methylation 
patterns following DNA replication and shows a preference for hemi-methylated DNA 
(Hermann, Goyal, and Jeltsch 2004). It has been previously shown that absence of 
Dnmt1 in ESCs causes apoptosis whenever ESCs are induced to generate embryoid 
bodies, therefore suggesting that Dnmt1 is required for ESC differentiation (Panning 
and Jaenisch 1996). Furthermore, another screen identified Dnmt1 to be required for 
the transition from ESC to EpiLC (Hackett et al. 2018). Dnmt1-deficient mouse ESCs 
show a global decrease in DNA methylation levels which does not affect proliferation 
but may have an effect on the initial ground state of the ESCs. Therefore, one potential 
explanation for the requirement of Dnmt1 in ESC differentiation is that maintenance of 
DNA methylation by Dnmt1 in ESCs may be crucial for propagating the changes in 
transcription that are necessary for differentiation. Methylation has been shown to be 
associated with transcriptionally silent chromatin by either impeding transcription 
factors to bind chromatin (Bell and Felsenfeld 2000) and recruitment of chromatin 
remodelling factors (Hendrich and Bird 1998) which would hence regulate 
transcription. Thus, in the absence of Dnmt1 and in the presence of a hypomethylated 
genome, these changes cannot be performed and therefore the transcription of genes 
required for differentiation cannot be regulated. Also this could potentially explain why 
Dnmt3a/b did not emerge as top hit in this screen. Dnmt3a/b-deficiency in mouse ESCs 
results in only a gradual loss of methylation in genomic sequences that requires more 
than 70 passages to reduce 90% of global methylation (Chen et al. 2003). Furthermore, 
unlike Dnmt1-deficient mouse ESCs (Tucker et al. 1996), Dnmt3a/b-deficient cells are 
still able to give rise to teratomas suggesting that these cells can differentiate. In the 
future it would be interesting to explore if indeed Dnmt1 is required to regulate the 
transcription of specific genes required for differentiation and to find which genes these 
may be. Having found Dnmt1 as the most depleted gene in EpiLCs permitted us to 
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conclude that the screening strategy coupled with the differentiation assay is permitting 
us to find factors required for these transition states. In addition to Dnmt1, we found 
other factors, such as Usp28, Rnaseh2a and Cdh1. We previously identified Usp28 have 
a selective advantage when disrupted in ESCs. Interestingly, this gene ranked second 
while comparing sgRNAs depleted in EpiLCs versus ESCs. This suggests that Usp28 
could be involved in the differentiation from ESCs to EpiLCs. However, since Usp28-
deficient mice grow to adulthood and are able to live and reproduce (Richter et al. 2018) 
we should first validate this hit by differentiating Usp28-deficient ESCs to EpiLCs and 
assess if indeed we observe a reduction in EpiLC formation. If this is the case, it would 
be interesting to understand if the defect observed is due to activation of Trp53 (which 
would be expected if Trp53 would also came out as a hit) or if it has to do with other 
functions of this gene.  
 After Usp28 in the gene rank list, we found Rnaseh2a to be depleted in the 
EpiLC population when comparing the sgRNAs with the ESC population. Rnaseh2a is 
a subunit of the heterotrimeric ribonuclease H enzyme (RNASEH2) (Jeong et al. 2004). 
RNASEH2 is the major source of ribonuclease H activity in mammalian cells and 
endonucleolytically cleaves ribonucleotides in genomic DNA (Hiller et al. 2012). 
RNASEH2 may also be important for the resolution of R-loops that arise during 
transcription (El Hage et al. 2010). In humans, mutations in RNASEH2 lead to Aicardi-
Goutières syndrome which is a type I interferonopathy in which type I IFN production 
and clinical features resemble a congenital viral infection of the brain (Crow et al. 
2015). Deletion of Rnaseh2a in mice causes embryonic lethality at E10.5 via a severe 
Trp53-mediated DNA damage response and with the first structural sign of embryonic 
defects occurring at the epiblast-to-gastrulation transition (Uehara et al. 2018). Since 
sgRNAs targeting the other subunits of the trimer were not initially present in the 
sgRNA library, we only observed the depletion of the subunit “a” of the trimer in 
EpiLCs. One explanation for the requirement of Rnaseh2a in EpiLCs may be that the 
DNA damage associated with absence of Rnaseh2a can be resolved in mouse ESCs but 
not in EpiLCs due to the differential use of DNA repair factors in these distinct cell 
types. Whereas ESCs would have robust DNA repair mechanisms to overcome such 
DNA damage it may be possible that EpiLCs induce an apoptotic response that would 
justify the reduction of sgRNAs targeting Rnaseh2a in this cell population. In addition 
to Rnaseh2a, we identified Cdh1, which encodes a cadherin. Cdh1 was included in our 
sgRNA library since it has been shown to promote NER via positively regulating the 
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transcription of Xpc and DNA damage-binding protein 1 (Ddb1) (Qiang et al. 2016). 
CDH1 is a calcium-dependent cell-cell adhesion protein comprised of five extracellular 
cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail 
(Overduin et al. 1995). Loss of function mutations in this gene in human patients is 
correlated with cancer invasion and metastasis (Vleminckx et al. 1991). In addition to 
this, Cdh1-deficient mice fail to survive embryonic development showing severe 
abnormalities before implantation (Riethmacher, Brinkmann, and Birchmeier 1995) 
Interestingly, Cdh1-deficient mouse ESCs show impaired differentiation to embryoid 
bodies, which is in agreement with our screening results (Mohamet, Lea, and Ward 
2010). However, the basis of this phenotype remains to be explored. In order to explore 
the requirement for Cdh1 during ESC to EpiLC differentiation, one would have to 
generate Cdh1-deficient ESCs, differentiate these cells into EpiLC and assess the 
number of EpiLCs produced in comparison to the Wild type. If a decrease in EpiLCs is 
observed, we could then interrogate what is the nature of this decrease: is the absence 
of Cdh1 causing cells to retain pluripotency, or to die during the differentiation 
protocol? 
 Using our screening strategy we have found potential novel factors required for 
the exit of pluripotency. Observing Dnmt1 in the top of our list and knowing that 
absence of this factor impairs mouse ESC differentiation allows us to conlcude that by 
coupling the ESC differentiation system with CRISPR-screening we can find new 
factors required for the different cell fate transitions.  
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5.4 - A dropout screen identifies novel repair factors required for 
PGC development 
 
Using the PGCLC differentiation system helped us to setup a CRISPR/Cas9 
screening platform to find genome stability factors with novel functions in PGCs. In 
the past, a screen for genetic factors required in PGCs had been performed. This screen 
combined inhibitory RNAs with the use of ESCs carrying a Stella-GFP reporter which 
were differentiated into embryoid bodies that generated putative PGCs expressing 
Stella-GFP (West et al. 2009). Using this strategy a genetic requirement for lin28 
(lineage 28) in mouse PGCs was identified and validated for the first time. The main 
caveats of this screen are that only 30 genes were interrogated, which stronly limits the 
search for novel factors required for PGC development. Also the use of inhibitory 
RNAs does not fully deplete gene expression which may cause an increase in the false 
negative hits in the screen. In addition to this, the PGCs derived from embryoid bodies 
are generated via random differentiation and activation of the Stella-GFP reporter in 
contrast with the PGCLC system in which cytokines required for PGC development are 
used to induce PGC differentiation which more closely resembles the specification of 
PGCs in vivo. In addition to this screen, two other research labs employed the PGCLC 
differentiation system for screening for novel factors required for PGC development. 
One of the labs performed a targeted screen looking for histone modifiers in PGC fate 
using small interfering RNA (Mochizuki et al. 2018). This screen aimed at 
understanding how known factors such as PRDM14 and BLIMP1 regulate the PGC 
transcriptional programme via histone modifications, therefore permiting to understand 
in more detail the determination of epigenetic fate in PGCs. The caveats of this screen 
were the need of transducing each siRNA individually instead of using a pool. This 
therefore greatly diminished the number of genes that could be analysed. Furthermore, 
siRNA does not cause complete depletion of gene expression. In addition to this screen, 
a CRISPR/Cas9 screen has been previously employed to search for novel regulators 
required for PGC development (Hackett et al. 2018). This screen was performed using 
a genome-wide library of sgRNAs, however the authors did not succeed in employing 
a convenient system to produce the required number of PGCLCs to perform a valid 
screen. Therefore the authors were able to sort only 1.7 million PGCLCs resulting in 
each sgRNA to be present in a cell only 19 times on average (this is also named the 
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fold-representation of a library in a respective population). Since at low representation 
the library becomes skewed, causing erroneous interpretation of the 
dropout/enrichment of sgRNAs, the results of this screen become more difficult to 
interpret. We have upscaled the generation of PGCLCs by using the Aggrewell plate 
system that allows us to generate a vast amount of PGCLCs, coupled to the use of a 
smaller library of sgRNAs in order to more easily cover all the sgRNAs with a higher 
representation and therefore generating more reliable data. Using this approach we were 
able to find candidate genes such as Pds5b, which have been reported to have PGC 
defects when depleted from mice, but we also discovered a few novel factors. The factor 
we found with known PGC defects, named Pds5b, encodes for a protein that interacts 
with the conserved protein complex named cohesin. The cohesin complex holds 
together sister chromatids and facilitates accurate chromosome segregation during 
mitosis and meiosis. Additionally, mutations in cohesion proteins are associated with 
the developmental disorder Cornelia de Lange syndrome in humans. Pds5b knockout 
mice died shortly after birth (Zhang et al. 2007). These mice exhibited multiple 
congenital abnormalities, including heart defects, cleft palate, fusion of the ribs, short 
limbs, distal colon aganglionosis, abnormal migration and axonal projections of 
sympathetic neurons, and germ cell depletion, many of which are similar to 
abnormalities found in humans with Cornelia de Lange syndrome. Also, in vertebrates 
PDS5B, unlike PDS5A, contains a DNA-binding domain and localizes in the nucleolus 
(Zhang et al. 2007). Interestingly, the PGC defect is the only phenotype observed in 
Pds5b–deficient mice that is not observed in Pds5a-deficient mice (Zhang et al. 2009). 
This suggests that some function performed by Pds5b alone is essential for complete 
development of this population and is independent of the other phenotypes observed in 
Pds5a-deficient mice. Since cohesins have been shown to be involved in 
transcriptionally regulating gene expression, it would be interesting to test if in the 
absence of Pds5b in PGCs there are changes in the transcriptome that may ultimately 
lead to loss of this cell population. 
 In addition to Pds5b, we found a new factor with no published mouse 
phenotype. This factor is named Spidr and has been shown to play a role in HR. SPIDR 
has been shown to physically interact with BLM and RAD51 (Wan et al. 2013). Also, 
depletion of SPIDR from human cells causes an increase in sister chromatid exchange 
and defects in HR (Wan et al. 2013). Interestingly, two girls from a consanguineous 
family with mutations in the SPIDR gene have been shown to display failure to reach 
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puberty, primary ovarian insufficiency and very high levels of the hormones that 
stimulate gonad development (Smirin-Yosef et al. 2017). Such a phenotype would be 
expected from patients exhibiting failure to correctly develop PGCs during embryonic 
development. Furthermore, Spidr-deficient mice generated by the Jackson lab with 
phenotype descriptions available in the Mouse Genome Informatics online resource 
shows that both male and female adult mice are sterile. 
 Interestingly, other factors involved in HR such as Mcm8 and Mcm9 when 
depleted from mice also cause fertility problems related to PGC defects and it has been 
shown that Mcm9 has a PGC numerical attrition as early as E11.5 (Luo and Schimenti 
2015; Lutzmann et al. 2012). However, the requirement for Mcm9 in PGCs has been 
shown to act on a different pathway as the Fanconi gene Fancm (Luo and Schimenti 
2015). Therefore one can speculate that during PGC development there may be an 
additional requirement for HR factors, to deal with different sources of DNA damage 
and maintain the integrity of the genome. In the future it will be interesting to assess if 
Spidr is required for fertility in both sexes. Then it would be of interest to understand 
if this phenotype is caused by a numeric reduction of PGCs during embryonic 
development. Since HR is a less mutagenic form of DSB repair we can speculate that 
the germ line may devise this strategy to avoid mutations to be transmitted to the next 
generation. 
  
  123 
5.5 - A dropout screen identifies Rev1 as a novel factor required for 
PGC development 
 
 In addition to Pds5b, we found Rev1 targeting sgRNAs to be depleted in the 
PGCLC population when compared to the same sgRNAs present in the EpiLCs. Rev1 
is a deoxycytidyl transferase enzyme that also acts as a scaffold to recruit DNA 
polymerases involved in TLS (Masuda et al. 2001; Pustovalova, Bezsonova, and 
Korzhnev 2012). Rev1-deficient mice have been generated previously and exhibited 
growth retardation and impaired class-switch recombination (Jansen et al. 2006). 
Interestingly, the germ cell or fertility defects observed in these mice have not been 
characterised until now. We have found a genetic requirement for Rev1 in early PGC 
development. Rev1-deficient mice show a reduction in PGC numbers early in PGC 
development which culminates in loss of germ cells in both male and female adult mice. 
 Since Rev1 and Ercc1 both function in ICL repair one could hypothesise that 
these factors deal with the same DNA lesion during PGC development. However, the 
temporality and magnitude of the PGC numerical reduction observed in the Rev1-
deficient embryos is distinct from the one observed in the absence of Ercc1 (Hill, R.J. 
and Crossan, G.P. 2019). PGC numbers were reduced in Ercc1-deficient embryos at 
E11.5 whereas for Rev1 the PGC defect emerged prior to E9.5. This is also observed in 
the histology of adult mice in which Ercc1-deficient mouse testis still have some 
tubules with germ cells whereas Rev1-deficient testis have tubules completely devoid 
of germ cells. Furthermore, unlike for Rev1 targeting sgRNAs, we did not observe 
sgRNAs targeting Ercc1 to be depleted in the PGCLC screen we performed. This may 
be because the PGC numerical reduction observed in Ercc1-deficient embryos occurs 
around E11.5 and the PGCLCs at day 4 resemble E10.5 PGCs, where a significant 
numerical reduction is not yet observed. These results therefore suggest that there may 
be more than one insult during germ cell development that requires distinct DNA repair 
pathways during different periods. 
 The discovery of the requirement for Rev1 in PGCs is particularly interesting 
because it is known that Rev7-deficient mice and ESCs have reduced abilities to 
generate PGCs in vivo and in vitro, respectively (Pirouz, Pilarski, and Kessel 2013; 
Rahjouei et al. 2017; Watanabe et al. 2013). Therefore this suggests that the absence of 
Rev7 impairs the development of PGCs due to its role in TLS, similarly to Rev1. To 
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corroborate this, we observed that the defect observed in PGCLCs in the absence of 
Rev1 and Rev7 is comparable. In the future, it will be interesting to test if the absence 
of the C-terminus region of Rev1, required for interacting with Rev7, is required for 
PGC development (Ross, Simpson, and Sale 2005). Also, it would be interesting to 
generate embryos deficient for both Rev1 and Rev7 to ascertain if these factors are 
required for the same function in PGC development.  
 Interestingly, from E8.5 to E9.5 there is a switch from the G2-arrest in the cell 
cycle to a proliferative state (Seki et al. 2007). Also, during this period the germ cells 
undergo an extensive epigenetic reprogramming process starting between E7.5 and 
E8.5. This epigenetic reprogramming may therefore pose a challenge to the genome 
stability for example via the release of alkylating or crosslinking agents in close 
proximity to DNA during histone demethylation. The DNA damage encountered during 
epigenetic reprogramming could therefore cause PGCs to be dependent on the TLS 
tolerance pathway. Interestingly, for Ercc1 mutants the PGC defect emerges later at 
E11.5, which is when the second wave of DNA demethylation occurs. This may 
indicate that the challenge encountered early at E9.5 may only be observed later in the 
absence of Ercc1 or there is a different challenge that occurs later in PGC development. 
 We have employed an in vitro system that permitted us to study the genetic 
requirement for DNA repair factors in PGCs. Using this system we performed a 
CRISPR/Cas9 screen which identified Rev1 as a critical factor for PGCLC 
development. This selected hit from the screen was then validated both in vitro and then 
in vivo and we also showed that the catalytic activity of REV1 is dispensable for the 
development of PGCs. Interestingly, whilst aiming to find DNA repair factors that 
suppress mutagenesis in the germ line we found a factor belonging to the error-prone 
TLS pathway. In the future it will be interesting to explore if other TLS factos are also 
required during this temporal window in early PGC development. Furthermore, the 
observation that TLS is required early in PGC development suggests that the PGCs 
employ this mutagenic tolerance pathway to promote the evolution of the genome in 
mammals.  
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Chapter 6 - Materials and Methods 
 
General techniques in molecular cloning 
 
 Molecular cloning was performed following standard protocols  (Sambrook and 
Russel 2001). Ligation reactions were performed using high concentration T4 DNA 
ligases according to manufacturers instructions. Ligation reactions were transformed 
into chemically competent E. coli DH5α. DNA was prepared from bacteria using 
QIAprep Spin Miniprep kit (QIAgen) or QIAprep Maxiprep kit (Qiagen) following the 
manufacturers instructions. 
 
Plasmids 
 
 The pLentiguide puro and px458 plasmids were used to express gene specific 
sgRNAs. For cloning sgRNA sequences into the pLentiguide Puro and px458 the 
restriction sites BsmbI and BbsI were used, respectively. In order to generate a 
doxycycline inducible Cas9 expressing vector we replaced the puromycin resistance 
cassette in the pCW Cas9 plasmid for the hygromycin resistance cassette in the pCW57-
MCS1-2A-MCS2 (Hygro) vector using the restriction enzymes BamHI and XbaI. 
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ESC culture, transfection and selection of clones 
 
 ESCs were grown in N2B27 medium complemented with PD0325901 (Axon 
Medchem) (MEKi), CHIR99021 (Axon Medchem) (GSK3i) and mLIF (MRC 
Cambridge Stem Cell Institute) – 2i + mLIF, at 37 °C in 10% CO2. ESC were always 
grown in plates or dishes previously coated well with 16.6 μg/ml of fibronectin 
(Milipore) in PBS for 1 hour at 37 °C. Transfections were performed as follows: 0.3 x 
106 ESC were plated the day before transfection in a well of a 6 well-plate and allowed 
to grow overnight at 37 °C in a 10% CO2 incubator. Cells were transfected using 
Xfect™ Transfection Reagent (TaKaRa, Japan): 2 μg of DNA were mixed with the 
provided buffer and polymer for 10 minutes and then added to cells. After 4 hours of 
transfection, the media was replaced. One day after transfection, cells were transferred 
to a 10 cm dish previously coated fibronectin and containing 8 mL of media. The 
following day, when required, neomycin selection was performed by adding neomycin 
to a final concentration of 150 μg/ml. For puromycin, a final concentration of 0.5 μg/ml 
was used and for hygromycin 110 μg/ml. After 7-10 days colonies started to emerge 
which were handpicked and expanded into 96 well-plates. 
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DNA fragment analysis 
 
 Genomic DNA was extracted from cells in 96 well-plates using the DirectPCR 
Lysis Reagent (Viagen) with 1:100 proteinase K (Viagen): the cells were resuspended 
in the the lysis reagent for 45 minutes at 55 °C and subsequently for 45 minutes at 85 
°C to inactivate the proteinase K. The genomic DNA was used for PCR amplification 
of the targeted locus with fluorescent primers tagged with FAM™ and HEX™ and an 
amplicon spanning 200-500 bp. The corresponding PCR products were diluted in Hi-
Di™ Formamide (Invitrogen) and GeneScan™ 600 LIZ™ Dye Size Standard 
(Invitrogen) and analysed by capillary electrophoresis using a ABI 3130XL. 
 
Gene Targeted exon  Amplicon FAM Fw primer (5’ – 3’)  HEX Rev primer (5’ – 3’) 
Fan1 3 416 TAAAGACATGGGCTACCGGC TCAGAGATCCAGCAGCCTCT 
Mus81 9 300 TTCCTGCCTTCCCTGTCTCT GTGTGGACATTGGCGAAACC 
Snm1b 2 250 TGCTGAAGGAACCTGCTCTG AGGTGAGCAAGGCACAAAGA 
 
Table 2 – Primers used for screening of CRISPR-disrupted genome stability genes 
in mouse ESCs by fragment analysiss. This table shows sequence of the primers and 
respective amplicon size to screen for disruptions in exonic regions of Fan1, Mus81 
and Snm1b. 
 
 
ESC induction into PGCLCs 
 
 In order to differentiate ESCs into PGCLCs we followed the protocol developed 
by Hayashi et al. (Hayashi et al. 2011). ESCs grown in 2i + mLIF grown in a well of a 
6 well-plate were trypsinised with 0.4 ml of Tryple for 4 minutes at 37°C and washed 
with 1.6 ml of DMEM/F-12 (Invitrogen) supplemented with 0.15% BSA (Invitrogen). 
The cells were then counted and plated in a fibronectin coated 12 well-plate at 0.1 x 106 
cells per well in 1 ml EpiLC medium (N2B27 supplemented with FGFb (MRC 
Cambridge Stem Cell Institute), mLIF and KnockOut Serum Replacement (Invitrogen) 
for 42 hours. The cells were fed after 16 hours. After 42 hours the cells were washed 
with 1 ml of Phosphate-buffered saline (PBS) and then trypsinised with 0.4 ml of 
TryPLE for 2 minutes at room temperature and washed with 1.6 ml of DMEM/F-12 
(Invitrogen) supplemented with 0.15% BSA (Invitrogen). The EpiLCs were then spun 
down at 230 x g for 3 minutes and ressuspended in 1 ml of GK15 medium. For PGCLC 
differentiation in 96 well Lipidure-Coat plates EpiLC were plated at a density of 0.02 
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x 106 cells in PGCLC medium (GK15 containing BMP4 (PeproTech), SCF (R&D 
Systems), mLIF and mEGF (R&D Systems)). For PGCLC differentiation in Aggrewell 
800 μm plates (StemCell Technologies) the plates were previously treated with 500 μl 
of Rinsing solution, according to manufacturer’s instructions. Then the plates were 
spun down at 2000 x g for 5 min. The Rinsing solution was removed and the wells were 
washed with 2 ml of PBS. After washing, 1 ml of PGCLC media with 0.6 x 106 cells 
was added to the well, spun down at 100 x g for 3 minutes and allowed to grow at 37 
°C in a 10% CO2 incubator. 
 
Ercc1 targeting vector assembly 
 
 Mouse genomic DNA was used as template to amplify the two homology arms 
for the Ercc1 targeting vector by PCR using the LA Taq polymerase (TaKaRa, Japan). 
The Neo resistance cassette was amplified from the plasmid pL452. The amplification 
products were then purified on an agarose gel and assembled using a Gibson assembly 
reaction with PC1 digested with AgeI and NotI. To confirm the correct assembly of the 
four DNA templates, Sanger sequencing was performed using the M13RP (5’-
CAGGAAACAGCTATGAC-3’) and TKRP (5’-
TGCTTCCCTCTTGAAAACCACACTGCTCGAC-3’) oligos. 
 
sgRNA cloning 
 
 The px458 plasmid containing both Cas9 and GFP being expressed under a 
cytomegalovirus promoter and separated by a self-cleaving peptide (T2A) was digested 
with the restriction enzyme BbsI. Then, the digestion product was run on an agarose 
gel and gel purified. Both the upper and lower oligo sequences corresponding to the 
sgRNA were phosphorylated with PNK and annealed by being incubated at 37°C for 1 
hour followed by five minutes at 95°C and a temperature ramp from 95°C to 25°C at 
0.1°C per second which permits the oligos to cool slowly allowing the annealing. The 
annealed sgRNAs were then ligated into the BbsI digested px458. To confirm the 
correct assembly of the sgRNA into the px458 backbone, Sanger sequencing was 
performed using the U6 primer (5-GAGGGCCTATTTCCCATGATTCC–3’). 
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Gene sgRNA name Oligo sequence (5’ – 3’) 
Ercc1 
Ercc1_12 CACCGATAGCATCATCGTAGCCCG AAACCGGGCTACGATGATGCTAT 
Ercc1_13 CACCGATAGCATCATCGTGAGCCCG AAACCGGGCTCACGATGATGCTAT 
Fan1 
Fan1_309 CACCGAACCACAGGGGTTAAGTCGG AAACCCGACTTAACCCCTGTGGTTC 
Fan1_310 CACCGTGCCTCCGACTTAACCCCTG AAACCAGGGGTTAAGTCGGAGGCAC 
Fan1_311 CACCGCTGGATTAAAATGAGTAAAC AAACGTTTACTCATTTTAATCCAGC 
Mus81 
Mus81_389 CACCGTCCAACGTGTAGCTTGCGTA AAACTACGCAAGCTACACGTTGGAC 
Mus81_392 CACCGGTGTAGCTTGCGTACGGTGT AAACACACCGTACGCAAGCTACACC 
Mus81_396 CACCGTGTAACTCTCGGAGCATTTC AAACGAAATGCTCCGAGAGTTACAC 
Snm1b 
Snm1b_703 CACCGTGGGAACTGTCGGATTAGC AAACTGCTAATCCGACAGTTCCCAC 
Snm1b_707 CACCGGGTTCTTCCTTCCCGACAAG AAACCTTGTCGGGAAGGAAGAACCC 
Rev7 
Rev7_367 CACCGACGTCAGCCACCACTGTGGT AAACACCACAGTGGTGGCTGACGTC 
Rev7_377 CACCGCCTGATTCTCTATGTGCGCG AAACCGCGCACATAGAGAATCAGGC 
Rev1 Rev1_091 CACCGTAGCTACACACACAGCATCG AAACCGATGCTGTGTGTGTAGCTAC 
 
Table 3 – sgRNA sequences used to generate CRISPR-disrupted DNA repair genes 
in mouse ESCs. Synthetic oligonucleotides were designed and chosen from the 
CRISPR Finder tool available on the Sanger website 
(https://www.sanger.ac.uk/htgt/wge/find_crisprs). The targeted genes, the sgRNAs and 
both the upper and lower oligo required for annealing each sgRNA are represented. 
 
 
Colonogenic survival assay 
 
 ESCs were cultured in KOLIF medium and plated in duplicate in 6 well-plates 
at a concentration of 2.000, 200 and 20 cells per well. Increasing concentrations of 
mitomycin C were added to the medium and the cells were allowed to grow for 6 days. 
After 6 days, the cells were washed with 2 mL of PBS and fixed/stained with 
glutaraldehyde (6% v/v) and crystal violet (0.5% w/v.). 
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Sequencing of CRISPR deletions in ESCs 
 
 In order to determine the nature of the genetic perturbation induced in the locus 
of CRISPR/Cas9 targeted genes, genomic DNA was extracted from the putative clones 
using the Puregene protocol and the targeted genomic regions were amplified by PCR, 
cloned into a TOPO Zero Blunt vector (Life Technologies) and Sanger sequencing was 
performed. 
 
Quantitative real-time PCR and gene expression analysis. 
 
 Total RNA was extracted from sorted cells using the Picopure kit (Life 
Technologies) and cDNA was synthesised using the Superscript III reverse 
transcriptase (Life Technologies) following the manufacturers instructions. Relative 
gene expression levels were normalised to Gapdh. 
 
 
Western blotting analysis 
 
 Whole cell extracts of 2 x 106 ESCs were obtained using RIPA buffer and 
incubating the cells on ice for 15 minutes. The remaining cells were then sonicated for 
10 cycles of 30 seconds using a Bioruptor. The extracts were then spun down (21.000 
x g) at 4°C and the supernatant was collected. Protein concentration was determined 
using the DC Protein Assay (Biorad). Extracts were diluted in the same concentration 
for equal loading and run on a 4-12% Tris-Glycine Protein gel (Novex) for 1 hour at 
200 V. Protein was transferred to a Nitrocellulose membranes of 0.2 μm pore size via 
wet electroblotting at 30V for 1 hour. Membranes were blocked with TBST containing 
5% BSA and primarily incubated with rabbit monoclonal anti-ERCC1 antibody for 1 
hour (1:100 dilution in TBST with 5% BSA (Invitrogen). Horse Radish Peroxidase 
(HRP) coupled anti rabbit IgG was used as a secondary antibody (1:2000 dilution in 
TBST). HRP signal detection was performed using ECL (GE Healthcare UK Ltd) and 
the membranes were exposed on Super RX films (Fujifilm). 
 
  
  131 
Flow Cytometry 
 
 To obtain a single-cell suspension, the cells were collected to a 1.5 mL 
eppendorf and spun down at 230 x g for 10 minutes. The pellet was then incubated with 
ES Trypsin at 37°C for 5 minutes, trypsinised, incubated for 5 more minutes, added 2 
μl of benzonase (Milipore), trypsined and incubated for 5 additional minutes. After 
trypsinisation, 5% foetal calf serum in PBS was added to inactivate the trypsin. The 
cells were then spun down at 230 x g for 10 minutes. Finally, the pellet was resuspended 
in 100 μl of conjugated antibody (1:100 dilution in PBS with 2.5% foetal calf serum) 
and allowed to stain for 10 min at room temperature. Subsequently, the cells were 
resuspended in 300 μl of PBS with 2,5% foetal calf serum and strained through 70 μm 
meshes. For PGCLC experiments, data were acquired using the Becton Dickinson 
LSRFortessa. For in vivo experiments data were acquired using the Sony Biotechnology 
Inc. Eclipse analyser. To sort mouse tissues and tissue culture cells the Sony 
Biotechnology Synergy High Speed Cell Sorter was used. Data analysis was performed 
using the FlowJo version v10.1r5. 
 
Antibody Clone Manufacturer Species 
Poly or 
monoclonal 
Dilution Fluorochrome 
anti-ERCC1 D-10 SantaCruz mouse monoclonal 1:100 None 
anti-SSEA1 MC-480 BioLegend mouse monoclonal 1:100 Alexa Fluor 647 
anti-Cas9 7A9 3A3 Cell Signaling mouse monoclonal 1:100 None 
anti-CD117 2B8 BioLegend rat monoclonal 1:100 Alexa Fluor 647 
 
Table 4 – List of antibodies. Details of the antibodies used for both Western blotting 
and Flow cytometry experiments. 
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Animal Husbandry 
 
 All animals were maintained in specific pathogen-free conditions. In individual 
experiments all mice were matched for age and gender. All animal experiments 
undertaken in this study were done so with the approval of the UK Home Office Licence 
70/8325. 
 
 
Mouse Genotyping 
 
 To genotype animals genomic DNA was obtained from the embryonic heads 
using PCR Tail Solution (Viagen Biotech). The DNA was then used for PCR using the 
following oligonucleotides: Ercc1F2 (5’-TGGCCTACAGTTACCCAGAACAA-3’), 
Ercc1R1 (5’-CTGGGGCAATTTTAGTGTCAGTG-3’) and En2A (5’-
GCTTCACTGAGTCTCTGGCATCTC-3’) for Ercc1 mice; and FL097 (5’-
ATTGTGAGTCTCTAGCGTTTG-3’), FL098 5’-GCTGGAATTGAAATTCTAGG-
3’) and FL099 (5’-GCTTCCATTGCTCAGCGGTG-3’) for Rev1 mice. For genotyping 
Rev1AA embryos and mice a Taqman based assay was used. 
 
 
Histology 
 
 Tissues were fixed in 10% neutral-buffered formalin for 24-36 hours and 
transferred to 70% ethanol. Fixed samples were embedded in paraffin and 4 μm sections 
cut, deparaffinised, rehydrated and stained with haematoxylin and eosin following 
standard methods. Images were captured using a Zeiss AxioPlan 2 microscope (Zeiss) 
and tissue architecture was scored blind. 
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Statistical analysis 
 
 The number of independent biological samples and technical repeats (n) are 
indicated in the figure legends. Unless otherwise stated, data are shown as mean ± 
standard error of the mean (s.e.m) and a student t-test was used to determine statistical 
significance. Analysis was perfomed using GraphPad Prism version 7. 
 
Lentiviral production, titre determination and transduction 
 
 To produce lentiviruses, 1.5 x 106 HEK293T cells were plated in a p60 dish 
containing 5 ml of HEK293T media. The following day the cells were transfected with 
the lentiviral packaging and envelope plasmids (0.8 μg psPAX2 and 0.2 μg of pMD2.G, 
respectively) and 1 μg of plentiguide Puro plasmids containing the library of sgRNAs 
using polyethylenimine (PEI) in DMEM (Invitrogen). After 16 hours the media was 
replaced by 2i + mLIF. After 48 hours of transfection the media containing the viruses 
was filtered through a 0.45 μm filter and collected and stored at -80°C. 
 In order to determine the titre of the lentiviral particles obtained from the pooled 
library of sgRNAs in transducing units per ml (TU/ml) we performed a cologenic 
survival assay based on puromycin resistance. In order to achieve this, we first coated 
seven 10 cm dishes with 6 ml of 16.6 μg/ml of fibronectin in PBS for 1 hour at 37°C. 
Then, the lentiviral particles (stored at -80°C) were thawed at room temperature. During 
this period, the mouse ESCs previously grown in 10 cm dishes we were trypsinised 
with 5 ml of Tryple for 4 minutes at 37°C and washed with 20 ml of DMEM/F-12 
(Invitrogen) supplemented with 0.15% BSA (Invitrogen). Then we performed 10-fold 
serial dilutions of the lentiviruses starting from 10-2 to 10-6 dilutions in 20 ml of 
2i+mLIF media. The viable cells were then counted using a Beckman Coulter Vi-
CELL™ Cell Viability Analyzer. 1.2 x 106 ESCs per condition were spun down at 230 
x g for 10 minutes and resuspended with the respective lentivirus concentration in the 
presence of 8 μg/ml of polybrene (Milipore) in 8 ml of 2i+mLIF media. In addition to 
the 5 dilutions of lentiviruses 1.2 x 106 ESCs (from 10-2 to 10-6) two other sets of ESCs 
were also resuspended in 2i+mLIF media containing no lentiviruses. There uninfected 
ESCs would allow us to first check that all ESCs would die in the presence of 
puromycin, whereas the other set would be used in the absence of both lentiviruses and 
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puromycin to check for plating efficiency. After mixing the ESCs with the lentiviruses 
and polybrene, fibronectin was removed from the 10 cm dishes and the ESCs were 
plated and allowed to grow in the 37°C incubator for 16 hours. Then, the media was 
replaced with 2i+mLIF media to remove remaining lentiviral particles and polybrene. 
The following day the media was replaced by adding 2i+mLIF supplemented with 0.5 
μg/ml of puromycin (Invitrogen). After two days of puromycin treatment, the cells were 
replaced again with 2i+mLIF supplemented with 0.5 μg/ml of puromycin and after four 
days the media was finally replaced without supplementation of puromycin. One to two 
weeks after, colonies started to emerge and were counted using a light microscope. 
Finally, we obtained the transducing units per ml (TU/ml) by multiplying the number 
of colonies per ml of media with the dilution factor. 
 
CRISPR/Cas9 Screening 
 
 45 x 106 iCas9 #8 ESCs were transduced with the lentiviral library at a MOI of 
0.3 and 0.5 μg/ml of puromycin was added to the medium 2 days after to select for 
transductants. Selection was continued for 4 days post transduction. After selection of 
cells that stably expressed the sgRNAs, puromycin was removed from the media and 
the cells were grown for 21 days in 2.5 μg/ml of doxycycline to induce Cas9 expression 
and generate a pool of CRISPR knockouts. Subsequently, ESCs were induced to 
differentiate into EpiLCs in 10 cm dishes, fed after 16 hours and 42 hours after the 
EpiLCs were induced to differentiate into PGCLCs in Aggrewell 800 μm plates 
(StemCell Technologies). After 4 days of differentiation, the PGCLC aggregates were 
collected as follows: an entire plate was resuspended to a 50 ml falcon. Washed once 
with PBS by centrifuging at 230 x g for 5 minutes. Then the cell pellet was resuspended 
in 500 μl of ES Trypsin containing 3.3 μl of benzonase (Milipore) for 1 minute and 15 
seconds at 37 °C. Subsequently, the cells were resuspended and incubated at 37°C for 
an additional 1 minute and 15 seconds. The cell suspension was finally resuspended in 
PBS containing 5% of Fetal Calf Serum, stained and sorted based on the Stella-GFP 
and SSEA1-APC signal using the Sony Biotechnology Synergy High Speed Cell 
Sorter. Sample cell pellets were frozen in every cell type and differentiation step. A 
library coverage of ≥ 2000 cells per sgRNA was maintained at every step. gDNA from 
cell pellets was isolated using the DNeasy Blood & Tissue kit (Qiagen) and genome-
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integrated sgRNAs were PCR amplified using the Herculase II Fusion DNA 
Polymerase (Agilent). Multiplexing barcodes were added in a second round of PCR to 
distinguish between different cell type populations. The concentration of gel-purified 
PCR products was determined using a KAPA Library Quantication Kit 
(KAPABIOSYSTEMS). The PCR poducts were then used for sequencing on Illumina 
HiSeq4000 to determine sgRNA representation in each population sample. 
 
 
Screen statistical analysis 
 
 First, in order to assign the sequencing reads to the different populations of the 
screen (plasmid pool, ESC, EpiLC and PGCLC) a demultiplexing step took the raw 
NGS data and assigned it to the different cell populations corresponding to the different 
barcodes used in the PCR amplification step. Then an algorithm is used to assign to 
every sequencing read the respective sgRNA and to count the number of each sgRNA 
targeting a specific gene in the different populations. Having the sgRNA count we used 
R to perform the analysis and graphs shown in Chapter 3 as described in Winter et al. 
2016. The data for each population were normalized by quantile and the Z-scores for 
every gene were calculated. The Z-score represents the number of standard deviations 
from the mean a data point is. Only the value of three sgRNAs of a total of four was 
used to obtain the Z-score value of each gene, in order to avoid the effect of sgRNAs 
with low effect that were close to the mean. These data were represented as a list of 
genes with highest depletion in determined population and also in a graph showing the 
4 sgRNAs targeting a specific gene and what is the distance between these sgRNAs and 
the average sgRNA in two populations.
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General Reagents 
 
DNA loading dye 
 
50% glycerol 
1x TBE 
1% bromophenol blue (w/v) 
1% xylene cyanol 
 
 
RIPA buffer 
 
20 mM Tris-HCl (pH 7.5) 
150 mM NaCl 
1 mM Na2EDTA 
1 mM EGTA 
1% NP-40 
1% sodium deoxycholate 
2.5 mM sodium pyrophosphate 
1 mM b-glycerophosphate 
1 mM Na3VO4 
1 μg/ml leupeptin. 
 
5x SDS-PAGE reducing sample buffer 
 
300 mM Tris-HCl pH 6.8 
10% SDS 
25% glycerol 
0.05% bromophenol blue 
10% β-mercaptoethanol 
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Western blot transfer buffer 
 
25 mM Tris 
192 mM glycine 
20% ethanol 
 
 
2xTY 
 
1.6% bactopeptone 
1% yeast extract 
0.5% NaCl 
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N2B27 medium 
 
N2B27 medium is a basal medium used for both maintenance of ESCs and 
differentiation of EpiLCs. Preparation of this medium is based on Hayashi et al. (2013) 
instructions (Hayashi and Saitou 2013). Prepare each component, DMEM/F-12 + N2 
and Neurobasal + B27, as follows: 
 
DMEM/F-12 + N2 
 
N2 
3.6 ml DMEM/F-12 
0.5 ml apo-transferrin (stock solution at 100 mg/ml) (Sigma-Aldrich) 
0.33 ml 7.5% (wt/vol) BSA 
16.5 μl progesterone (stock solution at 0.6 mg/ml) (Sigma-Aldrich) 
50 μl putrescine (stock solution at at 160 mg/ml) (Sigma-Aldrich) 
5 μl sodium selenite (stock solution at 7.5 nM) (Sigma-Aldrich) 
 
495 ml of DMEM/F-12 (Invitrogen) 
0.5 ml Insulin (stock solution at 25mg/ml) (Sigma-Aldrich) 
 
Neurobasal + B27 
 
480 ml Neurobasal (Invitrogen) 
10 ml of B27 supplement minus vitamin A (Invitrogen) 
5 ml penicillin-streptomycin 
5 ml of l-Glutamine (stock solution at 200 mM) (Invitrogen) 
 
For 1l of N2B27 medium: 
 
mix 500 ml of DMEM/F-12 + N2 with 500 ml of Neurobasal + B27 
add 1.8 ml of β-mercaptoethanol (stock solution at 50mM) 
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ES trypsin 
 
Trypsin (Difco) 2.5g/L 
EDTA 0.4g/L 
NaCl 7g/L 
KH2PO4 0.24g/L 
KCl 0.37g/L 
D-Glucose< 1g/L 
Tris 3g/L 
Phenol Red 1ml/L 
Adjust pH to 7.6
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